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Abstract. 
Clinical guidelines surrounding transition from paediatric to adult health services 
are based on qualitative research. This study assessed whether routine 
datasets could provide empirical evidence for the need of transitional health 
care. Health outcomes were analysed for individuals diagnosed with type 1 
diabetes (T1D) or cancer in childhood (under 15 years) or young adulthood (15 
to 29 years) with up to 35 years of follow-up time, including mortality in the 
Yorkshire Register of Diabetes in Children and Young People (YRDCYP) using 
death certification data, HbA1c levels and hospitalisations for individuals 
receiving Continuous Subcutaneous Insulin Infusion (CSII) therapy in the Leeds 
Children and Young People’s Diabetes Service (LCYPDS) and hospitalisations 
in the Yorkshire Specialist Register of Cancer in Children and Young People 
(YSRCCYP) using hospital episode statistics.  
Analysis from the YRDCYP showed evidence for higher mortality during the 
transitional care period due to diabetic ketoacidosis. Individuals diagnosed with 
T1D during the transitional care period (15 to 29 years) had higher mortality 
rates compared with those diagnosed in childhood. CSII therapy for T1D was 
found to significantly reduce HbA1c values for up to 4 years in the LCYPDS, 
indicating it is an effective treatment option for managing T1D during the 
transitional care period.  
In the YSRCCYP, a previous mental health admission increased the odds of an 
A&E attendance and non-attendance to an outpatient appointment. There was 
evidence of poorer adherence during the transitional care period compared with 
younger age groups. Attending an outpatient appointment increased the odds of 
an inpatient admission by 50%, suggesting that missing an outpatient 
appointment could lead to less opportunity for referral for an inpatient 
admission. 
Previous research into transition focused on ages under 25 years. This study 
showed that individuals over this age should not be overlooked. Socio-
demographic factors should also be considered for targeted interventions. 
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Chapter 1 Introduction. 
In England, around 15 million people suffer from a long-term condition (LTC), 
requiring routine surveillance and management (1). LTCs create a major burden 
on the healthcare system, costing the National Health Service (NHS) around 
70% of total expenditure (2). The majority of LTCs occur in older people, where 
58% of people over 60 have at least one LTC (3). However, LTCs do not just 
occur in the older population. LTCs with childhood onset include asthma, 
epilepsy, cystic fibrosis, childhood cancer and type 1 diabetes (T1D). According 
to the General Lifestyle Survey, the percentage of under 15-year olds with a 
long-standing illness increased by around 5 to 6% between 1972 and 2011. 
Around a fifth of all people reporting an LTC in England are under 16 years old 
(3). These children and young people are typically treated in paediatric services. 
As they grow older, due to the organisational structure of the healthcare system, 
these young people will eventually have their care transferred into adult 
services. This time of changeover coincides with multiple life transitions, forming 
part of an overarching multidisciplinary transitional care period.  
This thesis examined health outcomes from two LTCs – childhood and young 
adult (CYA) cancer and type 1 diabetes, with a focus on the transitional care 
period.  
 
1.1 Defining the transitional care period. 
Adolescents and young adults (AYAs) with LTCs need to transform from being 
a passive receiver of healthcare, where primary responsibility is placed on 
parents/caregivers in paediatric services, to become fully engaged participants 
within adult health services, where there is an expectation that the patient has 
the necessary skills and knowledge to self-manage their condition with a 
reduced level of support (4–6). This is an extensive discrete change in 
environment, culture and relationships with health professionals, requiring major 
adjustment. Experiencing this change as a one-off transfer event may be a 
struggle for some young people, leading to non-adherence with treatment and 
non-attendance at scheduled appointments which could consequently have a 
detrimental effect on their health. Instead, expert consensus suggest 
undergoing a gradual process to provide continuity of care between paediatric 
and adult services which is “uninterrupted, coordinated, developmentally 
appropriate, psychosocially sound, and comprehensive” (7, p.570), requiring a 
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multidisciplinary outlook including non-health related spheres such as 
education, employment, mental health and social services (8). This reflects 
recent legislation, such as the Children and Families Act 2014, towards 
integrating services to provide support for the ‘whole child’ as opposed to a 
single focus approach (9,10).  
Assessing the outcomes of all multidisciplinary interventions involved during the 
transitional care period at a population level is challenging, particularly when 
interventions are non-standardised and implemented according to individual 
needs. In this study, an age group (15 to 29 years) was used as a proxy 
measure for the transitional care period, coinciding with the age of late CYA 
cancer and T1D onset. This age group was used as it includes the typical age 
range of the transfer event from 16 (the age of consent to a medical procedure 
without parental involvement) to 25 years (the upper age covered by the 
Children and Families Act 2014), with a minimum of one year of preparation 
before the transfer event and a minimum period of four years in adult services. 
This longer period of follow-up in adult services was included to capture the 
later period of ‘emerging adulthood’.  
Emerging adulthood describes the period after adolescence where the full 
social status of adulthood is yet to be achieved, despite reaching the legal adult 
age (11). For example, in England and Wales, 1.87 million 18 to 24-year olds 
are in full-time education, so are likely to be reliant on family members for 
financial support (12). Parental financial support can also remain for older age 
groups due to rising living costs, with 1 in 4 young adults aged 20 to 34-year 
olds still living at home (12). This means that parental involvement is present in 
everyday life for many young adults, making this age group distinct from older 
adults as they lack the experience and skills of complete independence. For 
AYAs with an LTC who still rely on parental support, exclusion of family 
members during appointments in adult services where parental involvement is 
no longer the norm can cause stress and anxiety, leading to negative health 
outcomes. Even when AYAs are living fully independently from family members, 
recent advances in brain imaging technology have found that the pre-frontal 
cortex and limbic system are still developing into the mid to the late twenties. 
These areas of the brain are connected to emotions, motivation, decision-
making and suppression of risk-taking behaviours (13,14). This can have 
important effects on the self-management of an LTC in the AYA population, as 
they may not have the necessary mental capacity to make the right decisions to 
maintain optimal healthcare. For example, for an AYA with T1D, they may be 
more likely to be motivated by peer approval (a short-term gain) to miss insulin 
injections, despite risking diabetic ketoacidosis (DKA) and longer-term 
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complications. This neurological distinction from older adults places greater 
emphasis on the importance of including emerging adulthood in research 
regarding the transitional care period (15). 
 
1.2 The need for empirical evidence on transitional health care. 
At present, there is wide variation in delivery of specialist services during the 
transitional care period. For CYA cancer survivors, there is a national model of 
care services in England, where 16 to 18-year olds are admitted to specialist 
Teenage and Young Adult Principal Treatment Centres. For 19 to 24-year olds, 
they are given a choice of entering a Teenage and Young Adult Principal 
Treatment Centre or they can enter adult services directly (16,17). In contrast, 
although there are some services dedicated to providing transitional services for 
the AYA T1D population, this is not standard across England and Wales in the 
same way that Principal Treatment Centres exist for cancer. An increase in 
children surviving LTCs into adulthood will mean that this population of AYA 
patients will increase, placing larger demand for services during the transitional 
care period. In global comparisons, the UK and Australia are the only two 
countries with published government documentation on supported transition 
strategies. The Transition support programme provided funding between 2008 
to 2011 to 11 NHS regions in England to develop transition systems, alongside 
the appointment of a National Clinical Director for Children, Young People and 
Transition to Adulthood. Standardised clinical guidance on transition was 
introduced in 2016 (18), showing that the UK government has acknowledged 
the importance of improving health care during the transitional care period (19).  
However, the evidence base for clinical guidelines, policy and recommendations 
on transition largely come from qualitative interview data and surveys from 
health professionals, patients or family members. Empirical research into 
whether providing specialist care is actually needed during the transitional care 
period is sparse (20,21). This is problematic as specialised transitional health 
care is resource intensive, so there needs to be quantifiable measures to 
provide justification for funding these services. In this study, health outcomes 
during the transitional care period were compared with health outcomes before 
and after the transitional care period. It was hypothesised than an increase in 
negative health outcomes (i.e. complications or death) during the transitional 
care period would provide evidence to support the need of specialist care in this 
age group. 
Empirical research can also determine whether specific sections of the patient 
population have greater needs for transitional health care. This provides useful 
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information for deciding where funding and resources should be allocated and 
whether interventions need to be tailored to specific groups. In this study, health 
outcomes were analysed by socio-demographic groups (sex, age at onset, 
ethnicity and deprivation), cancer type and previous mental health history.  
Maintaining service engagement by attending scheduled outpatient 
appointments is a major aim for transitional health care. However, there is a 
lack of evidence suggesting that appointment attendance during and after the 
transitional care period improves health outcomes, particularly in the long-term 
(8). This study examined whether non-attendance at outpatient appointments 
increased the risk of negative health outcomes. If appointment attendance 
affected health outcomes, this would provide evidence for clinicians and policy 
makers in deciding whether interventions should be focused on trying to 
increase appointment attendance to reduce negative health outcomes.  
One reason for the lack of rigorous data analysis to assess the needs of 
transitional health care is due to the lack in availability of datasets with 
extensive follow-up time collected specifically to investigate transition outcomes. 
To overcome this, historic routine health datasets can be used to provide a 
novel approach to overcome the paucity of research in this area, particularly for 
long-term outcomes. In this study, population-based disease registry data from 
CYA cancer and T1D were linked with other routine datasets (death registration 
data and hospital admissions data) to assess health outcomes during the 
transitional care period. 
 
1.3 Childhood and young adult (CYA) cancer and type 1 
diabetes (T1D) epidemiology. 
Cancer and T1D are two diseases with major differences in treatment and 
service provision during the transitional care period. Examining two contrasting 
LTCs provides the opportunity to compare differences and similarities during the 
transitional care period and between health outcomes.   
 
1.3.1 Childhood and young adult (CYA) cancer. 
Childhood cancers (diagnosed in under 15-year olds) and cancers diagnosed in 
AYAs (between 15 to 24 years) are distinct from adult cancers but also from 
each other. Both age groups, for example, have their own cancer classification 
system (see Appendix A) (22,23) due to the need to classify the morphological 
features of young people’s tumours.  
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Incidence of cancer in children has increased internationally since the 1980s. 
This is partly due to better methods for diagnosis (24). Leukaemia accounts for 
a third of all childhood cancers, with 57% of cases in England diagnosed in 
under 5s (25). In England, incidence of cancer in AYAs (1,970 new cases in 
2014; incidence rate of 276 per million in 2011-2013) is higher than childhood 
cancer (1,412 new cases in 2014; incident rate of 152.9 per million in 2011-
2013), with most cases diagnosed in the 20 to 24 age group (1,261 cases in 
2014) (26). Lymphomas are the most common cancer in AYAs for both sexes. 
However, most female AYA cancers are carcinomas (including cervix and ovary 
cancer) and most male AYA cancer are germ cell tumours (including testicular 
tumours). These sex differences are not as apparent in childhood cancers (27).  
Cancer treatment is disruptive to daily life and usually consists of one or more 
therapies including surgery, radiotherapy, chemotherapy and immunotherapy. 
Once treatment ceases, the patient is labelled as a ‘survivor’, implying that they 
have overcome their illness. Some survivors incorporate this into their identity, 
whilst others view cancer as ‘a thing of the past’, particularly those diagnosed 
before 5 years old who may have no memory of treatment (28). This can be 
problematic for service engagement for follow-up care. Although a daily medical 
routine is not usually necessary (29), follow-up care is needed to prevent and 
manage late effects (LEs) right into adulthood (30). Many LEs are a 
consequence of cancer therapies and can depend on the type and intensity of 
the treatment (31). Around 74% of childhood cancer survivors will develop an 
LE such as cardiovascular disease (CVD), recurrent and/or subsequent cancer, 
endocrine diseases and neurocognitive deficits (32) with a third developing a 
severe or life-threatening condition (33).  
 
1.3.2 Type 1 diabetes (T1D). 
The incidence of T1D is higher in childhood (2,873 cases and incidence rate of 
26.5 per 100,000 in 2014-15 in under 16s in England and Wales) than in AYAs, 
peaking in the 10 to 14 year old age group (34,35). Unlike cancer, at present, 
there is no sub-categorisation of T1D at diagnosis. T1D is a homogenous 
disease where daily insulin administration is the standard treatment for all 
patients and continues into adulthood. The Diabetes Control and Complications 
Trial (DCCT) was a seminal study, showing that intensive insulin therapy (three 
or more injections) greatly reduced negative health outcomes in individuals with 
T1D (36). However, the treatment can be burdensome and difficult to manage. 
Insulin is either administered through multiple daily injections (MDI) or via 
continuous subcutaneous insulin infusion (CSII) therapy to maintain blood 
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glucose levels. Poor glycaemic control can lead to life-threatening acute 
complications such as severe hypoglycaemia where insulin levels become too 
high or DKA where there is not enough insulin in the body. In the long-term, 
poor T1D management can increase the risk of developing chronic 
microvascular (damage to small blood vessels) and macrovascular (damage to 
large blood vessels) complications (37). As blood vessels are present 
throughout the body, this can affect various organs, such as the eyes, kidneys 
and brain.  
CSII therapy is recommended by the National Institute for Health and Care 
Excellence (NICE) if a patient cannot maintain their HbA1c (glycated 
haemoglobin which measures average blood glucose for the last two to three 
months) target with MDI as it delivers insulin continuously and more precisely 
(38). CSII therapy provides added automation in insulin delivery compared with 
MDI. It involves the permanent attachment of a programmable pump device to 
deliver a basal rate of insulin throughout the day and bolus insulin during meal 
times (38). Although CSII therapy can offer more practical benefits compared 
with MDI, issues still arise with self-management of T1D during the transitional 
care period. Wearing a permanent device can be burdensome and can lead to a 
negative psychological association with the treatment (39,40) and limited clinical 
success. There is little published research on individuals with poorer clinical 
outcomes during CSII therapy and whether certain patient groups are more 
likely to discontinue CSII therapy during the transitional care period. This study 
compared health outcomes (i.e. HbA1c level as an indicator of T1D control and 
hospitalisation rate) between individuals who continued and those who 
discontinued CSII therapy, by socio-demographic groups. This provided 
evidence for health professionals and policy makers in determining whether 
discontinuing CSII therapy leads to an increased risk of negative health 
outcomes and whether certain groups of individuals need to be targeted for 
specific interventions during the transitional care period. 
 
1.4 Aims, objectives and hypotheses. 
The overall aim of this thesis was to use routine health data to assess health 
outcomes from the transitional care period (15 to 29 years) for individuals 
diagnosed with an LTC (cancer or T1D) in childhood (under 15 years) or young 
adulthood (15 to 29 years). Health outcomes included mortality for the Yorkshire 
Register of Diabetes in Children and Young People (YRDCYP) cohort and 
HbA1c levels and hospitalisations for the Leeds Children and Young People’s 
Diabetes Service (LCYPDS) cohort and hospitalisations (i.e. inpatient 
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admissions, accident and emergency (A&E) and mental health attendances and 
outpatient appointments) for the Yorkshire Specialist Register of Cancer in 
Children and Young People (YSRCCYP) cohort.  
It was hypothesised that there would be an increase in negative health 
outcomes during the transitional care period compared with before and after. 
This hypothesis was assessed using analysis of linked routine datasets. An 
increase in negative health outcomes during the transitional care period for 
contrasting diseases (T1D and CYA cancer) would provide evidence of the 
need for specialist transition services across diseases. Analysis by socio-
demographic (age, sex, ethnicity, deprivation) and clinical characteristics 
(cancer type, complication type, appointment attendance) would determine 
whether there is a need for further targeted interventions for specific groups of 
individuals.  
To achieve the overall aim, the following objectives were identified: 
1. Compare differences in health outcomes between different age groups 
before, during and after the transitional care period. 
This objective assessed whether the transitional care period was associated 
with an increase in negative health outcomes compared with younger and older 
age groups. An increase in negative health outcomes in the transitional care 
period would support the need for transitional health care. 
2. Compare health outcomes between individuals diagnosed with an LTC 
before and during the transitional care period.  
This objective assessed whether there were any differences in health outcomes 
depending on whether LTC onset occurs before or during the transitional care 
period. Any differences found between onset groups would indicate the need to 
consider age at LTC onset in transitional health care policy and practice. 
3. Compare health outcomes by socio-demographic groups (sex, ethnicity 
and deprivation). 
This objective assessed whether some socio-demographic groups have worse 
health outcomes compared to other groups. If any differences were found, this 
would provide evidence for the need of targeted care directed towards certain 
socio-demographic groups. 
The following objective was specific to the YSRCCYP cohort: 
4. Compare health outcomes by cancer type. 
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Due to the heterogeneity of CYA cancer types, health outcomes may differ 
between cancer types. This would provide evidence for the need of any cancer 
specific support. 
5. Compare health outcomes by hospital outpatient appointment 
attendance. 
This objective assessed whether attending outpatient appointments were 
associated with rates of inpatient admission, A&E or mental health attendance. 
If higher rates of appointment attendance were associated with lower 
hospitalisations, this would provide evidence for the importance of appointment 
attendance in reducing negative health outcomes. 
6. Compare health outcomes by mental health history. 
This objective assessed whether attending with a previous history of a mental 
health admission was associated with outpatient appointment attendance rates, 
inpatient admission rates and A&E attendances. If a higher hospitalisation rate 
or higher rate of non-attendance to outpatient appointments was found, this 
would indicate a need for specific support targeted at those with mental health 
issues. 
The following objective was specific to the LCYPDS cohort: 
7. Assess whether CSII therapy improves health outcomes. 
This objective assessed whether CSII therapy could improve health outcomes, 
particularly within the transitional care period. Analysis included comparisons 
between individuals who continued and those who discontinued CSII therapy 
whilst attending the LCYPDS. Health outcomes were assessed by CSII duration 
to determine whether any improvements were sustained. 
 
1.5 Outline of this thesis. 
The literature review in Chapter 2 includes three sections; a review of the 
concepts and issues around transition, health outcomes in T1D and health 
outcomes in CYA cancer.  
Chapter 3 describes the routine datasets that have been used in this analysis. It 
describes the source of the datasets, data linkage methodology and the 
cleaning rules to produce the final datasets. Methodology and statistical 
analyses used in each dataset are described separately in Chapter 4, Chapter 5 
and Chapter 6. 
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Chapter 4 includes the results of data analysis from the YRDCYP cohort linked 
to mortality data.  
Chapter 5 includes the results of data analysis from the LCYPDS cohort who 
started CSII therapy. 
Chapter 6 describes results from analysis on CYA cancer hospitalisation and 
mental health outcomes in the YSRCCYP cohort.  
Chapter 7 discusses the results from chapter 4 to 6 in detail, including the 
implications of the study and how this will direct future research in the topic of 
transitional health care. 
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Chapter 2 Literature review. 
This chapter provides a description of current practices and experiences of 
transitioning between paediatric and adult services and assessed whether 
potential factors during this process may influence short-term and long-term 
health outcomes. This involved reviewing studies from a variety of LTCs to 
assess common generalised issues surrounding transition. If an increase in 
negative health outcomes were to be found during the transitional care period, 
this section of the literature review would have assessed some of the reasons 
why these increases may have occurred.  
This chapter also identified short-term and long-term negative health outcomes 
associated with T1D and CYA cancer. For CYA cancer, only studies on LEs 
after the remission period were reviewed. The purpose of reviewing these 
negative health outcomes was to determine what routine datasets were needed 
for this study and which health outcomes were important to assess during 
analysis. 
 
2.1 Literature search methodology. 
EMBASE and Ovid Medline databases were used for three searches covering 
the topics of transition, outcomes of T1D and CYA cancer. A combination of 
mapped terms and keywords were used before restricting to full text availability, 
English language and human only research. Details of the search strategies, 
exclusion criteria and total of articles included for each topic are found in 
Appendix B. The relevance and quality of research papers were assessed by 
using a standardised checklist for qualitative studies (41), case-control studies 
(42), cohort studies (43) and systematic reviews (44).  
 
2.2 The transition process. 
Most studies on the topic of transition focused on a single LTC. These LTCs 
included epilepsy, inflammatory bowel disease, end stage renal disease, human 
immunodeficiency virus, sickle cell disease, cerebral palsy, transplant 
recipients, cystic fibrosis and juvenile idiopathic arthritis, as well as CYA cancer 
and T1D. Studies on mental health, autism and attention deficit hyperactivity 
disorder were also included. The majority of these studies included individuals 
who were diagnosed with an LTC during childhood. There were few studies 
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which included AYAs who were diagnosed during the transitional care period. 
All studies either used small scale interview or survey data to describe the 
experience of transition prior to the transfer event. Few empirical studies 
compared models or interventions of transition or outcomes of transition. 
Therefore, this review was based on qualitative or survey research from small 
samples, so may suffer from selection bias, creating difficulty in generalising 
these results to the general population.  
The period before the transfer event was often referred to as ‘transition 
preparation’ or ‘transition planning’. Although there is consensus that the 
transition process should be individualised according to a patient’s needs, there 
have been attempts to standardise transition preparation by expert working 
groups to help reduce the variation in the transition experience that is often 
found between different organisations and specialities (45–47). There are some 
overlaps in recommendations between groups, although these often refer to a 
single LTC. The NICE guidelines on transition from paediatric to adult services 
for England and Wales cover all chronic illnesses and recommend the inclusion 
of key components in transition planning. These include starting the transition 
process early, having a named worker to coordinate the transition, involvement 
from the patient, building independence in the patient and involvement from 
parents/caregivers (20). Each of these components are discussed below, 
followed by an examination of how transition has been measured. 
 
2.2.1 Starting the transition process at an early age. 
A major theme from interview and survey data for AYAs diagnosed with a LTC 
during childhood was a desire to start the transition process early and gradually 
taking more responsibility that was developmentally appropriate (47–49). 
Opinions on the recommended age ranges for the start of transition varied 
between studies from 11 to 15 years (46,50,51). In practice, some individuals 
did not start the transition process until after this age range, with some patients 
and parents reporting to have not received any transition preparation at all 
(48,52–54). Few studies suggested a better experience for the patient when the 
transition process began at a later starting age (55,56). Among Brazilian 
rheumatology clinicians, 88% who were surveyed said that transition 
preparation should start from 15 years, with 60% stating 15 to 17 to be the 
optimal age (57). However, it was not apparent from these studies as to 
whether ‘transition’ was clearly distinguished from ‘transfer’ or at least there was 
no defined event to signify the start of transition. In some studies, the first 
conversation with the paediatric provider around transition has been used as 
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the starting point of transition (52–54), although there was no mention of a 
requirement to formally record when these conversations occurred or what 
content should be included. Eklund and colleagues found that although 75% of 
a sample of 91 patients with attention deficit hyperactivity disorder had no 
discussions around transition with professionals, the other 25% had said the 
discussion was only brief (54). Because of this subjectivity at the beginning of 
the transition process, this has created difficultly in measuring transition. There 
are no standardised methodologies to quantify how many individuals have 
started the transition process, so completing a needs assessment and 
measuring the quality of transition services cannot be achieved (58).  
 
2.2.2 Involvement from a transition coordinator. 
From the patient’s perspective, lack of coordination between paediatric and 
adult services was commonly reported (59–61) and was often a reason reported 
for disengagement in adult services (48,59–65). To navigate between the 
paediatric and adult services, a single named worker could be a useful 
coordinator during the transitional care period between the services 
(8,20,55,57,66,67). The NICE guidelines recommended a named worked for 6 
months before and 6 months after transfer event at a minimum (18). However, 
there was a lack of evidence to support the view that the presence of a 
transition coordinator makes a positive contribution to the transition experience. 
In a study by Jensen and colleagues, a social worker transition coordinator 
improved satisfaction at a transition clinic for rheumatology diseases, although 
satisfaction levels were still low at 42% (68). In contrast, a transition coordinator 
who also provided psychosocial interventions to a group of 27 rheumatology 
patients had higher levels of psychological wellbeing compared with 23 
individuals receiving conventional treatment (69). Access to psychosocial care 
and mental health services was deemed to be important during the transitional 
care period in a number of studies (46,60,70–72), although in practice, few 
individuals had access to these services (57,64).  
From a provider perspective, paediatric providers tend to find transition 
coordinators more useful compared with adult providers (45). Although there 
was general consensus that both paediatric and adult services were responsible 
for transition, a cultural norm persists where all transitional work and the 
success of transition depends on paediatric services (50,63,73–76). Few 
studies assessed whether the adult service that AYAs transitioned to was 
adequate or appropriate (57,77–79). Many adult providers reported a lack of 
training around transitional issues (57,80) and a lack of specialist adult services 
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for some childhood LTCs, making them feel unprepared to take on AYAs 
(63,67,81). However, positive moves have been made to improve collaboration 
between services and to provide better staff training in adult providers on AYA 
and transition issues (60,73,82,83). 
 
2.2.3 Independence and involvement of patient. 
Surveys with health professionals found that the main reasons for deciding 
when a transfer event took place were due to external factors with no 
involvement in decision making from the patient. These factors included the 
patient’s age, patient’s moving away from home, the need for more resource for 
new paediatric patients or whether the patient had children of their own (57,59). 
Without patient involvement in decision making during the transition process, 
patients reported higher levels of anxiety surrounding transfer, even if they felt 
too old for paediatric care (48,57,81,84–87).  
Including patients in decision making around their care increased feelings of 
control and reduced anxiety, as well as increasing the level of independence 
and responsibility to deal with their illness. Professionals agreed that AYAs 
need to be assessed for a certain number of skills (e.g. gathering knowledge 
about their illness, self-efficacy, self-advocacy, decision making and problem 
solving) before deciding whether they can be transferred to adult care (51). 
Readiness tools have been developed to assess these skills, either by the 
patient themselves, parents or clinicians. There was no data on the use of 
readiness tools in the UK as they are not mandatory during the transition 
process. In the USA, the use of these tools tend to differ between different 
LTCs, suggesting differences in approaches to transitional care between 
paediatric providers (88,89).  
Due to differing expert opinion as to which skills are most important in adult 
services, tools lack consistency and standardised criteria to determine 
readiness (50). In a review of 10 readiness tools, it was found that some tools 
included knowledge of illness, whilst others focused on self-management. There 
was also a lack of validation for these tools using more than one study and most 
were disease specific (90). Another criticism of these tools was that there has 
been no consideration of weighting for more important skills. For example, Hait 
and colleagues surveyed adult gastroenterologists in the USA (34% response 
rate) who scored knowledge about medications, prior medical history and 
impact of smoking and drugs as more important during transition. Less 
important skills were attending appointments alone and researching condition 
outside appointments. However, these assessments are based on opinions with 
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no evidence to determine which skills lead to better health outcomes after 
transition (91).  
Readiness tools rarely included assessment of emotional readiness or life 
events (90,92,93). Garvey and colleagues suggest a distinction should be made 
between ‘preparation’ (practical skills and knowledge) and ‘readiness’ (the 
emotional and psychosocial) (95), as some patients reported feeling that they 
did not necessarily need to have all the skills to be ready to transfer to adult 
care (51,96–98) and that confidence and maturity were more important factors 
(51,77,99). It can be argued that adults themselves do not always have the 
required knowledge and skills on which AYAs are assessed on, with a lack of 
research on preparation or readiness conducted in adult care.  
 
2.2.4 Inclusion of family members. 
Parental presence is not usually expected in adult services and parents have 
experienced exclusion from these services (77,100). Although it is assumed that 
there would be a correlation between increased independence in AYAs with 
decreasing involvement from parents, qualitative studies show that even though 
many AYAs want to be more independent, they still want their 
parents/caregivers involved in their treatment (47,48,61,70,91,101,102). The 
role of the parent shifted from supervisory involvement to consultant presence 
(48,77). Some AYAs described wanting their families present for emotional 
support and as a backup when they could not remember certain details. For 
example, cancer survivors who were diagnosed and treated before 2 years had 
little or no memory of their illness and were more likely to rely on their parents 
for detailed knowledge of the experience (87). However, balancing parental 
involvement with increased independence can be a challenge. Annunziato and 
colleagues found that when more independence was given to adolescent 
transplant recipients, they showed increased non-adherence to medications. 
Increased parental monitoring was associated with improved adherence (70). 
However, no studies were found to assess whether this non-adherence was 
associated with worse outcomes, particularly in the longer term. It may be that 
‘helicopter parenting’, where parents struggle to let go of the primary 
responsibility of their child’s healthcare can prevent independence and self-
management in AYAs (49,57,60,66,103) leading to disengagement during 
appointments as they assume their parents will retain all the knowledge (61). 
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2.2.5 Differences in transition between socio-demographic groups.  
Stollen and colleagues found that paediatric professionals for sickle cell disease 
viewed socio-demographic factors as having an influence on the transition 
experience (104). Evidence for this statement comes from the 2009-10 National 
Survey of Children with Special Health Care Needs (NS-CSHCN) in the USA 
where transition preparation was more likely to occur in older children and 
females compared with younger children and males. The most important factor 
in whether transition preparation occurred was the ability for parents to 
communicate with health professionals to increase their medical knowledge 
(8,105,106). Patient knowledge was associated with income levels for 19 to 32-
year old cancer survivors who attended a transition clinic in the USA. Those 
with an income from $10,000 to $24,999 had less knowledge of their diagnosis 
than any other income group, including the under $9999 group where 74% were 
students (107). Despite these reported differences in knowledge, no association 
has been found between socio-demographic groups in readiness for transfer 
(52).  
Cheak-Zamora and colleagues found that 21% of individuals with autistic 
spectrum disorder (ASD) from the 2005-06 NS-CSHCN received transition 
preparation, compared with 43% of non-ASD individuals. Only 45% of ASD 
individuals were encouraged to take more responsibility for their health care 
compared with 74% of non-ASD individuals (108). This suggests that the type of 
LTC may also influence the experience of transition preparation (109).  
There was only one study that evaluated the difference between those who 
were diagnosed before and during the transitional care period. AYAs with 
inflammatory bowel disease who transitioned from paediatric to adult services 
had lower non-adherence rates to medications (13.2%) than those who were 
diagnosed and treated in adult services only (24.4%), although the difference 
was not significant (110).  
 
2.2.6 Measuring successful transition. 
With no standardised definition of the starting event for the transition process, 
the end point of transition is also unclear (51). This means that just as there is 
no method for measuring transition preparation, there is also no consensus of 
measuring the success of transition (8,111). Some studies have attempted to 
define successful transition by appointment attendances in adult services, 
varying from one clinic visit within 3 months or up to 1 year after transfer 
(52,112–114). Besides the financial cost, the effect of missed appointments is 
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not well known, including whether there is an implication for increased A&E 
attendance and complications. However, non-attendance does not necessarily 
mean non-adherence. Successful self-management may mean that 
appointments are only attended for treatment issues. Koshy and colleagues 
examined the transition period and outcomes in 115 patients with renal 
transplants in Canada and found that although there was less hospital contact 
after transition, there was no increased risk of allograft loss. Therefore, 
attendance only cannot fully assess the degree of successful transition (116).  
The problem with using appointment attendance and biomedical outcomes as 
measures of successful transition is that they do not consider the 
multidisciplinary nature of transition (117). In a Dutch survey of 433 young 
adults (18 to 25 years) diagnosed with an LTC, five indicators were used to 
assess successful transition, including whether the patient was lost to follow-up, 
the number of missed appointments 3 years after transfer, quality of relationship 
was with adult provider, self-management and family satisfaction (118). 
 
2.2.7 Overview of the transition process. 
Qualitative evidence on the transition process provided examples of where 
discrepancies appear between clinical recommendations and current practice, 
such as starting the transition process at a later age, having no access to a 
transition coordinator, having no direct involvement of patients in decision 
making regarding the timing of the transfer event and no choice in involving 
parents/caregivers at appointments after transfer. These discrepancies were 
reported to have contributed to a negative experience of transition. Although 
NICE recommendations were aimed to bring standardisation of transitional 
health care across services in England and Wales, there is still a lack of 
consensus in definitions of key concepts, particularly the start and end points of 
the transition process. This imprecision makes it difficult to quantify whether 
these discrepancies are associated with health outcomes. Quantitative analysis 
of survey data has provided some assessment of differences between socio-
demographic groups in whether transitional care was received. However, this 
was not applied to the assessment of health outcomes.  
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2.3 Health outcomes of type 1 diabetes (T1D). 
2.3.1 Acute complications. 
The two most common types of T1D acute complications requiring 
hospitalisation are DKA and severe hypoglycaemia, with both complications due 
to poor treatment management. DKA occurs from deficient insulin levels 
resulting in high blood glucose levels, whilst severe hypoglycaemia occurs 
when blood glucose is low, which can be a consequence of too much insulin 
(119–122). In a Scottish register of all individuals with T1D, a j-shaped 
association was found between HbA1c levels (glycated haemoglobin which 
measures average blood glucose for the last two to three months) with the odds 
of a hospital admission, particularly DKA admissions with higher HbA1c levels. 
There was no increased admissions at low HbA1c levels due to severe 
hypoglycaemia (123). This supported the trend in other studies where 
hospitalisation rates for DKA were higher than for severe hypoglycaemia 
(124,125). For example, in England and Wales, 5% and 2.3% of children with 
T1D were admitted to hospital with DKA or severe hypoglycaemia, respectively 
(126). However, this did not include cases of severe hypoglycaemia where 
assistance was required from ambulance treatment, without a hospital 
admission. In a study of 10 NHS Diabetes centres in England and Wales, 71% 
of self-reported cases of severe hypoglycaemia over a 2-year period were 
attended to by ambulatory care with only 21% of these cases admitted to 
hospital (127). This suggests that not all cases of severe hypoglycaemia were 
being captured by hospital admissions data only, creating an underestimation of 
severe hypoglycaemia rates (123).  
CSII therapy has shown success in reducing HbA1c levels (128–136). However, 
there were mixed results as to whether CSII therapy can also decrease 
hospitalisations due to acute complications. Studies examining HbA1c levels in 
CSII therapy commonly used t-tests or ANOVAs to assess mean HbA1c before 
and after CSII initiation. These statistical methods are problematic as they do 
not account for repeated data within the same individuals, thus violating the 
assumption of independence between observations and resulting in flawed 
conclusions (137). To overcome this issue, multi-level modelling was used to 
account for repeated measures when analysing data from a previous study of 
the LCYPDS cohort. An overall reduction in mean HbA1c of 6mmol/mol (95% CI 
3 to 9mmol/mol) (0.5% (95% CI 0.3 to 0. 8%)) was found after one year of 
starting CSII therapy. There was also a reduction of hospital admissions 
incidence due to severe hypoglycaemia from 8.9 to 2.4 per 100 person years 
(138). This supports other studies where mild and severe hypoglycaemia 
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decreased following the introduction of CSII (130,132,135,139–145). Few 
studies have found no change in rate of severe hypoglycaemia after starting 
CSII (136,146).  
Studies examining DKA rates with CSII therapy have shown inconsistent 
results. Some studies have reported lower admissions with CSII therapy 
(128,134,140,141,145), some have reported no change at all with CSII therapy 
(136,143,146,147), whilst other studies have reported higher DKA 
hospitalisation rates with CSII therapy (131,144,148), including the latest 
National Paediatric Diabetes Audit (NPDA) report (126). This suggests that CSII 
therapy was beneficial in reducing rates of severe hypoglycaemia, but it was 
unclear as to whether CSII therapy reduces DKA. 
Despite the success of reducing HbA1c levels with CSII therapy, some 
individuals have reported difficulties in using the CSII device and returning to 
MDIs (39,40,149). Only one previous study has examined characteristics for 
individuals who discontinued CSII, where it was found that females were more 
likely to discontinue (150). There was little published research into the 
characteristics of individuals with poorer clinical outcomes during CSII therapy.  
 
2.3.2 Chronic complications. 
Common microvascular complications include diabetic nephropathy, diabetic 
retinopathy and neuropathy (151). In the DCCT cohort, it was found that 
intensive insulin treatment has been effective in reducing these complications 
by maintaining good HbA1c level and has been shown to reduce the risk of 
developing retinopathy by 76% and neuropathy by 60% compared with 
conventional treatment (36,152). After 8 years in the DCCT, despite the control 
group having similar HbA1c levels than the intensive group, the intensive had 
less retinopathy. This suggested that starting good HbA1c management as 
soon as possible after diagnosis contributed to good ‘metabolic memory’. This is 
where early intensive insulin treatment has a continued effect and can delay 
retinopathy and slows progression (153). This has great importance in AYAs, 
where there has been recent evidence that retinopathy and nephropathy 
(kidneys) complications can start to develop during the transitional care period 
(154–157).  
The DCCT also found that intensive insulin therapy reduced the risk of 
macrovascular complications, although the risk reduction for CVD was less than 
half for retinopathy and neuropathy at 30% after a 30 year follow-up (158).  In a 
Scottish T1D registry of individuals over 19 years between 2005 to 2007, the 
risk of CVD was found to be two to three times greater compared with the 
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general population and higher in females compared with males (159). CVD 
events in this study were defined as hospital admissions with International 
Classification of Diseases (ICD)-9 codes 410–414 and ICD-10 codes I20–I25, 
so excluded any CVD events recorded under a diabetes-related ICD code, thus 
possibly providing an underestimation of prevalence in the cohort.  
The brain has shown to be particularly susceptible to glycaemic extremes in 
AYAs during development, where recurrent DKA and severe hypoglycaemia 
were associated with longer term consequences on brain development (160–
162). Neuroimaging has shown some differences between T1D and non-T1D 
population in the brain with more white matter hyperintensities observed in T1D 
individuals compared with a non-T1D control group (163). White matter 
hyperintensities occur due to cerebral microvascular damage and is linked to 
neurocognitive problems, such as slower information processing, memory and 
language problems (161,164–166). Despite these neurological issues occurring 
more in the T1D population, there was no evidence that school performance 
was different from the non-T1D population (161,167). As school achievement 
may be associated with quality of life and deprivation levels in adulthood, this 
was a positive finding. However, these findings were based on small samples, 
so more research is needed to assess whether these results apply to larger 
populations. 
Although there was no evidence for detrimental academic performance, 
intensive insulin therapy may affect quality of life due to the negative 
psychological impact of a burdensome treatment. The rates of depression in 
T1D were found to be higher compared with the general population (168). 
Factors within the T1D population that increased the odds of depression 
included high HbA1c levels and rates of acute complications (149,168–171), 
being female (149,170), being part of an ethnic minority or having lower income 
and education achievement level (171).  
 
2.3.3 All-cause and cause-specific mortality. 
Despite the success of reducing risk of complications, intensive insulin therapy 
has only led to a slight reduction in overall mortality risk of 1/1000 patient-years 
with an additional 6.5 years of intensive insulin treatment during a 27-year 
follow-up period (172). An excess number of deaths has been found in T1D 
populations compared with the general population in 17 cohorts in a review of 
23 studies from different countries, with the highest standardised mortality rate 
(SMR) at 8.54 in a Cuban study (173). An overall SMR of 2 (95% CI 1.7 to 2.2) 
was calculated from 13 European registries, including a subset of the YRDCYP 
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cohort containing early T1D onset (under 15 years) individuals diagnosed since 
1989. The YRDCYP had the second highest SMR of all 13 registries at 4.2 
(95% CI 2.2 to 5.6) (174). This was similar to the SMR compared with the 
general population of England and Wales found in a previous study of the 
overall YRDCYP cohort including late T1D onset (15 to 29 years) diagnosed 
from 1978 at 4.7 (95% CI 3.8 to 5.6) (175).   
By age at onset, this previous study of the YRDCYP found a non-significantly 
higher SMR in the late onset group (15 to 29 years) compared with the early 
onset group (6.2 (95% CI 4.3 to 8.6) vs 4.2 (95% CI 3.2 to 5.5)) (175). Higher 
risk of mortality in late onset compared with early onset was also found in a 
Finnish cohort, particularly for deaths due to acute complications of T1D (176). 
Few population registries have included individuals with late T1D onset in 
mortality, so research into potential differences between onset groups is sparse. 
However, studies have shown that death due to acute complications was the 
leading cause of death for under 30 year olds, whilst CVD was the leading 
cause of death for older adults (177–183). As with complications, increased risk 
of death has often been linked with increases in HbA1c (184–187) which are 
difficult to control in AYAs who have the highest HbA1c levels due to changes in 
insulin resistance during puberty (188,189). Both the National Diabetes Audit 
(NDA) and NPDA showed the need for national improvements to raise 
standards of care for individuals with T1D, as only a third in England and Wales 
receive all necessary annual care processes, with less than 20% of individuals 
actually reaching recommended targets for HbA1c, blood pressure and 
cholesterol (190,191).  
The SMR for all-cause mortality was found to be higher in females than males 
in a number of studies (174,192–196). Studies examining sex differences for 
cause-specific mortality have shown mixed results with one study showing 
higher mortality for females in diabetes-related causes of death compared with 
males (177), whilst in a Norwegian cohort, the risk of death in women from 
acute complications was half than in women compared with men (182). The 
DCCT cohort also found that there were nominally more suicides in the 
intensive treatment group (n=5; 11.6%) compared with the conventional 
treatment group (n=2; 3.1%), although there were only a total of 7 deaths due to 
suicide in total, so these results cannot be generalised to population level (172). 
Socio-economic status has also been found to affect the risk of mortality, with 
an increase in risk found in the most deprived group for individuals diagnosed 
with early T1D onset (186,197–199). Conway also reported a high excess of 
deaths in the most deprived groups and found that the excess was higher in 
African Americans compared with white Americans (200), suggesting that 
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ethnicity may be a more important risk factor for mortality than deprivation. The 
Allegheny cohort in the USA also found differences in ethnic origin, where 
excess deaths due to acute complications were found in individuals with black 
ethnicity (201,202). There were no studies found exploring the association 
between ethnicity and mortality in the UK.  
 
2.3.4 Summary of type 1 diabetes (T1D) health outcomes. 
Maintaining good glycaemic control can be beneficial in preventing and delaying 
onset of T1D complications, especially when good self-management skills are 
implemented as early as possible after T1D diagnosis. This means that good 
HbA1c control during the transitional care period is vital in reducing the risk of 
negative health outcomes, not just in the short-term but also in the long-term. 
There was some evidence to suggest that AYAs have issues with self-
management, as it was shown that deaths from acute complications are 
increased at ages during the transitional care period. CSII therapy may be a 
suitable treatment option for AYAs as it was shown to be effective in reducing 
HbA1c, although there was less convincing evidence that hospitalisations were 
reduced. There was also a lack of research on individuals who are most likely to 
discontinue with CSII therapy and may need additional support.   
 
2.4 Health outcomes of childhood and young adult (CYA) 
cancer. 
Many LEs are due to treatments in children where they are more prone to later 
issues during organ development (203) and can depend on the type and 
intensity of the treatment (31). LEs can be categorised by CVD, subsequent 
cancer, endocrine (including fertility) and neurocognitive (32). Compared with 
samples from the general population, 5-year childhood cancer survivors were 
shown to have an excess in hospitalisations. The Childhood Cancer Survivor 
Study (CCSS) in the USA found a 1.6-fold risk of hospitalisation in survivors 
(204), whilst in a Dutch cohort the risk was 2.2-fold (205). 
 
2.4.1 Cardiac and Cardiovascular disease (CVD). 
Anthracyclines are commonly used in chemotherapy to treat a variety of cancer 
types, but has shown to have side effects resulting in direct cardiac injury due to 
the formation of free radicals and cardiotoxic alcohol metabolites. There may 
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also be an association between cancer therapies with the development of CVD 
due to an increase in insulin resistance such as lipid abnormalities, adiposity 
and hypertension (206). Using speckle tracking echocardiography for patients 
treated with anthracyclines, there was evidence of cardiotoxicity from after a 
year of treatment (207). Although it was not known whether this had led to 
future cardiac disease, other studies have shown that high dose heart radiation 
and anthracycline treatment was associated with risk of cardiac disease 
congestive heart failure (208–210). Compared with the general population, 
Kearney and colleagues used echocardiograms at rest and during exercise and 
found that cancer survivors had comparable left ventricle function with controls 
during rest but had reduced function compared with controls during exercise. 
Once a cancer patient gets cardiac dysfunction, the outcome was poor with 
50% survival rate after 5 years (208,210). In the British Childhood Cancer 
Survivor Study (BCCSS) cohort of 34,489 5-year survivors, there were 3.4 times 
the expected total of cardiac deaths. The BCCSS also found that excess deaths 
have reduced since the 1980s, coinciding with a reducing of anthracycline 
levels in cancer treatments (211).  
For CVD, a recent systematic review of 63 papers which included individuals 
diagnosed with cancer at 25 years and under found an average weighted 
prevalence of 19.7% for hypertension and 2.3% for stroke, although there was a 
lack of studies in the review which looked at socio-demographic factors or 
cancer type (212). Previous analysis on the YSRCCYP did find a difference in 
CVD between age at diagnosis groups, with an excess 3-fold risk of developing 
CVD for childhood cancer survivors compared with the general population, 
although no significant excess is CVD was found for those diagnosed during the 
transitional care period (15 to 29 years) compared with the general population 
(213). However, for cerebrovascular events (including cerebral haemorrhage, 
cerebral infarction and subarachnoid haemorrhage), the Teenage and Young 
Adult Cancer Survivor Study did find a higher excess for those diagnosed 
during the transitional care period. Of the 178,962 15 to 39-year olds diagnosed 
with cancer in England and Wales between 1971 and 2006, there was a 40% 
increased risk of hospitalisation for a cerebrovascular events compared with 
general population, with the highest risk for those who were diagnosed in the 15 
to 19-year age group by 3.6-fold (214). 
 
2.4.2 Subsequent malignant neoplasms. 
Subsequent malignant neoplasms are distinct from initial cancer diagnosis. 
Pooled analysis from four studies showed a radiation dose-related association 
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with increased risk of developing thyroid cancer in childhood cancer survivors, 
where the risk remained higher after decades since initial radiation treatment, 
with or without chemotherapy (215). Although beyond moderate doses of 
radiation, the risk of thyroid cancer plateaus, possibly due to cell death (216). A 
reduction in risk developing subsequent cancers in the 1990s was found 
compared to the 1970s, coinciding with reductions in radiation intensity and 
dosage in cancer treatment (217). 
The BCCSS found that the most common subsequent cancers in 17,981 5-year 
childhood cancer survivors were central nervous system (CNS) neoplasms, 
breast cancer, non-melanoma skin cancer, digestive, genitourinary. Those who 
were initially diagnosed with CNS neoplasms, leukaemias, Hodgkins lymphoma 
and Wilms tumours had the highest percentages of subsequent cancers (218). 
This was similar to the CCSS in the USA where individuals initially diagnosed 
with Hodgkins lymphoma, leukaemia, soft issue, bone and CNS neoplasms had 
the highest percentages of subsequent cancers. There was a cumulative 
incidence of 9.3% for a subsequent cancer after 30 years follow-up of initial 
cancer diagnosis in 14,358 childhood cancer survivors with 5-year survival. 
Females and young age at initial cancer diagnosis were risk factors for 
subsequent cancer compared with males and older age group, respectively 
(219).  
 
2.4.3 Endocrine conditions. 
Around 57.6% of childhood cancer survivors have at least one endocrine 
condition (220). Endocrine conditions due to high dose radiation, chemotherapy 
exposure and stem cell transplantation include growth deficiency (221), reduced 
bone health (32,222–224) and fertility issues (225).  
In a Dutch cohort of 573 childhood cancer survivors, around 10% of the cohort 
had a significantly reduced height in adulthood. A radiation dose-related 
association was found where those who had higher doses of radiotherapy 
during cancer treatment had significantly shorter height in adulthood, with 
greatest height loss in individuals who received total body radiation and 
craniospinal radiation. This could be due to spinal radiation causing skeletal 
damage in the spinal column and cranial radiation causing damage to the 
hypothalamo-pituitary axis, which can both lead to growth reductions (226). This 
theory could be supported by a study of brain tumour survivors, where growth 
was found to be impaired for a higher percentage of individuals at 60%, which 
included individuals with a growth hormone deficiency (227). 
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Fertility issues have been shown to arise when children were treated for cancer 
during puberty. For females, radiotherapy has been associated with damage 
and size reductions to both the ovaries and uterus, which can lead to adverse 
fertility and pregnancy outcomes such as infertility, miscarriage and low 
birthweight (228–230). Those who received pelvic, spinal or total body radiation 
were at increased risk of these adverse outcomes due to uterine volume. 
Individuals who received chemotherapy during cancer treatment were found to 
be at risk for ovary deficiencies only. Hodgkin lymphoma survivors were found 
to have the greatest reductions in ovarian reserve compared with individuals 
diagnosed with leukaemia, sarcoma and other lymphomas (230). Despite these 
deficiencies, there was no evidence for an increase in adverse pregnancy 
outcomes compared with the general population (231–233).   
Fertility issues were also reported in males survivors. Azoospermia has been 
reported in 18% of male survivors in a Swedish cohort (225). Almost 80% of 
males who have conceived were reported to be able to do so naturally (234). 
These studies are descriptive and there were no studies with comparison to the 
general population.  
 
2.4.4 Neurocognitive deficits. 
Compared with sibling controls, survey data from the Swiss Childhood Cancer 
Survivor Study reported a higher percentage of childhood cancer survivors who 
had cognitive deficiencies (20% vs 40%), with highest risk in individuals 
diagnosed with CNS neoplasms and individuals who received cranial radiation 
with or without chemotherapy during treatment (235). These cancer treatments 
increased the risk of damage to neurons and a reduction in progenitor cells in 
the hippocampus, particularly during brain growth (236). Survivors of paediatric 
brain tumours were shown to have lower hippocampal, putamen and whole 
brain volume compared with controls (237). This can create problems with 
memory and attention (235,237,238). Other reported cognitive deficits included 
language, mathematics and perceptual motor skills in survivors of CNS 
neoplasms, acute lymphoblastic leukaemia and non-Hodgkin lymphoma 
(32,237,239,240). 
Exposure to cranial radiation was also associated with increased rates of 
depression in non-Hodgkin lymphoma survivors (241). However, it was not clear 
if this was due to deficits in the brain or whether cancer survivors, regardless of 
diagnosed cancer type, experienced lower quality of life compared with the non-
cancer population (238). Recklitis and colleagues found an association between 
health outcomes and suicide ideation, particularly those with CNS neoplasms 
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who had more neurocognitive difficulties affecting occupational, educational and 
social life circumstances (242). A significant association between psychological 
disorder and quality of life was found in a French study including childhood 
cancer survivors and controls, with a higher risk of psychological disorder and 
alcoholism in survivors compared with the general population (243).  
Schwartz and Drotar (2006) found that although most childhood cancer 
survivors had adjusted well into young adulthood (18 to 28 years), childhood 
cancer survivors were 5 times more likely to develop post-traumatic stress 
disorder (PTSD) compared with the general population (odds ratio 4.67 95% CI 
(1.14 to 19.15)) (244).  Although PTSD has been linked to post-traumatic 
growth in other life-changing stressors (e.g. physical assault or terrorist attack), 
there was weak evidence that this occurred in cancer survivors, possibly due to 
multiple stressors and no real end-point in trauma (245,246). Cancer diagnosis 
during adolescence and treatment severity were also found to be possible risk 
factors for psychosocial issues (247). Good relationships with providers, family 
and peers have been show to provide great support for AYAs with cancer 
during the transitional care period (248).  
 
2.4.5 Summary of childhood and young adult (CYA) cancer health 
outcomes. 
LEs are varied in CYA cancer survivors as they depend on the type and 
intensity of the treatment received during their primary cancer diagnosis. 
Although the incidence of LEs have been reducing over time due to a decrease 
in the intensities of treatments, there is still an excess of hospitalisations in 
survivors compared with the general population. It is important that survivors 
are monitored after treatment completion, particularly during the transitional 
care period to detect developmental deficiencies and to provide any additional 
psychosocial support. Appointment attendance has been used as a measure for 
successful transition in previous studies from other LTCs. However, these 
studies have rarely assessed whether appointment attendance was associated 
with long-term outcomes.   
For both T1D and cancer, existing studies have mostly included cohorts with 
early disease onset diagnosed before 15 years. There were few studies which 
compared health outcomes between individuals diagnosed before and during 
the transitional care period. There has also been a lack of assessment between 
socio-demographic groups, particularly for ethnicity and deprivation. 
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2.5 Chapter summary. 
This chapter summarises current experience and practice of transitional care 
across multiple LTCs and explored the difficulties in achieving standardisation 
of care which may affect the risk of negative health outcomes. These negative 
health outcomes for T1D and CYA cancer were also assessed to help 
determine which routine datasets were to be used for analysis. Descriptions of 
these routine datasets, alongside data linkage and data cleaning methodology 
before data analysis are described in Chapter 3.  
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Chapter 3 Routine datasets. 
The registry data analysed in this study were the Yorkshire Register of Diabetes 
in Children and Young People (YRDCYP) and the Yorkshire Specialist Register 
of Cancer in Children and Young People (YSRCCYP). These were population-
based registers for individuals diagnosed with T1D (YRDCYP) and cancer 
(YSRCCYP) before 30 years of age (249,250). Both these registers had data 
collected over at least a 35-year period, providing a lengthy follow-up time to 
assess long-term health outcomes. These datasets were linked to other routine 
datasets for analysis of health outcomes. In addition, data from T1D patients 
receiving CSII therapy at the Leeds Children and Young People Diabetes 
Service (LCYPDS) were analysed to assess whether CSII was effective in 
reducing negative health outcomes in the transitional care period.  
Each of the routine datasets used in this study were collected for different 
purposes. They were compiled over different time periods and geographical 
coverage, using different sources of information and data collection 
methodologies. This meant that each dataset had their own unique issues in 
data cleaning and data linkage. In this chapter, details on data collection, data 
cleaning and data linkage methodology to other routine datasets are described 
for each disease cohort. Methodology for statistical analysis for each cohort is 
presented separately alongside the results in chapters 4, 5, and 6.  
 
3.1 Yorkshire Register of Diabetes in Children and Young 
People (YRDCYP). 
The YRDCYP is a population-based register of all individuals diagnosed with 
T1D, identified from all specialist diabetes services, hospital admissions with a 
diabetes discharge and primary care records, within the former Yorkshire 
Regional Health Authority (YRHA). Data were extracted from clinical notes from 
these sources to provide diabetes diagnosis (diabetes type and diagnosis date) 
and demographic information (full name, sex, date of birth, address and 
postcode of residence at diagnosis) (249–251).  
 
3.1.1 Age at type 1 diabetes (T1D) onset group classification. 
The YRDCYP began collecting data retrospectively in 1989 on individuals 
diagnosed with early T1D onset (diagnosed in children under 15 years) and 
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treated in the former YRHA from 1978 (Figure 3.1). The region currently has an 
estimated population of 4 million (7% of the population of England and Wales) 
(252). From 1991, the YRDCYP extended the data collection criteria to include 
late T1D onset (diagnosed in young people aged between 15 to 29 years). The 
YRDCYP currently includes data up to 2013.  
 
Figure 3.1: Map of the former Yorkshire Regional Health Authority (YRHA). 
Due to consent issues, only data on individuals with early T1D onset who were 
resident in the YRHA at T1D diagnosis, and data on individuals from the late 
T1D onset group who were resident in West Yorkshire (Bradford, Calderdale, 
Kirklees, Leeds and Wakefield) at T1D diagnosis since 1991 could be included 
in the analysis. West Yorkshire comprised of approximately 57% of the total 
YRHA population (253). Any individuals who were resident outside the 
designated geographical area were excluded from this study. 
 
3.1.2 Ethnicity classification. 
Data on ethnicity were inconsistently recorded on the YRDCYP. Imputation for 
ethnicity was completed using a software algorithm called Onomap, which 
calculated probability scores for ethnic categories using full name. Although 
there were some sensitivity issues for classifying non-British ethnicities, 
Onomap had the advantage over other ethnicity algorithms by using multiple 
dimensions of identity (religion, geographic origin, ethnic background and 
language) for classification and by having a larger coverage of ethnic groups 
compared with other algorithms (254).  
Individuals with incomplete full names could not be used by Onomap and were 
classified with an unknown ethnicity. Any individuals with names classified by 
Onomap with an ambiguous origin were also classed with an unknown ethnicity. 
Figure	1.	Map	of	the	former	Yorkshire	Regional	Health	Authority	(YRHA),	UK
Yorkshire	Regional	Health	Authority
Yorkshire	Regional	Health	Authority	– West	Yorkshire
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3.1.3 Deprivation classification. 
Each individual in the YRDCYP cohort was assigned a deprivation score from 
the Townsend index, according to their ward area (derived from postcode of 
residence at the time of diagnosis). The Townsend index calculated deprivation 
using variables from the UK decennial census (unemployment, overcrowded 
households, car/van ownership, home ownership) (255). Townsend scores and 
ward areas were calculated from the census year 2001. This census year was 
chosen as this was approximately midway of the cohort period. Ward areas 
within the whole YRHA were ordered by Townsend index score and divided into 
five quantile groups; ‘Most deprived fifth’, ‘2nd most deprived fifth’, ‘3rd most 
deprived fifth’, ‘2nd least deprived fifth’ and ‘Least deprived fifth’.  
Individuals in the early T1D onset group were assigned to a deprivation group 
based on geocoding the former YRHA ward area of their place of residence at 
diagnosis. West Yorkshire included many of the most deprived wards in the 
former YRHA, so geocoding ward area for individuals in the late onset group 
using the same geocoding as the early onset group would inflate the most 
deprived totals. Therefore, ward areas within West Yorkshire only were also 
ordered and split into the five quantile groups, so the late T1D onset group 
could use geocoding from West Yorkshire only.  
The Index of Multiple Deprivation was also considered for assigning deprivation 
groups. This calculated deprivation by output area instead of ward code. Output 
areas were approximately equal in population size, so there would have been 
more of an equal spread across deprivation categories. However, the 
Townsend index was preferred due to its focus on material deprivation.  
 
3.1.4 Data cleaning. 
The YRDCYP dataset was stored in a Structured Query Language (SQL) 
database across multiple tables (Table 3.1).  
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Table 3.1: Structured Query Language (SQL) table descriptions of the Yorkshire 
Register of Diabetes in Children and Young People (YRDCYP) database. 
SQL table name SQL table description 
dbo.patient 
Identifiable data including full name, sex, date of birth 
and ethnicity (if recorded). 
 
Linked to dbo.diagnosis and dbo.patient_addresses by 
the individual identifier p_id. 
dbo.diagnosis 
Diagnosis data including diagnosis date, diabetes type. 
 
Linked to dbo.patient by the individual idenitifer p_id. 
 
Linked to dbo.patient_addresses by the individual 
identifier p_id and also the diagnosis identifier d_id. 
dbo.patient_addresses Residential address of the patient at T1D diagnosis. 
 
These tables were joined by a SQL query via an individual identifier (p_id) 
available in all tables and a diagnosis identifier (d_id) found in the dbo.diagnosis 
and dbo.patient_addresses tables. Within the SQL query, the data were 
cleaned to provide the final YRDCYP cohort.  
All individuals with a diagnosis of T1D on the YRDCYP were included in the 
analysis, except in the following circumstances: 
- Individuals diagnosed with more than one diabetes type if T1D was not 
recorded at the latest diagnosis date. Any diabetes type diagnosis 
occurring before the latest date of diagnosis was assumed to be 
incorrect.  
- Individuals diagnosed with T1D as a secondary condition (e.g. secondary 
to cystic fibrosis). These types of diabetes have different characteristics 
from primary T1D. 
- Individuals with a T1D diagnosis within 6 months from birth as they 
should have been classified with neonatal diabetes instead of T1D. 
- Individuals with missing residential address at date of diagnosis as it 
could not be determined whether the individual was resident in the YRHA 
area for early onset individuals or in West Yorkshire for late onset 
individuals.  
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- Individuals with late T1D onset who were diagnosed before 1991 due to 
consent issues. 
- Individuals with missing/incomplete demographic or clinical data 
essential for analysis: 
o One person with missing date of birth was excluded from the 
cohort as it could not be determined whether this person had early 
or late onset T1D. 
o Two individuals had no recorded date of diagnosis. Of these two 
individuals, one person did have a diagnosis age recorded so date 
of diagnosis was imputed using diagnosis age and date of birth. 
There was no information available for the other individual to 
impute date of diagnosis, therefore, this individual was deleted 
from the cohort. 
o Five individuals from the early onset group had missing sex data. 
Sex was imputed by examining the first name of four of these 
individuals. The remaining person had a first name which could be 
classed as male or female and was left with an unknown sex 
code. 
o After data linkage to the Office for National Statistics (ONS) death 
certification data (described in section 3.1.5), one person was 
deleted from the cohort as they were reported on the ONS death 
dataset with missing date of death and underlying cause of death. 
Both these fields were essential for analysis. 
The stages of data cleaning are summarised in Figure 3.2.  
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Figure 3.2: Data cleaning for Yorkshire Register of Diabetes in Children and Young People (YRDCYP) cohort. 
469 individuals deleted where T1D is not diagnosed at latest diagnosis date: 6,776 individuals
5,110 individuals diagnosed under 15 years old 1,643 individuals diagnosed between 15 to 29 years old
202 individuals deleted who were diagnosed before 1991: 1,441 individuals191 individuals deleted where residential address at diagnosis was missing: 4,919 individuals 
7,246 individuals from the YRDCYP had data sent for linkage to ONS death certification data
1 individual deleted where diabetes diagnosis date is invalid: 7,245 individuals
3 individuals deleted where T1D is a secondary diagnosis: 6,773 individuals
273 individuals deleted where residential output area code at 
diagnosis was not in West Yorkshire: 1,117 individuals
17 individuals with missing date of birth
12 individuals with date of birth found on spreadsheet sent to ONS
2 individuals with missing diagnosis date
1 individual with diagnosis date calculated from diagnosis age
101 individuals deleted where residential address at diagnosis 
could not be mapped to an output area code: 4,818 individuals
4 individuals with date of birth found on spreadsheet sent to ONS
29 individuals deleted where residential address at diagnosis 
could not be mapped to an output area code: 1,390 individuals435 individuals deleted where residential output area 
code at diagnosis was not in the YRHA: 4,383 individuals
22 individuals deleted where residential address at diagnosis was missing: 1,419 individuals
5,498 individuals in cohort
1 individual deleted with incomplete death data: 1,116 individuals
7 individuals deleted where T1D was diagnosed before 6 months of age: 6,766 individuals
1 individual deleted where diagnosis date and 
date of death were equal: 4,382 individuals
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3.1.5 Data linkage to death certification data from the Office for 
National Statistics (ONS). 
Personal identifiable data (NHS number, date of birth and name) from the 
YRDCYP were previously sent to the ONS for data linkage to death certification 
data. The data from the ONS included details from the original death certificates 
such as place and date of death, as well as any free text. This free text was 
used by the ONS to create a number of coded cause of death variables and a 
single underlying cause of death variable, using the ICD-10 coding system. 
Underlying cause of death was defined as "the disease or injury which initiated 
the train of morbid events leading directly to death, or the circumstances of the 
accident or violence which produced the fatal injury" (252, p.31).  
As the coding for underlying cause of death at ONS was not clinically validated, 
this variable was assessed by a specialist clinician. This involved assessing all 
the free text from the ONS dataset to determine whether the current underlying 
cause of death code was correct. If an individual was assessed as having an 
inaccurate code, a new ICD-10 was used assigned to the underlying cause of 
death variable.  
Death certification data were received by ONS in csv format, with death 
information on the YRDCYP up to 31st December 2015 (Figure 3.3). These 
were uploaded onto the SQL database as a view. Data from this view were 
joined to the YRDCYP SQL tables to create a final dataset extracted on 
26/11/2016 for analysis in STATA (257).  
 
 
Figure 3.3: Timeline for Yorkshire Register of Diabetes in Children and Young 
People (YRDCYP) and Office for National Statistics (ONS) death certification 
datasets. 
 
 
 
YRDCYP	data	-	early	onset	data
YRDCYP	data	-	late	onset	data
ONS	death	certification	data
1978 2013
1991 2013
1978 2015
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3.2 Leeds Children and Young People’s Diabetes Service 
(LCYPDS). 
The LCYPDS delivers care to under 19-year olds newly diagnosed with 
diabetes. The service offers CSII therapy to patients in accordance with NICE 
guidelines. Administrative data were extracted for T1D patients attending the 
LCYPDS who had started CSII therapy between 2002 and 2013.  
The dataset included clinical data on diabetes diagnosis date, CSII start date 
(and CSII end date for any individuals who discontinued CSII therapy) and 
HbA1c values at each appointment attended at the LCYPDS up to 2015. Data 
on any recorded hospitalisations (hospital inpatient admission or A&E 
attendance) whilst attending the LCYPDS were also included. Demographic 
data included age and sex. Deprivation and ethnicity could not be included due 
to missing data.  
 
3.2.1 Data cleaning. 
There was a previous STATA dta file containing data on the LCYPDS for 
individuals attending the service on CSII therapy from 2002 to the end of 
October 2007. These data had already been cleaned and analysed. 
A list of individuals attending the LCYPDS up to 2013 was obtained from the 
lead clinician. This list had been verified by the lead clinician as having correct 
and up to date demographic and clinical data. Health professionals at the 
LCYPDS enter their patient data into a Microsoft Access database. The Access 
database included clinical and demographic data across a number of tables. A 
copy of the database, updated up to April 2016, was made available to extract 
data for the listed individuals. Table 3.2 includes the Access tables and their 
descriptions for the extracted data. 
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Table 3.2: Microsoft Access database tables for the Leeds Children and Young 
People’s Diabetes Service (LCYPDS). 
Access table name Access table description 
Patient 
Identifiable data including full 
name, sex, date of birth, 
ethnicity (if recorded) and CSII 
start date. CSII date was also 
collected if the individual 
discontinued CSII therapy during 
attendance to the LCYPDS. 
 
ClinicalBaselineData 
Clinical data (including HbA1c 
measurements) collected from 
type 1 diabetes diagnosis date 
and before the recorded CSII 
start date. 
ClinicalData 
Clinical data (including HbA1c 
measurements) collected on and 
after the recorded CSII start date 
but before any recorded CSII 
end date. 
ClinicalDataqPostCSIITherapyAnnualReview 
Clinical data (including HbA1c 
measurements) collected on and 
after the recorded CSII end date. 
Hospital Admissions 
Any recorded inpatient 
admission or A&E attendance 
during attendance at the 
LCYPDS. 
These tables were extracted from Access into multiple sheets in an Excel file. 
From these multiple datasheets, a single table was created and included a new 
variable to determine whether an appointment occurred before, during or after 
CSII therapy.  
The Excel file was exported into STATA, where it was formatted and joined to 
the old dataset. For individuals with data in both new and old datasets, it was 
found that the old data had been duplicated in the new dataset and included 
more recent information. Therefore, data from the new dataset were used for 
these individuals.  
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The stages of data cleaning are summarised in Figure 3.4. All individuals with a 
diagnosis of T1D were included in analysis, except in the following 
circumstances: 
- Individuals diagnosed with more than one diabetes type if T1D was not 
recorded at the latest diagnosis date. Any diabetes type diagnosis made 
before the latest date of diagnosis was assumed to be incorrect.  
- Individuals diagnosed with T1D as a secondary condition (e.g. secondary 
to cystic fibrosis), as these types of diabetes have different 
characteristics from primary T1D. 
- Individuals with a T1D diagnosis within 6 months from birth as they 
should have been classified with neonatal diabetes instead of T1D. 
- Individuals who did not have HbA1c values recorded both before and 
after the CSII start date as both pre- and during-CSII HbA1c values were 
needed to examine HbA1c change with CSII therapy. 
Records for individuals were deleted in the following circumstances: 
- 18 records were deleted as the date of the clinical record was invalid (i.e. 
year was recorded as 1900). 
- Any hospitalisation recorded before the T1D diagnosis date was deleted. 
- Any clinical records where date of clinical record was after CSII end were 
only included in analysis for comparisons between individuals who 
continued and discontinued CSII. 
There were seven individuals where sex code was derived using first names.  
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Figure 3.4: Data cleaning for Leeds Children and Young People’s Diabetes Service (LCYPDS) cohort. 
74	individuals included	on	the	previous	dataset
146	individuals included	on	the	Microsoft	Access	database
14	individuals	deleted	with	no	updated	or	incorrect	records:	132	individuals
Combine	old	and	new	dataset	(27	individuals	in	both	 new	and	old	datasets):	179	individuals
2	individuals	deleted	where	diagnosis	date	was	under	6	months	of	age:	177	individuals
16	individuals	deleted	with	no	pre-CSII	clinical	data:	161	individuals
161	individuals	in	cohort
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3.2.2 Defining the pre-, during and after continuous subcutaneous 
insulin infusion (CSII) time periods. 
HbA1c values and hospitalisations were categorised as occurring pre-CSII, 
during CSII or after CSII therapy (for individuals who discontinued CSII therapy 
only) (Figure 3.5).  
 
 
Figure 3.5: Timeline for pre-, during and after continuous subcutaneous insulin 
infusion (CSII) time periods. 
 
Pre-CSII therapy included the period from the T1D diagnosis date to the day 
before the CSII therapy start date. 
During CSII therapy included the period from the CSII start date. CSII duration 
ended on the last recorded appointment date if there was no CSII end date. If a 
CSII end date was recorded, CSII duration ended on the day before a recorded 
CSII end date. 
For individuals who discontinued CSII therapy, the CSII end date marked the 
beginning of the after CSII period. 
There was one person who ended CSII therapy but then started again around 4 
years after. This person was counted twice. Each CSII period for this person 
was calculated using the following method (Figure 3.6): 
- The mid-point between ending CSII and starting CSII for the second time 
was calculated. 
- Dates from the day after the CSII end date to the day before the mid-
point were classed as after CSII end. 
- Dates from the day of the mid-point to the start of the second CSII start 
date were classed as pre-CSII for the second CSII period.  
 
 
CSII	start	date
HbA1c	values
Hospitalisations Pre-CSII	hospitalisation Hospitalisations	during	CSII
HbA1c	values	during	CSII
Last	appointment	date	for	
those	with	CSII	end	date	
HbA1c	values	after	CSII	end	
date
CSII	end	date/last	
appointment	dateT1D	diagnosis	date
Pre-CSII	HbA1c	values
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Figure 3.6: Pre-, during and after continuous subcutaneous insulin infusion 
(CSII) duration with more than one CSII therapy periods. 
 
3.3 Yorkshire Specialist Register of Cancer in Children and 
Young People (YSRCCYP). 
The YSRCCYP is a population-based register of all individuals under the age of 
15 who were diagnosed with childhood cancer from 1974 in the former YRHA. 
From 1990, data on individuals diagnosed with late cancer onset (aged between 
15 and 29 years) were also collected. The tertiary referral paediatric oncology 
centre at Leeds General Infirmary and the Northern and Yorkshire Cancer 
Registry and Information Service are the main sources for the YSRCCYP. 
Records are annually cross-checked with the National Cancer Registration 
Service. As an ongoing register where data are updated regularly, the number 
of people within the cohort depends on when an extract of the data is taken. In 
this analysis, a cohort from the register was taken on 7th February 2017. 
The data from the YSRCCYP included sex, date of birth, date of cancer 
diagnosis and cancer type and residential address at the time of cancer 
diagnosis. Date of death information from Public Health England was also 
included in the YSRCCYP extract. Any individuals with a date of death within 
the first five years after their first recorded cancer diagnosis were excluded from 
this analysis. 
 
3.3.1 Cancer type classification. 
The cancer type at diagnosis was defined from the YSRCCYP data from the 
first recorded diagnosis date. This field classified cancer types by the 12 major 
diagnostic groups described by the International Classification of Childhood 
Cancer-3 (ICCC-3) for both early and late cancer onset groups.  
The YSRCCYP data extract included 259 individuals where their tumour could 
not be classified under the ICCC-3. These individuals were excluded from this 
analysis as their tumours were identified as having a benign histology. 
Mid-point	between	first	CSII	
end	date	and	second	CSII	
start	date
CSII	end	date
First	pre-CSII	duration First	CSII	duration
Duration	after	CSII	end	
date
Second	pre-CSII	
duration Second	CSII	duration
Last	appointment	dateFirst	CSII	start	dateT1D	diagnosis	date
Second	CSII	start	
date
  
40 
If an individual was diagnosed with more than one cancer type on different 
dates, the cancer type diagnosed on the earliest date was assigned to the 
individual. No individuals had more than one cancer type on the same date on 
the earliest cancer diagnosis date. 
 
3.3.2 Ethnicity classification. 
As with the YRDCYP, ethnicity was inconsistently recorded on the YSRCCYP. 
Therefore, imputation for ethnicity was also completed using Onomap. 
However, the Onomap software was used to assign ethnicity on the YSRCCYP 
cohort from an extract taken on 06/07/2016 (before the extraction date in this 
analysis) with 9,001 people. Therefore, ethnicity could not be assigned to all 
individuals in the cohort. The Onomap software could not be run on the current 
extract due to licencing issues of the software. 
 
3.3.3 Deprivation classification. 
As with the YRDCYP cohort, the Townsend index was used to determine 
deprivation group. This used the same methodology as for the YRDCYP 
(section 3.1.2) of using residential address at time of diagnosis. 
 
3.3.4 Duplicate records and exclusions in the YSRCCYP dataset. 
Data extracted from the register on 07/02/2017 included 9,470 people with 
9,885 records. There were duplicate records for 148 people for the following 
reasons: 
- 18 people were recorded with more than one cancer diagnosis of the 
same cancer type on the same day. These duplicate records were 
deleted. 
- 123 people had two cancer diagnoses of different cancer types on 
different days. The first cancer diagnosis was included and the second 
diagnosis was deleted. 
- 7 people had three cancer diagnoses of different cancer types on 
different days. The first cancer diagnosis was included and the second 
and third diagnoses were deleted. 
In addition, 2,232 people were excluded from the analysis as they had a date of 
death within the first 5 years after initial cancer diagnosis. Therefore, the total 
individuals in the cohort was 7,238. 
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3.3.5 Hospital Episodes Statistics (HES) datasets and the Mental 
Health Minimum Data set (MHMDS). 
The YSRCCYP cohort was linked to Hospital Episode Statistics (HES), which 
included data on outpatient appointments and hospital inpatient admissions and 
accident and emergency (A&E) attendances recorded in any secondary care 
NHS hospitals in England. In addition, the YSRCCYP was also linked to the 
Mental Health Minimum Data set (MHMDS) which included data on admissions 
to secondary mental health services.  
These datasets provided assessment of whether attendance to follow-up 
outpatient appointments reduced complications. Data on inpatient admissions, 
A&E attendances and mental health admissions were used as proxy measures 
for complications. If a reduction in hospitalisations was found, this would 
indicate the importance of increasing attendance to follow-up outpatient 
appointments in reducing complications. 
HES data for the YSRCCYP cohort had previously been requested from NHS 
Digital (formerly the Health and Social Care Information Centre). This involved 
sending YSRCCYP data to NHS Digital where this could be linked to HES data 
via personal identifiable data (NHS number, date of birth, sex and postcode at 
cancer diagnosis). The YSRCCYP identifier field was also sent to NHS Digital 
and was included in the final linked HES dataset. 
The linked HES data received from NHS Digital included separate datasets on 
inpatient admissions, outpatient appointments and A&E attendances, as well as 
data from the MHMDS.  
The different datasets covered different time periods between 1997 to 2017. 
This was due to the availability of the HES datasets and the different timings of 
when each dataset was requested. Figure 3.7 illustrates the time coverage of 
the different datasets in comparison with the YSRCCYP data.  
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Figure 3.7: Timeline for Yorkshire Specialist Register of Cancer in Children and 
Young People (YSRCCYP), Hospital Episode Statistics (HES) and Mental 
Health Minimum Data set (MHMDS). 
 
The reporting period for the HES data covered one year from 1st April to 31st 
March the following year. For example, 2014-15 covered the period 1st April 
2014 to 31st March 2015. 
Due to the different number of datasets covering different time periods, a 
number of raw data files were received from NHS Digital (Table 3.3).  
 
Table 3.3: Raw Hospital Episode Statistics (HES) and Mental Health Minimum 
Data set (MHMDS) file names and descriptions. 
Raw HES/MHMDS file name Raw HES/MHMDS file 
description 
LeedsUni_OP_03.txt Outpatient HES files linked to 
YSRCCYP cohort for HES years 
2003-04 to 2010-11. 
These separate files had 
previously been combined into a 
single STATA file 
(outpatient_hes_2003_2011_raw.
dta) 
 
LeedsUni_OP_04.txt 
LeedsUni_OP_05.txt 
LeedsUni_OP_06.txt 
LeedsUni_OP_07.txt 
LeedsUni_OP_08.txt 
LeedsUni_OP_09.txt 
LeedsUni_OP_10.txt 
HES	A&E	data	-	YSRCCYP	cohort
2006 2015
2017
2017
MHMDS	data	-	YSRCCYP	cohort
HES	outpatient	data	-	YSRCCYP	cohort
HES	inpatient	data	-	YSRCCYP	cohort
2015
1997
2015
1974
2003
2007
YSRCCYP	data
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extract_Leeds_OP_1112.txt Outpatient HES files linked to 
YSRCCYP cohort for HES years 
2011-12 to 2014-15. 
These separate files had 
previously been combined into a 
single STATA file 
(outpatient_hes_2011_2014_raw.
dta) 
extract_Leeds_OP_1213.txt 
extract_Leeds_OP_1415.txt 
extract_Leeds_AE_0708.txt 
A&E HES files linked to 
YSRCCYP cohort for HES years 
2007-08 to 2013-14. 
These separate files had 
previously been combined into a 
single STATA file 
(A&E_hes_2007_2014_raw.dta) 
extract_Leeds_AE_0809.txt 
extract_Leeds_AE_0910.txt 
extract_Leeds_AE_1011.txt 
extract_Leeds_AE_1112.txt 
extract_Leeds_AE_1213.txt 
extract_Leeds_AE_1314.txt 
AE_1415_APPROVED_2319_09052016_8
.txt 
A&E HES file linked to YSRCCYP 
cohort for HES year 2014-15. 
extract_Leeds_MHLDDS_0607.txt 
MHMDS file linked to YSRCCYP 
cohort for HES year 2006-07. 
extract_Leeds_MHLDDS_0708.txt 
MHMDS file linked to YSRCCYP 
cohort for HES year 2007-08. 
extract_Leeds_MHLDDS_0809.txt 
MHMDS file linked to YSRCCYP 
cohort for HES year 2008-09. 
extract_Leeds_MHLDDS_0910.txt 
MHMDS file linked to YSRCCYP 
cohort for HES year 2009-10. 
extract_Leeds_MHLDDS_1011.txt 
MHMDS file linked to YSRCCYP 
cohort for HES year 2010-11. 
extract_Leeds_MHLDDS_RECORDS_111
2.txt 
MHMDS file linked to YSRCCYP 
cohort for HES year 2011-12. 
extract_Leeds_MHLDDS_RECORDS_121
3.txt 
MHMDS file linked to YSRCCYP 
cohort for HES year 2012-13. 
extract_Leeds_MHLDDS_RECORDS_131
4.txt 
MHMDS file linked to YSRCCYP 
cohort for HES year 2013-14. 
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extract_Leeds_MHLDDS_RECORDS_141
5.txt 
MHMDS file linked to YSRCCYP 
cohort for HES year 2014-15. 
LeedsUni_APC_97.txt 
Inpatient HES files linked to 
YSRCCYP cohort for HES years 
1997-98 to 2016-17 
These separate files had 
previously been combined into a 
single STATA file 
(inpatientHES_1997_2017.dta) 
LeedsUni_APC_98.txt 
LeedsUni_APC_99.txt 
LeedsUni_APC_00.txt 
LeedsUni_APC_01.txt 
LeedsUni_APC_02.txt 
LeedsUni_APC_03.txt 
LeedsUni_APC_04.txt 
LeedsUni_APC_05.txt 
LeedsUni_APC_06.txt 
LeedsUni_APC_07.txt 
LeedsUni_APC_08.txt 
LeedsUni_APC_09.txt 
LeedsUni_APC_10.txt 
LeedsUni_APC_11.txt 
NIC155843_APC_201199.txt 
NIC155843_APC_201299.txt 
NIC155843_APC_201399.txt 
NIC155843_APC_201499.txt 
NIC155843_APC_201599.txt 
NIC155843_APC_201612.txt 
 
Some of these separate files for the different HES years had previously been 
imported into STATA and combined to create single files for the inpatient, 
outpatient, A&E and MHMDS datasets. However, some additional files required 
linkage to include all available HES data. 
Due to the different timings of the requested HES datasets, different extracts of 
the YSRCCYP data were sent to NHS Digital for data linkage. Therefore, each 
HES dataset had to be linked back to the current YSRCCYP data extracted for 
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this study. This meant that some records could not be linked and were deleted 
and excluded from analysis. To maximise record linkage between datasets, 
some identifiers for some HES and MHMDS records were amended. Amending 
identifiers incorrectly could lead to erroneous results during analysis, so 
amendments were only performed where duplicate records could be identified 
before being linked to the current YSRCCYP data. 
 
3.3.5.1 Duplicate records in the Hospital Episode Statistics (HES) 
datasets. 
The HES datasets included identifier variables generated by NHS Digital at 
record (‘attendkey’ for the outpatient appointment dataset, ‘aekey’ for the A&E 
dataset and ‘epikey’ for the inpatient admissions dataset) and person (‘HESID’) 
level. The datasets also included the YSRCCYP identifiers (‘yctr_id’ and 
‘patient_id’) provided in the original files sent to NHS Digital for data linkage.  
As there were unique characteristics for each HES dataset, cleaning rules were 
specific to each HES file. However, data cleaning for duplicate records were 
followed for most HES datasets. Including duplicate records in analysis could 
lead to overestimations in results. In contrast, incorrectly deleting unique 
records could mean losing vital information and underestimating results. 
However, for each HES dataset, there were at most 1% of duplicate records, so 
any incorrectly deleted or retained records would have minimal impact on the 
result. Even so, creating an algorithm for dealing with duplicate records was 
important to minimise any bias. 
 
3.3.5.1.1 Duplicate records assigned to the same Hospital Episode Statistics 
(HES) record identifier. 
For the outpatient and A&E datasets, it was found that some records assigned 
with different unique HES record identifiers were identified as duplicate records 
(Table 3.4).  
 
Table 3.4: Record and individual level identifiers for Hospital Episode Statistics 
(HES) datasets. 
 Outpatient A&E Inpatient 
HES record attendkey aekey epikey 
HES person HESID 
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identifier 
YSRCCYP person 
identifier 
yctr_id before 2011 and patient_id after 2011 
Unique record 
variables 
HESID/ 
YSRCCYP id, 
date of 
appointment 
and treatment 
speciality 
HESID/ 
YSRCCYP id, 
date of 
admission 
HESID/ 
YSRCCYP id, 
date of 
admission, 
diagnosis code 
These records were examined individually to ensure only one HESID was linked 
to one YSRCCYP id. 
 
3.3.5.1.2 One HESID linked to more than one Yorkshire Specialist Register of 
Cancer in Children and Young People (YSRCCYP) identifier. 
Where a HESID was linked to more than one YSRCCYP identifier, records were 
either deleted or the HESID was amended, depending on the following 
circumstances: 
1. The ‘match rank’ variable in the HES data indicated the quality of 
matching of individuals between the HES and YSRCCYP datasets. A 
scoring system between 1 and 8 was used based on a matching 
algorithm from various identifiable variables (Table 3.5), where a higher 
score indicated a poorer quality match. Therefore, the record for the 
YSRCCYP identifier with the highest match rank score for a duplicate 
HESID would be deleted. For example, record 2 would be deleted in 
Table 3.6. 
 
Table 3.5: Matching algorithm for individuals in the Yorkshire Specialist Register 
of Cancer in Children and Young People (YSRCCYP) linked to Hospital 
Episode Statistics (HES).   
Match 
Rank 
NHS 
number 
Date of 
birth Sex Postcode 
 
1 Exact Exact Exact Exact  
2 Exact Exact Exact    
3 Exact Partial Exact Exact  
4 Exact Partial Exact    
5 Exact     Exact  
6   Exact Exact Exact 
where NHS number does not 
contradict the match and date 
of birth is not 1 January and 
the POSTCODE is not in the 
'ignore' list 
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7   Exact Exact Exact 
where NHS number does not 
contradict the match and date 
of birth is not 1 January 
8 Exact     
 
 
Table 3.6: Example of duplicate Hospital Episode Statistics (HES) record 
deletion using 'match rank'. 
 Record id HESID patient_id match 
rank 
Lower match rank 
score – keep record 
1 123456789 abcd 1 
Higher match score 
– delete record 
2 123456789 efgh 8 
 
2. If the YSRCCYP identifiers were all included in the current extract and 
the match rank was the same for each YSRCCYP identifier, it could not 
be determined which person the HES record should be assigned to. 
Therefore, the HES record remained linked to each person. The HESID 
was amended so that it remained unique for each person (see example 
in Table 3.7).  
 
Table 3.7: Example of duplicate Hospital Episode Statistics (HES) record 
amendment to HESID. 
 Record id HESID patient_id match rank 
Two records with 
same HESID and 
match rank score but 
different patient_ids 
1 123456789 abcd 1 
2 123456789 efgh 1 
Amended record 2 
with a new HESID 
1 123456789 abcd 1 
2 12345678X efgh 1 
 
3. Since the YSRCCYP data were sent to NHS Digital for data linkage, 
some individuals were identified as having more than one YSRCCYP 
identifier and their duplicate record was removed from the register. In this 
case, the HES record was linked to the same person with multiple 
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YSRCCYP identifiers. Therefore, the record with the old YSRCCYP id 
was deleted (example of original record to amended record in Table 3.8). 
Table 3.8: Example of Hospital Episode Statistics (HES) record with YSRCCYP 
identifier from old extract provided during the linkage process. 
 Record id HESID patient_id 
Original patient_id sent to NHS 
Digital for data linkage 
1 123456789 aaaa 
Amended patient_id on 
updated YSRCCYP data  
1 123456789 aaab 
 
3.3.5.1.3 One Yorkshire Specialist Register of Cancer in Children and Young 
People (YSRCCYP) identifier linked to more than one HESID. 
There was no way to check if these HES records were supposed to match to 
two different individuals, as the HES identifiable data would match the 
corresponding YSRCCYP record. However, if there were a method to determine 
whether these records belonged to separate individuals, there would be no way 
to be sure which individual the HES record belonged to. Therefore, HESIDs 
were amended to be the same so only one HESID would match to one 
YSRCCYP id (example in Table 3.9). 
Table 3.9: Example of two HESIDs matched to a single Yorkshire Specialist 
Register of Cancer in Children and Young People (YSRCCYP) identifier. 
 Record id HESID patient_id 
Two records with same HESID and 
match rank score but different 
patient_ids 
1 123456789 abcd 
2 999999999 abcd 
Amended record 2 with a new HESID 
1 123456789 abcd 
2 123456789 abcd 
 
3.3.5.2 Deleting records before a 5-year follow-up. 
Analysis from the YSRCCYP cohort for this study included examining outcomes 
of LEs for the first diagnosed cancer. Any hospital activity which occurred within 
the first 5 years of a cancer diagnosis would be regarded as cancer treatment or 
assessment for relapse. Therefore, only inpatient, outpatient and A&E HES data 
on or after the 5-year anniversary of the first recorded cancer diagnosis were 
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included. Consequently, individuals from the YSRCCYP who had a first cancer 
diagnosis recorded within the last 5 years of the HES dataset time period would 
not be eligible for analysis due to insufficient follow-up time. The numbers of 
eligible individuals for analysis by each HES dataset are presented in Table 
3.10. 
 
Table 3.10: Total of individuals from the Yorkshire Specialist Register of Cancer 
in Children and Young People (YSRCCYP) eligible for Hospital Episode 
Statistics (HES) analysis. 
 Outpatient 
and A&E 
MHMDS Inpatient 
Total individuals from YSRCCYP 
eligible for matching on HES 
5,294 7,238 5,833 
 
Analysis using data for mental health admissions included assessment of a 
mental health episode occurring before the first cancer diagnosis, during the 5-
year follow-up period and after the follow-up time. Therefore, all individuals from 
the YSRCCYP were included in the analysis. 
 
3.3.5.3 Data cleaning for Mental Health Minimum Data set (MHMDS). 
The total number of records on the MHMDS raw files are summarised in Table 
3.11.  
 
Table 3.11: Total number of records in raw Mental Health Minimum Data set 
(MHMDS) files. 
File year Total records 
2006-2007 310 
2007-2008 274 
2008-2009 222 
2009-2010 191 
2010-2011 198 
2011-2012 208 
2012-2013 244 
2013-2014 235 
2014-2015 256 
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The raw files were combined and included a total of 2,138 records for 610 
individuals. In addition, there were 103 individuals in the HES inpatient data with 
a mental health admission. There were 62 individuals with records on both the 
MHMDS and inpatient datasets. Duplicate records were deleted so each 
individual had only one record. This record included a variable called ‘Year of 
first known psychiatric care’, with some records with dates prior to the start of 
the data collection period (2006-2007). Each individual had a single ‘First known 
contact’ date by using the earliest date recorded for the individual from any of 
their MHMDS episode records. If this field was blank for all records for this 
individual, the earliest episode start date from any of the recorded episode for 
these individuals was used instead. For individuals with records on both the 
MHMDS and inpatient data, the first known contact date would be replaced by a 
mental health inpatient admission date if this date was prior to the existing first 
known date recorded on the MHMDS.  
In total, 603 individuals with a mental health admission were matched on the 
YSRCCYP extract. One individual was excluded as their earliest MHMDS date 
was before their date of birth (Figure 3.8).  
 
Figure 3.8: Data cleaning for the Yorkshire Specialist Register of Cancer in 
Children and Young People (YSRCCYP) cohort linked to Mental Health 
Minimum Data set (MHMDS). 
 
3.3.5.4 Data cleaning for outpatient Hospital Episodes Statistics (HES) 
dataset. 
Table 3.12 provides a summary of the total number of outpatient HES records 
before data cleaning.  
 
 
7,238	individuals	
extracted	from	YSRCCYP	
on	07/02/2017
610	individuals	on	
MHMDS	2006-2015
1	individual	deleted	– first	known	mental	health	admission	before	date	of	birth
Total	cohort:	602	 individuals
603	individuals	matched	on	YSRCCYP
103	individuals	on	HES	
inpatient	1997-2017
62	records	deleted	– duplicate	individuals	
on	both	MHMDS	and	HES	inpatient	file
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Table 3.12: Total of all and unique records in the outpatient Hospital Episode 
Statistics (HES) data files before data cleaning. 
File year 2003-2011 2011-2014 2014-2015 
Total records 214,990 104,582 35,858 
Total unique ‘attendkey’ 214,642 104,315 35,799 
Total unique HESIDs 5,773 5,378 4,550 
Total unique YSRCCYP id 5,767 5,382 4,556 
 
Figure 3.9 illustrates each data cleaning stage for the outpatient HES data and 
data linkage to the current YSRCCYP cohort. 
There were some individuals who had more than one appointment on the same 
day. Multiple records on the same day were kept if they were assigned to 
different treatment specialty groups, as it was possible for individuals to attend 
two appointments within different departments on the same day.  
Some individuals had more than one record of an appointment on the same 
date and within the same treatment specialty but with different ‘attend’ values, 
e.g. one record with an ‘attended’ value and the other record with a ‘did not 
attend’ flag. In this case, the record with the ‘attended’ value would be kept and 
the ‘did not attend’ record would be deleted. This was because there would be 
no possible way of checking which record was correct and as most people were 
likely to have attended the appointment, ‘attended’ was chosen as the default 
option. 
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Figure 3.9: Data cleaning for the Yorkshire Specialist Register of Cancer in Children and Young People (YSRCCYP) cohort linked to 
Hospital Episode Statistics (HES) outpatient data. 
7,238	individuals	
extracted	from	YSRCCYP	
on	07/02/2017
214,990	records	on	
outpatient	HES	2003-2011
104,582	records	on	
outpatient	HES	2011-2014
35,858	records	on	
outpatient	HES	2014-2015
3,962	duplicate	
records	deleted
7	people	with	2	
HESIDs	–
amended	to	one	
HESID	for	each	
person
2	pairs	or	people	
with	the	same	
HESID	– HESID	
amended	for	one	
person	per	pair
1,280	duplicate	
records	deleted
2	pairs	with	2	
HESIDs	–
amended	one	
HESID	for	each	
person
2 pairs	of	people	
with	the	same	
HESID	– HESID	
amended	for	one	
person	per	pair
8,805	duplicate	
records	deleted
17	pairs	of	people	
with	the	same	
HESID	– HESID	
amended	for	one	
person	per	pair
205,844	records	(5,668	people)
100,620	 records	(5,375	people)
34,578	 records	(4,550	people)
1,064	records	deleted –
duplicates	on	different	HES	files
172,058	records	deleted	– before	5	years	after	cancer	diagnosis
Total	cohort:	122,422	records	 (4,735	people)
294,828	 records	(6,097	people)	matched	on	YSRCCYP
292	records	deleted	– death	date	before	outpatient	record
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3.3.5.5 Data cleaning for inpatient Hospital Episode Statistics (HES) 
dataset. 
Each record on the inpatient HES dataset represented an episode of 
hospitalisation under one consultant. A continuous inpatient spell (CIPS) 
consisted of multiple episodes for an individual, which may have involved 
transfers between consultants and/or providers. To be counted as part of the 
same CIPS, a new episode had to begin within two days of the previous 
episode ending (258).  
For this study, inpatient data were analysed at CIPS level, using the information 
from the first episode in the CIPS for clinical analysis. CIPS level analysis was 
preferred over episode analysis to avoid double counting individuals. 
The inpatient dataset had previously been cleaned and combined into a single 
data file, so required minimum data cleaning and processing before data 
linkage to the YSRCCYP dataset.  
There were 104 duplicate ‘epikey’ records found in the cleaned file. However, it 
was found that these were not true duplicate records. Unlike the outpatient and 
A&E datasets, the HES record level identifier was not unique across HES years. 
Therefore, these records were kept and a new record level identifier was 
created. Figure 3.10 shows the data cleaning stages and data linkage to the 
YSRCCYP cohort dataset. 
 
Figure 3.10:  Data cleaning for the YSRCCYP cohort linked to inpatient HES 
data. 
 
7,238	individuals	
extracted	from	YSRCCYP	
on	07/02/2017
180,749	records	on	HES	
inpatient	1997-2017
7	duplicate	
records	deleted
2	people	with	2	
HESIDs	–
amended	to	one	
HESID	for	each	
person
11	pairs	of	people	
with	the	same	
HESID	– HESID	
amended	for	one	
person	per	pair
180,749	records	(7,915	people)
85,255	 records	deleted	– before	5	years	after	cancer	diagnosis
31	records	deleted	– date	of	death	before	continuous	 inpatient	spell	start	date
Total	cohort:	26,203	records	 (3,660	individuals)
145,310	 records	(6,754	people)	matched	on	YSRCCYP
1,652	records	deleted	– subsequent	admissions	after	the	
continuous	 inpatient	spell	start	date
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3.3.5.6 Data cleaning for accident and emergency (A&E) Hospital Episode 
Statistics (HES) dataset. 
Table 3.13 provides a summary of the total number of A&E HES records before 
data cleaning.  
 
Table 3.13: Total of all and unique records in the accident and emergency 
(A&E) Hospital Episode Statistics (HES) data files before data cleaning. 
File year 2007-2014 2014-2015 
Total records 16,476 2,500 
Total unique aekey 16,460 2,496 
Total unique HESIDs 4,725 1,585 
Total unique YSRCCYP id 4,710 1,588 
 
Figure 3.11 illustrates each data cleaning stage for the A&E HES data and data 
linkage to the current YSRCCYP cohort. 
Some individuals had more than one A&E record on the same day. To ensure 
that only one A&E attendance was included on a single day, the record with the 
earliest arrival time was included and any later records were deleted. 
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Figure 3.11: Data cleaning for the Yorkshire Specialist Register of Cancer in Children and Young People (YSRCCYP) cohort linked to 
accident and emergency (A&E) data. 
7,238	individuals	
extracted	from	YSRCCYP	
on	07/02/2017
16,476	records	on	A&E	
HES	2007-2014
2,500	records	on	A&E	HES	
2014-2015
7	duplicate	
records	deleted
2	people	with	2	
HESIDs	–
amended	to	one	
HESID	for	each	
person
2	pairs	of	people	
with	the	same	
HESID	– HESID	
amended	for	one	
person	per	pair
21	duplicate	
records	deleted
18	pairs	of	people	
with	the	same	
HESID	– HESID	
amended	for	one	
person	per	pair
16,455	 records	(4,706	people)
2,493	records	 (1,586	people)
33	records	deleted – duplicates	
on	different	HES	files
6,956	records	deleted	– before	5	years	after	cancer	diagnosis
Total	cohort:	9,985	 records	 (3,034	people)
16,972	 records	(4,516	people)	matched	on	YSRCCYP
31	records	deleted	– date	of	death	before	A&E	record
3	people	with	2	
HESIDs	–
amended	to	one	
HESID	for	each	
person
313	records	deleted – duplicate	
A&E	attendances	on	 the	same	
day
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3.3.5.7 Combining Hospital Episode Statistics (HES) and Mental Health 
Minimum Data set (MHMDS). 
To determine whether the attendance status of an outpatient appointment was 
associated with either an A&E attendance or inpatient admission 90 days after 
the outpatient appointment date, the outpatient HES data were combined with 
both the A&E and inpatient datasets. The time period coverage of the combined 
datasets with the total eligible individuals for analysis in the YSRCCYP cohort 
are presented in Table 3.14. 
 
Table 3.14: Time period coverage of outpatient dataset combined with accident 
and emergency (A&E) and inpatient datasets. 
HES dataset 
combined with 
outpatient dataset 
Outpatient 
dataset time 
period 
Linked HES 
dataset time 
period 
Total eligible 
individuals 
A&E 
31/03/2007 to 
31/12/2014 
01/04/2007 to 
31/03/2015 
5,221 
Inpatient 
01/04/2003 to 
31/03/2015 
02/04/2003 to 
29/06/2015 
4,735 
 The MHMDS was combined with the A&E, inpatient and outpatient datasets to 
determine whether a previous mental health admission was associated with 
attendance status of an outpatient appointment, attendance to A&E and non-
mental health related inpatient admission. All recorded first mental health 
admission dates before an outpatient, inpatient or A&E attendance were 
included in the analysis.  
 
3.4 Chapter summary. 
This chapter summarises the sources and content of the routine data analysed 
in this study, alongside the complexities of the dataset-specific cleaning rules 
before analyses could be carried out. The results of these analyses are 
described in chapters 4, 5 and 6.  
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Chapter 4 Mortality in type 1 diabetes. 
This chapter outlines the statistical methodology used for analysing data from 
the YRDCYP linked to ONS death certification data and reports the results from 
these data analyses. It begins by defining any categorisations of the data and 
continues with a description of the statistical methods used in the analysis. All 
analyses were performed using STATA 14 (257).  
Mortality was the outcome examined from the YRDCYP cohort. Analysis 
included the calculation of mortality rates, survival estimates and SMRs by age 
at death, age at T1D diagnosis, sex, ethnicity and deprivation group. Analysis 
was performed for all-cause and cause-specific mortality.  
 
4.1 Variable definitions. 
4.1.1 Age categories at type 1 diabetes (T1D) diagnosis and at 
death. 
The age variable (attained age and age at death) was grouped into discrete 
categories to compare health outcomes by age before (under 15 years), during 
(15 to 29 years) and after (30 and over) the transitional care period. To provide 
further detailed analysis by age, the YRDCYP was also categorised by 5-year 
age groups. Individuals from the YRDCYP diagnosed with T1D before the 
transitional care period are defined as having ‘early T1D onset’. Individuals 
diagnosed during the transitional care period are defined as having ‘late T1D 
onset’. 
 
4.1.2 Defining cause-specific mortality categories. 
The ICD-10 code for the underlying cause of death variable recorded on the 
ONS death certification data by a clinical coder was verified by a clinical 
diabetologist. Table 4.1 tabulates the classification of T1D and non-T1D related 
underlying causes of deaths and any related subcategories. 
T1D-related deaths due to chronic circulatory complications included stroke and 
ischaemic heart disease (IHD). Any other T1D-related deaths which could not 
be classified under acute or chronic complications were classed as T1D-related 
deaths with other/no/unknown complications. This group was not reported on 
separately in the results section. 
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Table 4.1: Underlying cause of death classification for cause-specific mortality 
analysis. 
T1D-related deaths Non-T1D 
related deaths 
Other/ 
unknown 
causes 
Acute 
complications 
Chronic 
complications 
Other/no/ 
unknown 
complications 
Diabetic 
ketoacidosis 
(DKA) 
Renal 
complications 
Respiratory 
failure 
Neoplasms 
Severe 
hypoglycaemia 
Circulatory 
complications  
Accidents and 
violence 
Mental disorder 
Suicide 
 
 
4.2 Statistical methodology. 
4.2.1 Mortality rates. 
Mortality rates were calculated for the whole follow-up period in the YRDCYP. 
All-cause and cause-specific mortality rates were calculated by dividing the total 
number of deaths in the YRDCYP by the total person-years of follow-up for the 
whole cohort. The mortality rate was expressed as the total number of deaths 
per 10,000 person-years over the cohort time period with 95% confidence 
intervals calculated using the Poisson distribution. The YRDCYP cohort 
mortality data met the assumptions of the Poisson distribution where instances 
of death were independent between individuals and occurred at random. All-
cause and cause-specific mortality rates by age, sex, ethnicity and deprivation 
were calculated for comparison against total cohort rates. This determined 
whether there were any statistically significant differences for any particular 
socio-demographic group compared with overall cohort rates. 
 
4.2.2 Survival analysis: Kaplan-Meier estimators. 
Although mortality rates were useful to provide a basic descriptive analysis of 
mortality in the YRDCYP, there was an assumption that these rates were 
constant over time. Mortality rates could have been calculated by T1D duration 
periods by different socio-demographic groups. However, grouping T1D 
duration into discrete categories would limit the accuracy of measuring mortality 
for specific time points and would also create a large number of mortality rates 
calculated by subgroups which would be inefficient for analysis.  
Survival analysis considered time to event (in this analysis the event was death) 
and also accounted for censored data. The YRDCYP data included individuals 
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who were diagnosed with T1D between 1978 and 2013 and were followed-up to 
death if deaths were recorded before 1st January 2016. For individuals who did 
not have a death recorded, data were censored on 31st December 2015.  
Kaplan-Meier estimates are non-parametric estimators which can be used to 
produce graphical presentation of the survivor function. The survivor function is 
the probability of survival past a certain time point. Kaplan-Meier graphs were 
plotted according to different socio-demographic groups and by different 
underlying causes of death for the YRDCYP cohort. This allowed for a visual 
comparison between age at T1D onset, sex, ethnicity, deprivation groups and 
by underlying causes of death. To test for any overall statistically significant 
differences between any two Kaplan-Meier curves, univariable log-rank tests 
were calculated.  
Cumulative survival and cumulative mortality over T1D duration can both be 
plotted using Kaplan-Meier estimates. Both types of graphs represent the same 
information but are visually different. Cumulative survival graphs show 
decreasing plots compared with cumulative mortality graphs which show 
increasing plots. Pocock and colleagues recommended using cumulative 
mortality plots for data where more than 30% of the cohort have survived. This 
was so that the y-axis can be truncated after the maximum cumulative mortality 
estimate rather than truncating the y-axis below the minimum cumulative 
survival estimate which could lead to misinterpretations when comparing graphs 
between different groups (259). In this analysis, cumulative mortality graphs 
were plotted as more than 30% of the YRDCYP survived at the end of the 
follow-up period. 
The cumulative mortality graphs used Kaplan-Meier survival estimates from 
T1D diagnosis date to either date of death or to 31st December 2015 for 
individuals with no death certification. T1D duration (time since T1D diagnosis) 
was used as analysis time as opposed to attained age as attained age would 
skew plots for the individuals in the late T1D onset group. 
 
4.2.3 Survival analysis: Cox regression models. 
Kaplan-Meier estimates with log-rank tests provided useful descriptive analysis 
for mortality against T1D duration between demographic groups within the 
YRDCYP. However, Kaplan-Meier estimates could not be adjusted for 
confounders or other covariates. Therefore, Cox proportional hazards 
regression modelling was also performed.  
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Cox regression is a semiparametric modelling method and can examine the 
relationship of the hazard function to multiple predictors without the need to 
determine the underlying hazard function. This has advantages over parametric 
methods where incorrectly specifying assumptions around the underlying 
hazard function can lead to inaccurate results. Flexible parametric methods 
remove some of these constraints around these assumptions and offers direct 
modelling of the underlying hazard function, which cannot be completed with 
Cox regression modelling. However, modelling the underlying hazard function 
was not required for this study, thus Cox regression was the preferred method 
to assess comparisons of hazards between groups (260).  
Cox regression models were run for all-cause mortality. Separate models were 
also run for T1D-related and non-T1D related deaths. Separate Cox regression 
models were performed for T1D-related deaths due to acute complications and 
T1D-related deaths due to chronic complications. No models were run for T1D-
related deaths due to DKA, severe hypoglycaemia, renal or circulatory 
complications. Likewise, there were no separate models run by each non-T1D 
related underlying cause of death. This was due to the small numbers for these 
subcategories. 
When examining different groups using Cox regression, there is an assumption 
that the different groups must have proportional hazards over time. This 
assumption was checked by calculating Schoenfeld residuals to produce an 
overall global test of the model. If the global test indicated any violation of the 
proportional hazards assumption, tests by variable were produced to examine 
any violation at global level (261). 
To decide which covariates to include in the Cox regression models, a Directed 
Acyclic Graph (DAG) was completed (Figure 4.1) based on discussions with 
and advice from clinical specialists. DAGs capture causal links between 
exposure and outcome variables to identify the minimal adjustment set of 
confounder variables for statistical modelling (262). The DAG included age 
group at T1D onset as the exposure and death as the outcome. Sex, ethnicity 
and deprivation were found to be confounders and should all have been 
included in the Cox regression models. However, as more than a fifth of deaths 
had a missing ethnicity code and there were small numbers of South Asians by 
underlying cause of death, ethnicity was excluded from the models.  
Attained age, diabetes duration and year of diagnosis were found to be 
mediators. All mediators, except year of diagnosis were excluded from the 
models. Year of diagnosis was included in the models as a continuous variable 
as changes in T1D treatment changed during the data collection period, so the 
year of diagnosis may have influenced the risk of death.  
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Confounders = sex, ethnicity, deprivation 
Mediators = attained age, diabetes duration, year of diagnosis 
Figure 4.1: Directed Acyclic Graph (DAG) for Cox regression model for mortality 
in the Yorkshire Register of Diabetes in Children and Young People (YRDCYP) 
cohort.  
 
4.2.4 Standardised Mortality Ratios (SMRs). 
To compare mortality in the YRDCYP against the general population, SMRs 
were calculated. SMRs are a ratio between the observed and the expected 
number of deaths in the YRDCYP. The expected numbers of deaths were 
calculated by applying England and Wales all-cause and cause-specific 
mortality rates to the YRDCYP cohort using population and mortality data 
between 1978 and 2014. These data were available by 5-year age group and 
sex (263). The Poisson distribution was used to calculate the SMR 95% 
confidence intervals.  
It would have been preferable to use the geographical region of the former 
YRHA as the general population for the early T1D onset group and the West 
Yorkshire region as the general population for the late T1D onset group (191). 
However, population and mortality data for the general population at this level 
for the required years and demographic breakdowns were unavailable.  
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The England and Wales population and mortality rates included individuals with 
T1D, which may have caused bias in the SMRs. However, as the prevalence of 
T1D was less than 0.5% (264) this bias in SMRs was low according to Jones 
and Swerdlow’s (1998) recalculated unbiased SMRs (265).  
As the general population does not die from T1D-related underlying causes, 
SMRs by T1D-related deaths were not calculated. Calculating SMRs using the 
same standardisation for T1D-related deaths would lead to inflated SMRs for 
the YRDCYP cohort. However, individuals who died from a T1D-related 
underlying cause were included in all-cause mortality SMR calculations. Any 
analysis for T1D-related deaths was limited to mortality rates and survival 
analysis.  
 
4.3 Results of analysis from the Yorkshire Register of Diabetes 
in Children and Young People (YRDCYP). 
4.3.1 Demographics. 
The YRDCYP cohort included a total of 5,498 individuals (100,959 person-years 
of follow-up) (Table 4.2). More individuals with early T1D onset were diagnosed 
in later years, with a third diagnosed from 1999 with 16 years or less follow-up 
time. This contributed to similar median follow-up times per person between the 
early (17.7 years (range 1.5 to 38 years)) and the late T1D onset group (16.3 
years (range 0.3 to 25 years)), despite data collection beginning 13 years earlier 
in the early T1D onset group. 
The majority of the YRDCYP (n=3,712; 67.5% of the total cohort) were 
classified as being of white or South Asian ethnic origin. There were 14 
individuals who were classified with either black or East Asian ethnicity. These 
individuals have been included under the ‘Other’ ethnicity category. In the South 
Asian/Other group, 75.3% were classified in the most deprived fifth. This is 
compared with 24.9% of individuals with white ethnic origin who were classified 
in the most deprived fifth (Table 4.3). 
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Table 4.2: Number (and percentage) of individuals and person-years by age at type 1 diabetes (T1D) diagnosis and sex. 
 
Age at T1D diagnosis Sex Total 
0 to 14 years 15 to 29 years  Males Females Unknown 
Total individuals 4,382  
(79.7%) 
1,116 
(20.3%) 
2,970 
(54.0%) 
2,527 
(46.0%) 
1 
(0.0%) 
5,498 
Total person-years 83,097.2 
(82.3%) 
17,861.9 
(17.7%) 
53,854.7 
(53.3%) 
47,097.5 
(46.7%) 
6.8 
(0.0%) 
100,959.0 
Mean person-years per individual 19.0 16.0 18.1 18.6 - 18.4 
Median person-years per individual 17.7 16.3 17.1 17.5 - 17.3 
Age at T1D 
diagnosis 
0 to 14 years  
(early onset) 
- - 2,276 
(51.9%) 
2,105 
(48%) 
1 
(0.0%) 
4,382 
15 to 29 years  
(late onset) 
- - 694 
(62.2%) 
422 
(37.8%) 
- 1,116 
Sex Males 2,276 
(76.6%) 
694 
(23.4%) 
- - - 2,970 
Females 2,105 
(83.3%) 
422 
(16.7%) 
- - - 2,527 
Unknown 1 
(100.0%) 
- - - - 1 
Ethnicity White 2,707 
(81.0%) 
636 
(19%) 
1,762 
(52.7%) 
1,581 
(47.3%) 
- 3,343 
South Asian/Other 272 
(72.9%) 
101 
(27.1%) 
192 
(51.5%) 
181 
(48.5%) 
- 373 
Unknown 1,403 
(78.7%) 
379 
(21.3%) 
1,016 
(57.0%) 
765 
(42.9%) 
1 
(0.0%) 
1,782 
Deprivation  Most deprived fifth 1,248 
(81.5%) 
284 
(18.5%) 
822 
(53.7%) 
710 
(46.3%) 
- 1,532 
2nd most deprived fifth 1,048 
(82.5%) 
222 
(17.5%) 
677 
(53.3%) 
593 
(46.7%) 
- 1,270 
3rd most deprived fifth 902 
(81.2%) 
209 
(18.8%) 
592 
(53.3%) 
518 
(46.6%) 
1 
(0.0%) 
1,111 
 2nd least deprived fifth 675 (77.1%) 
200 
(22.9%) 
473 
(54.1%) 
402 
(45.9%) - 875 
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 Least deprived fifth 509 (71.7%) 
201 
(28.3%) 
406 
(57.2%) 
304 
(42.8%) - 710 
 
Table 4.3: Number (and percentage) of individuals and person-years by deprivation. 
 
Deprivation 
Total Most 
deprived fifth 
2nd most 
deprived fifth 
3rd most 
deprived fifth 
2nd least 
deprived fifth 
Least 
deprived fifth 
Total individuals 1,532  (27.9%) 
1,270  
(23.1%) 
1,111  
(20.2%) 
875 
(15.9%) 
710 
(12.9%)  5,498  
Total person-years 27,877.5 (27.6%) 
22,917 
(22.7%) 
20,616.6 
(20.4%) 
16,428.6 
(16.3%) 
13,119.4 
(13.0%)  100,959.0  
Mean person-years per individual 18.2 18 18.6 18.8 18.5  18.4  
Median person-years per individual 17.4 16.5 17.5 17.9 17.4  17.3  
Age at 
T1D 
diagnosis 
0 to 14 years (early onset) 1,248  (28.5%) 
1,048  
(23.9%) 
902  
(20.6%) 
675  
(15.4%) 
509  
(11.6%)  4,382  
15 to 29 years (late onset) 284  (25.4%) 
222  
(19.9%) 
209  
(18.7%) 
200  
(17.9%) 
201  
(18.0%)  1,116  
Sex 
Males 822  (27.7%) 
677  
(22.8%) 
592  
(19.9%) 
473  
(15.9%) 
406  
(13.7%)  2,970  
Females 710  (28.1%) 
593  
(23.5%) 
518  
(20.5%) 
402  
(15.9%) 
304  
(12.0%)  2,527  
Unknown - - 1  (0%) - -  1  
Ethnicity 
White 831  (24.9%) 
825  
(24.7%) 
709  
(21.2%) 
563  
(16.8%) 
415  
(12.4%)  3,343  
South Asian/Other 281  (75.3%) 
53  
(14.2%) 
22  
(5.9%) 
13  
(3.5%) 
4  
(1.1%)  373  
Unknown 420  (23.6%) 
392  
(22.0%) 
380  
(21.3%) 
299  
(16.8%) 
291  
(16.3%)  1,782  
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4.3.2 Deaths by cause-specific mortality before and after clinical 
validation. 
There were 229 (4.2% of the cohort) death certificates, of which 123 mentioned 
diabetes of any type; forty-eight specifically mentioned T1D. After clinical 
validation of underlying cause of death, 53 (23.1%) deaths were reclassified. 
The majority were reclassified with T1D (n=119; 52%), including 10 deaths 
originally classified as being due to IHD and 5 deaths originally classified under 
renal disease. These deaths were reclassified as T1D-related deaths due to 
chronic complications. Twenty-three deaths which were originally coded as 
‘Other/Unknown’, were re-classified as deaths due to ‘Accidents and violence’ 
after clinical validation (Table 4.4).  
Table 4.4: Classification of underlying cause of death between the original 
clinical coder at the Office for National Statistics (ONS) and specialist 
diabetologist. 
Underlying cause of death Clinical coder  (% of total deaths) 
Specialist clinician 
(% of total deaths) 
Diabetes* 85 (37.1%) 119 (52.0%) 
Ischemic heart disease (IHD) 10 (4.4%) 0 
Stroke 1 (0.4%) 1 (0.4%) 
Renal disease 5 (2.2%) 0 
Respiratory failure 12 (5.2%) 7 (3.1%) 
Neoplasms 13 (5.7%) 13 (5.7%) 
Mental disorder 10 (4.4%) 10 (4.4%) 
Accidents and violence 18 (7.9%) 27 (11.8%) 
Suicide 14 (6.1%) 14 (6.1%) 
Other/Unknown 61 (26.6%) 38 (16.6%) 
Total 229 229 
*Specified, non-specified or unknown diabetes type for clinical coder. T1D for specialist clinician. 
Of the 119 deaths with an underlying cause of T1D, fifty-six deaths (around a 
quarter of all deaths) were due to T1D-related acute complications (DKA and 
severe hypoglycaemia). There were twice as many deaths due to DKA 
compared with severe hypoglycaemia. For T1D-related deaths due to chronic 
complications, there were 16 deaths due to renal complications and 17 deaths 
due to circulatory complications (16 deaths due to IHD and 1 death due to 
stroke) (Table 4.5).  
The accidents and violence category included the highest percentage of deaths 
for non-T1D related mortality (Table 4.6).
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Table 4.5: Number of type 1 diabetes (T1D) related deaths (and percentage of total deaths) by socio-demographic groups. 
  All T1D-related 
deaths  
Acute complications Chronic complications Total 
deaths DKA Hypoglycaemia Renal Circulatory 
Total individuals 119 (52%) 38 (16.6%) 18 (7.9%) 16 (7%) 17 (7%) 229 
Age at T1D 
diagnosis 
0 to 14 years (early onset) 88 (56.4%) 28 (17.9%) 15 (9.6%) 11 (7.1%) 15 (9.6%) 156 
15 to 29 years (late onset) 31 (42.5%) 10 (13.7%) 3 (4.1%) 5 (6.8%) 2 (2.7%) 73 
Sex Males 83 (50.3%) 26 (15.8%) 12 (7.3%) 8 (4.8%) 13 (7.9%) 165 
Females 36 (56.3%) 12 (18.8%) 6 (9.4%) 8 (12.5%) 4 (6.3%) 64 
Ethnicity    White 85 (50.3%) 30 (17.8%) 13 (7.7%) 10 (5.9%) 11 (6.5%) 169 
South Asian/Other 2 (22.2%) 0 0 1 (11.1%) 0 9 
Unknown  32 (62.7%) 8 (15.7%) 5 (9.8%) 5 (9.8%) 6 (11.8%) 51 
Deprivation  Most deprived fifth 30 (44.1%) 11 (16.2%) 2 (2.9%) 3 (4.4%) 4 (5.9%) 68 
2nd most deprived fifth 33 (58.9%) 2 (33.3%) 5 (8.9%) 7 (12.5%) 5 (8.9%) 56 
3rd most deprived fifth 27 (57.4%) 13 (50%) 6 (12.8%) 4 (8.5%) 2 (4.3%) 47 
2nd least deprived fifth 16 (34%) 1 (2.9%) 2 (6.1%) 1 (3%) 4 (12.1%) 33 
Least deprived fifth 13 (39.4%) 5 (10.4%) 3 (12%) 1 (4%) 2 (8%) 25 
Age at 
death 
5 to 9 1 (33.3%) 1 (33.3%) 0 0 0 3 
10 to 14 2 (33.3%) 2 (33.3%) 0 0 0 6 
15 to 19 17 (65.4%) 13 (50%) 2 (7.7%) 0 0 26 
20 to 24 13 (38.2%) 1 (2.9%) 4 (11.8%) 1 (2.9%) 2 (5.9%) 34 
25 to 29 21 (43.8%) 5 (10.4%) 5 (10.4%) 3 (6.3%) 2 (4.2%) 48 
30 to 34 22 (52.4%) 8 (19%) 7 (16.7%) 2 (4.8%) 3 (7.1%) 42 
35 to 39 24 (64.9%) 6 (16.2%) 14 (37.8%) 8 (21.6%) 4 (10.8%) 37 
40 to 44 11 (52.4%) 1 (4.8%) 5 (23.8%) 1 (4.8%) 3 (14.3%) 21 
45 to 49 6 (66.7%) 0 5 (55.6%) 1 (11.1%) 2 (22.2%) 9 
50 and over 2 (66.7%) 1 (33.3%) 1 (33.3%) 0 1 (33.3%) 3 
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Table 4.6: Number of non-type 1 diabetes (T1D) related deaths (and percentage of total deaths) by socio-demographic groups. 
  All non-
T1D 
related 
deaths 
Respiratory 
failure 
Neoplasms Accidents 
and violence 
Mental 
disorder 
Suicide Other/ 
Unknown 
Total 
deaths 
Total individuals 71 (31%) 7 (3.1%) 13 (5.7%) 27 (11.8%) 10 (4.4%) 14 (6.1%) 39 (17%) 229 
Age at T1D 
diagnosis 
0 to 14 years (early onset) 41 (26.3%) 5 (3.2%) 7 (4.5%) 18 (11.5%) 3 (1.9%) 8 (5.1%) 27 (17.3%) 156 
15 to 29 years (late onset) 30 (41.1%) 2 (2.7%) 6 (8.2%) 9 (12.3%) 7 (9.6%) 6 (8.2%) 12 (16.4%) 73 
Sex Males 53 (32.1%) 5 (3%) 9 (5.5%) 19 (11.5%) 7 (4.2%) 13 (7.9%) 29 (17.6%) 165 
Females 18 (28.1%) 2 (3.1%) 4 (6.3%) 8 (12.5%) 3 (4.7%) 1 (1.6%) 10 (15.6%) 64 
Ethnicity    White 52 (30.8%) 5 (3%) 7 (4.1%) 24 (14.2%) 9 (5.3%) 7 (4.1%) 32 (18.9%) 169 
South Asian/Other 7 (77.8%) 2 (22.2%) 3 (33.3%) 1 (11.1%) 1 (11.1%) 0 0 9 
Unknown  12 (23.5%) 0 3 (5.9%) 2 (3.9%) 0 7 (13.7%) 7 (13.7%) 51 
Deprivation   Most deprived fifth 24 (35.3%) 3 (4.4%) 5 (7.4%) 10 (14.7%) 4 (5.9%) 2 (2.9%) 14 (20.6%) 68 
2nd most deprived fifth 14 (25%) 3 (5.4%) 2 (3.6%) 4 (7.1%) 1 (1.8%) 4 (7.1%) 9 (16.1%) 56 
3rd most deprived fifth 12 (25.5%) 1 (2.1%) 2 (0%) 4 (8.5%) 3 (6.4%) 2 (4.3%) 8 (17%) 47 
2nd least deprived fifth 12 (36.4%) 0 (0%) 2 (6.1%) 6 (18.2%) 1 (3%) 3 (9.1%) 5 (15.2%) 33 
Least deprived fifth 9 (36%) 0 (0%) 2 (8%) 3 (12%) 1 (4%) 3 (12%) 3 (12%) 25 
Age at 
death 
5 to 9 1 (33.3%) 0 1 (33.3%) 0 0 0 1 (33.3%) 3 
10 to 14 3 (50%) 0 1 (16.7%) 2 (33.3%) 0 0 1 (16.7%) 6 
15 to 19 7 (26.9%) 1 (3.8%) 0 5 (19.2%) 0 1 (3.8%) 2 (7.7%) 26 
20 to 24 15 (44.1%) 4 (11.8%) 0 6 (17.6%) 2 (5.9%) 3 (8.8%) 6 (17.6%) 34 
25 to 29 19 (39.6%) 0 3 (6.3%) 8 (16.7%) 6 (12.5%) 2 (4.2%) 8 (16.7%) 48 
30 to 34 12 (28.6%) 2 (4.8%) 2 (4.8%) 4 (9.5%) 2 (4.8%) 2 (4.8%) 8 (19%) 42 
35 to 39 6 (16.2%) 0 1 (2.7%) 1 (2.7%) 0 4 (10.8%) 7 (18.9%) 37 
40 to 44 7 (33.3%) 0 4 (19%) 1 (4.8%) 0 2 (9.5%) 3 (14.3%) 21 
45 to 49 1 (11.1%) 0 1 (11.1%) 0 0 0 2 (22.2%) 9 
50 and over 0 (0%) 0 0 0 0 0 1 (33.3%) 3 
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4.3.3 Mortality analysis for the overall Yorkshire Register of 
Diabetes in Children and Young People (YRDCYP) cohort. 
4.3.3.1 Mortality rates. 
The overall mortality rate for all-cause mortality was 2.27 per 1,000 person-
years (95% CI 1.99 to 2.58) (Table 4.7).  
For T1D-related deaths due to acute complications, DKA had the highest 
mortality rate and was significantly higher compared with severe 
hypoglycaemia, which had the lowest mortality rate of all T1D-related causes. 
The DKA mortality rate was also significantly higher than the mortality rate for 
T1D-related deaths due to renal and circulatory chronic complications. No 
statistically significant difference in mortality rates was found between T1D-
related deaths due to renal and circulatory chronic complications (Table 4.7). 
There were no statistically significant differences in mortality rates between 
T1D-related and non-T1D related deaths. Accidents and violence had the 
highest mortality rate for non-T1D related deaths and was significantly higher 
than the mortality rate for deaths due to respiratory failure, which had the lowest 
mortality rate for non-T1D related causes (Table 4.8).
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Table 4.7: Mortality rates (and 95% CI) per 10,000 person-years for type 1 diabetes (T1D) related deaths by socio-demographic groups. 
  
All deaths 
T1D –related deaths 
All deaths DKA Severe hypoglycaemia Renal Circulatory 
Total cohort 2.27  (1.99 to 2.58) 
1.18  
(0.98 to 1.41) 
0.42  
(0.31 to 0.56) 
0.14  
(0.08 to 0.23) 
0.16  
(0.10 to 0.26) 
0.17  
(0.10 to 0.27) 
Age at T1D 
diagnosis 
0 to 14 years 
(early onset) 
1.88 
(1.60 to 2.20)+ 
1.06  
(0.86 to 1.31) 
0.37  
(0.26 to 0.53) 
0.14  
(0.08 to 0.25) 
0.13  
(0.07 to 0.24) 
0.18  
(0.11 to 0.30) 
15 to 29 years 
(late onset) 
4.09 
(3.25 to 5.14)**+ 
1.74  
(1.22 to 2.47) 
0.62  
(0.34 to 1.11) 
0.11  
(0.03 to 0.45) 
0.28  
(0.12 to 0.67) 
0.11  
(0.03 to 0.45) 
Sex Males 
3.06 
(2.63 to 3.57)**+ 
1.54  
(1.24 to 1.91) 
0.54  
(0.37 to 0.77) 
0.17  
(0.09 to 0.32) 
0.15  
(0.07 to 0.30) 
0.24  
(0.14 to 0.42) 
Females 
1.36 
(1.06 to 1.74)*+ 
0.76  
(0.55 to 1.06) 
0.28  
(0.16 to 0.48) 
0.11  
(0.04 to 0.26) 
0.17  
(0.08 to 0.34) 
0.08  
(0.03 to 0.23) 
Ethnicity    
White 
3.39 
(2.92 to 3.94)** 
1.71  
(1.38 to 2.11) 
0.66  
(0.47 to 0.93) 
0.20  
(0.11 to 0.37) 
0.20  
(0.11 to 0.37) 
0.22  
(0.12 to 0.40) 
South 
Asian/Other 
1.60  
(0.83 to 3.08) 
0.36  
(0.09 to 1.42) - - 
0.18  
(0.03 to 1.26) - 
Unknown  - - - - - - 
Deprivation   
Most deprived 
fifth 
2.44  
(1.92 to 3.09) 
1.08  
(0.75 to 1.54) 
0.39  
(0.22 to 0.71) 
0.07  
(0.02 to 0.29) 
0.11  
(0.03 to 0.33) 
0.14  
(0.05 to 0.38) 
2nd most 
deprived fifth 
2.44  
(1.88 to 3.18) 
1.44  
(1.02 to 2.03) 
0.44  
(0.23 to 0.81) 
0.22  
(0.09 to 0.52) 
0.31  
(0.15 to 0.64) 
0.22  
(0.09 to 0.52) 
3rd most 
deprived fifth 
2.28  
(1.71 to 3.03) 
1.31  
(0.90 to 1.91) 
0.49  
(0.26 to 0.90) 
0.15  
(0.05 to 0.45) 
0.19  
(0.07 to 0.52) 
0.10  
(0.02 to 0.39) 
2nd least 
deprived fifth 
2.01  
(1.43 to 2.83) 
0.97  
(0.60 to 1.59) 
0.43  
(0.20 to 0.89) 
0.06  
(0.01 to 0.43) 
0.06  
(0.01 to 0.43) 
0.24  
(0.09 to 0.65) 
Least deprived 
fifth 
1.91  
(1.29 to 2.82) 
0.99  
(0.58 to 1.71) 
0.30  
(0.11 to 0.81) 
0.23  
(0.07 to 0.71) 
0.08  
(0.01 to 0.54) 
0.15  
(0.04 to 0.61) 
*Statistically significantly lower than the mortality rate for the total cohort. 
**Statistically significantly higher than the mortality rate for the total cohort. 
+Statistically significantly different from other another group within the same socio-demographic variable.
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Table 4.8: Mortality rates (and 95% CI) per 10,000 person-years for non-type 1 diabetes (T1D) related deaths by socio-demographic 
groups. 
  
Non-T1D related deaths 
All deaths Respiratory failure Neoplasms Accidents and violence Mental disorder Suicide 
Total cohort 1.09  (0.9 to 1.31) 
0.07  
(0.03 to 0.15) 
0.13  
(0.07 to 0.22) 
0.27  
(0.18 to 0.39) 
0.10  
(0.05 to 0.18) 
0.14  
(0.08 to 0.23) 
Age at T1D 
diagnosis 
0 to 14 years 
(early onset) 
0.82  
(0.65 to 1.04)+ 
0.06  
(0.03 to 0.14) 
0.08  
(0.04 to 0.18) 
0.22  
(0.14 to 0.34) 
0.04  
(0.01 to 0.11)+ 
0.10  
(0.05 to 0.19) 
15 to 29 years 
(late onset) 
2.35  
(1.74 to 3.18)**+ 
0.11  
(0.03 to 0.45) 
0.34  
(0.15 to 0.75) 
0.5  
(0.26 to 0.97) 
0.39  
(0.19 to 0.82)+ 
0.34  
(0.15 to 0.75) 
Sex Males 
1.52  
(1.23 to 1.89)+ 
0.09  
(0.04 to 0.22) 
0.17  
(0.09 to 0.32) 
0.35  
(0.23 to 0.55) 
0.13  
(0.06 to 0.27) 
0.24  
(0.14 to 0.42) 
Females 
0.59  
(0.41 to 0.86)*+ 
0.04  
(0.01 to 0.17) 
0.08  
(0.03 to 0.23) 
0.17  
(0.08 to 0.34) 
0.06  
(0.02 to 0.2) 
0.02  
(0 to 0.15) 
Ethnicity    
White 
1.69  
(1.36 to 2.09)** 
0.1  
(0.04 to 0.24) 
0.14  
(0.07 to 0.29) 
0.48  
(0.32 to 0.72)+ 
0.18  
(0.09 to 0.35) 
0.14  
(0.07 to 0.29) 
South 
Asian/Other 
1.24  
(0.59 to 2.61) 
0.36  
(0.09 to 1.42) 
0.53  
(0.17 to 1.65) 
0.18  
(0.03 to 1.26) 
0.18  
(0.03 to 1.26) - 
Unknown  - - 
0.07  
(0.02 to 0.2) 
0.04  
(0.01 to 0.18)*+ - 
0.15  
(0.07 to 0.32) 
Deprivation   
Most deprived 
fifth 
1.36  
(0.99 to 1.87) 
0.11  
(0.03 to 0.33) 
0.18  
(0.07 to 0.43) 
0.36  
(0.19 to 0.67) 
0.14  
(0.05 to 0.38) 
0.07  
(0.02 to 0.29) 
2nd most 
deprived fifth 
1  
(0.67 to 1.51) 
0.13  
(0.04 to 0.41) 
0.09  
(0.02 to 0.35) 
0.17  
(0.07 to 0.47) 
0.04  
(0.01 to 0.31) 
0.17  
(0.07 to 0.47) 
3rd most 
deprived fifth 
0.97  
(0.63 to 1.5) 
0.05  
(0.01 to 0.34) 
0.1  
(0.02 to 0.39) 
0.19  
(0.07 to 0.52) 
0.15  
(0.05 to 0.45) 
0.10  
(0.02 to 0.39) 
2nd least 
deprived fifth 
1.03  
(0.64 to 1.66) - 
0.12  
(0.03 to 0.49) 
0.37  
(0.16 to 0.81) 
0.06  
(0.01 to 0.43) 
0.18  
(0.06 to 0.57) 
Least deprived 
fifth 
0.91  
(0.52 to 1.61) - 
0.15  
(0.04 to 0.61) 
0.23  
(0.07 to 0.71) 
0.08  
(0.01 to 0.54) 
0.23  
(0.07 to 0.71) 
*Statistically significantly lower than the mortality rate for the total cohort. 
**Statistically significantly higher than the mortality rate for the total cohort. 
+Statistically significantly different from other another group within the same socio-demographic variable.
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4.3.3.2 Survival analysis. 
Although there was no statistically significant difference in mortality rates 
between T1D-related and non-T1D related deaths, Kaplan-Meier curves 
indicated that there was significantly higher cumulative mortality for non-T1D 
related compared with T1D-related mortality over T1D duration (Figure 4.2).  
 
 
Figure 4.2: Cumulative mortality curves by type 1 diabetes (T1D) and non-T1D 
related deaths. 
 
Figure 4.3 showed a significantly higher cumulative mortality over T1D duration 
for deaths due to T1D-related acute complications compared with chronic 
complications.  
Log rank test: p<0.00 
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Figure 4.3: Cumulative mortality curves for type 1 diabetes (T1D) related deaths 
due to acute and chronic complications. 
 
Figure 4.4 showed the cumulative mortality curves for T1D-related deaths due 
to DKA and severe hypoglycaemia. This showed a higher cumulative mortality 
for T1D-related deaths due to DKA from around 6 years T1D duration.  
 
 
Log rank test: p<0.00 
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Figure 4.4: Cumulative mortality curves by diabetic ketoacidosis (DKA) and 
severe hypoglycaemia. 
 
Figure 4.5 showed the cumulative mortality curves for T1D-related deaths due 
to renal, circulatory and other complications. T1D-related deaths due to renal 
complications shows higher mortality compared with T1D-related deaths due to 
circulatory complications from around 13 years of T1D duration. 
 
Log rank test: p>0.05 
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Figure 4.5: Cumulative mortality curves by renal, circulatory and other deaths 
due to type 1 diabetes (T1D) related complications. 
 
When examining Kaplan-Meier cumulative mortality curves by non-T1D related 
underlying causes of death, mental disorders showed the highest mortality over 
T1D duration and neoplasms showed the lowest mortality (Figure 4.6).  
 
Log rank test (renal and circulatory): p>0.05 
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Figure 4.6: Cumulative mortality curves by non-type 1 diabetes (T1D) related 
underlying causes of death. 
 
4.3.3.3 Standardised mortality ratios (SMRs). 
Compared with the general population, the overall SMR for all-cause mortality 
found a significant excess of deaths in the YRDCYP of 4.3 (95% CI 3.8 to 4.9). 
SMRs for non-T1D related underlying cause of death found a significant excess 
of death compared with the general population for respiratory failure, mental 
disorder and suicide. There was no significant excess of deaths due to 
neoplasms and accidents and violence. The SMR for deaths due to mental 
disorder was significantly higher than the SMR for neoplasms (Figure 4.7). 
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Figure 4.7: Standardised mortality ratios (SMRs) by all-cause mortality and non-
type 1 diabetes (T1D) related deaths. 
 
4.3.4 Mortality analysis of the Yorkshire Register of Diabetes in 
Children and Young People (YRDCYP) cohort by age at death. 
There were 9 deaths before the transitional care period (under 15 years). A third 
of these deaths were due to DKA. There were no deaths due to severe 
hypoglycaemia or chronic T1D complications in this age group (Table 4.5).  
During the transitional care period, there were 108 deaths. Forty-seven per cent 
(n=51) of these deaths were due to T1D-related underlying causes and the rest 
were non-T1D related deaths. Of the 51 T1D-related deaths, 30 were due to 
acute complications, with over a third of deaths due to DKA in the 15 to 19-year 
age group. Deaths due to T1D-related chronic complications started in the 20 to 
24-year age group (Table 4.5). For non-T1D related deaths, the majority of 
deaths for respiratory failure, accidents and violence and mental disorder 
occurred during the transitional care period. Total deaths due to accidents and 
violence and mental disorder peaked within the 25 to 29-year old age group. 
The age group with the greatest total of deaths due to respiratory failure 
occurred in the 20 to 24-year age group (Table 4.6).  
After the transitional care period, there were 112 deaths. Nearly 60% of these 
deaths were due to T1D-related underlying causes, with most deaths due to 
severe hypoglycaemia. Most T1D-related deaths due to renal and circulatory 
complications occurred after the transitional care period. Total deaths due to 
severe hypoglycaemia and renal complications peaked within the 35 to 39-year 
age group (Table 4.5). For non-T1D related deaths, most deaths due to 
neoplasms and suicide also occurred after the transitional care period. The 5-
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year age groups with the greatest total of deaths for these causes occurred in 
the 40 to 44-year age group for neoplasms and 35 to 39 for suicide (Table 4.6). 
 
4.3.4.1 Mortality rates. 
Mortality rates for all-cause mortality by age at death showed a significantly 
lower mortality incidence rate for the 40 to 44 and the 45 to 49-year age groups 
compared with the overall all-cause mortality rate (Figure 4.8). 
 
Figure 4.8: Mortality rates for all-cause mortality by age at death. 
 
When comparing cause-specific mortality incidence rates by age at death, the 
15 to 19-year age group have a significantly higher mortality incidence for DKA 
compared with the overall DKA mortality incidence rate (Figure 4.9; Table 4.9).  
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Figure 4.9: Mortality rates for type 1 diabetes (T1D) related deaths due to 
diabetic ketoacidosis (DKA) by age at death. 
 
There were no other significant differences from the overall mortality rate for 
any T1D-related underlying cause of death (Table 4.9). 
For all non-T1D related deaths, the 45 to 49-year age group had a significantly 
lower mortality rate compared with the overall non-T1D related mortality rate. 
For deaths due to neoplasms, the 5 to 9-year age group showed a significantly 
higher mortality rate compared with the overall neoplasm mortality rate for all 
ages. There were no other significantly different mortality rates by age groups 
compared with the overall cause-specific mortality rates for any other non-T1D 
related underlying causes of death (Table 4.10).
0.01
0.02
0.03
0.06
0.13
0.25
0.50
1.00
2.00
4.00
8.00
16.00
5	
to
	9
10
	to
	14
15
	to
	19
20
	to
	24
25
	to
	29
30
	to
	34
35
	to
	39
40
	to
	44
45
	to
	49
50
	a
nd
	o
ve
r
M
or
ta
lit
y	r
at
e	
(p
er
	1
,0
00
	p
er
so
n-
ye
ar
s)
Age	at	death	(Years)
Overall	DKA	mortality	rate Overall	DKA	mortality	rate	95%	CI
  
79	
Table 4.9: Mortality rates (and 95% CI) per 10,000 person-years for all deaths and for type 1 diabetes (T1D) related deaths by age at 
death. 
Age at death All deaths 
Type 1 diabetes-related deaths 
All T1D 
deaths DKA 
Severe 
hypoglycaemia Renal Circulatory 
5 to 9 6.13 (1.98 to 19) 
2.04 
(0.29 to 14.5) 
2.04 
(0.29 to 14.5) - - - 
10 to 14 2.66 (1.2 to 5.93) 
0.89 
(0.22 to 3.55) 
0.89 
(0.22 to 3.55) - - - 
15 to 19 3.64 (2.48 to 5.35) 
2.38** 
(1.48 to 3.83) 
1.82** 
(1.06 to 3.13) - - - 
20 to 24 2.96 (2.11 to 4.14) 
1.13 
(0.66 to 1.95) 
0.17 
(0.04 to 0.7) 
0.35 
(0.13 to 0.93) 
0.09 
(0.01 to 0.62) 
0.17 
(0.04 to 0.7) 
25 to 29 3.39 (2.55 to 4.49) 
1.48 
(0.97 to 2.27) 
0.56 
(0.28 to 1.13) 
0.28 
(0.11 to 0.75) 
0.21 
(0.07 to 0.66) 
0.14 
(0.04 to 0.56) 
30 to 34 2.66 (1.97 to 3.6) 
1.39 
(0.92 to 2.12) 
0.51 
(0.25 to 1.01) 
0.06 
(0.01 to 0.45) 
0.13 
(0.03 to 0.51) 
0.19 
(0.06 to 0.59) 
35 to 39 2.13 (1.54 to 2.93) 
1.38 
(0.92 to 2.06) 
0.34 
(0.15 to 0.77) 
0.06 
(0.01 to 0.41) 
0.46 
(0.23 to 0.92) 
0.23 
(0.09 to 0.61) 
40 to 44 1.2* (0.78 to 1.84) 
0.63 
(0.35 to 1.13) 
0.06 
(0.01 to 0.4) 
0.23 
(0.09 to 0.61) 
0.06 
(0.01 to 0.4) 
0.17 
(0.06 to 0.53) 
45 to 49 0.75* (0.39 to 1.44) 
0.5 
(0.22 to 1.11) - - 
0.08 
(0.01 to 0.59) 
0.17 
(0.04 to 0.67) 
50 and over 1.14 (0.37 to 3.52) 
0.76 
(0.19 to 3.03) 
0.38 
(0.05 to 2.69) - - 
0.38 
(0.05 to 2.69) 
All ages 2.27 (1.99 to 2.58) 
1.18 
(0.98 to 1.41) 
0.42 
(0.31 to 0.56) 
0.14 
(0.08 to 0.23) 
0.16 
(0.1 to 0.26) 
0.17 
(0.1 to 0.27) 
*Statistically significantly lower than the mortality rate for all ages. 
**Statistically significantly higher than the mortality rate for all ages.
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Table 4.10: Mortality rates (and 95% CI) per 10,000 person-years for non-type 1 diabetes (T1D) related deaths by age at death. 
Age at death 
Non-T1D related deaths 
All deaths Respiratory failure Neoplasms 
Accidents 
and violence 
Mental 
disorder Suicide 
5 to 9 4.09 (1.02 to 16.34) - 
2.04** 
(0.29 to 14.5) - - - 
10 to 14 1.78 (0.67 to 4.73) - 
0.44 
(0.06 to 3.15) 
0.89 
(0.22 to 3.55) - - 
15 to 19 1.26 (0.66 to 2.42) 
0.14 
(0.02 to 0.99) - 
0.7 
(0.29 to 1.68) - 
0.14 
(0.02 to 0.99) 
20 to 24 1.83 (1.19 to 2.8) 
0.35 
(0.13 to 0.93) - 
0.52 
(0.23 to 1.16) 
0.17 
(0.04 to 0.7) 
0.26 
(0.08 to 0.81) 
25 to 29 1.9 (1.31 to 2.78) - 
0.21 
(0.07 to 0.66) 
0.56 
(0.28 to 1.13) 
0.42 
(0.19 to 0.94) 
0.14 
(0.04 to 0.56) 
30 to 34 1.27 (0.82 to 1.96) 
0.13 
(0.03 to 0.51) 
0.13 
(0.03 to 0.51) 
0.25 
(0.1 to 0.67) 
0.13 
(0.03 to 0.51) 
0.13 
(0.03 to 0.51) 
35 to 39 0.75 (0.43 to 1.29) - 
0.06 
(0.01 to 0.41) 
0.06 
(0.01 to 0.41) - 
0.23 
(0.09 to 0.61) 
40 to 44 0.57 (0.31 to 1.06) - 
0.23 
(0.09 to 0.61) 
0.06 
(0.01 to 0.4) - 
0.11 
(0.03 to 0.46) 
45 to 49 0.25* (0.08 to 0.77) - 
0.08 
(0.01 to 0.59) - - - 
50 and over 0.38 (0.05 to 2.69) - - - - - 
All ages 1.09  (0.9 to 1.31) 
0.07  
(0.03 to 0.15) 
0.13  
(0.07 to 0.22) 
0.27  
(0.18 to 0.39) 
0.1  
(0.05 to 0.18) 
0.14  
(0.08 to 0.23) 
*Statistically significantly lower than the mortality rate for all ages. 
**Statistically significantly higher than the mortality rate for all ages. 
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4.3.4.2 Standardised mortality ratios (SMRs). 
SMRs by age at death showed significant excess of deaths compared with the 
general population from the 10 to 14-year age group onwards (Figure 4.11). 
Although there are no significant differences in SMRs between age groups, 
there appeared to be an increasing trend in SMRs up to 5.9 (95% CI 4.4 to 7.8) 
in the 25 to 29-year age group. SMRs then began to decrease gradually for the 
older age groups. The 50 and over age group had the highest SMR at 6.7 (95% 
CI 2.1 to 20.7). However, there were only three deaths in this age group (Table 
4.5). 
 
Figure 4.10: Standardised mortality ratios (SMRs) by age at death. 
 
4.3.5 Mortality analysis of the Yorkshire Register of Diabetes in 
Children and Young People (YRDCYP) cohort by age of T1D 
onset group. 
There were more deaths in the group diagnosed with early T1D onset (n=156) 
compared with the group diagnosed with late T1D onset (n=73) (Table 4.5). 
However, the percentage of deaths in the late T1D onset group (6.5%) was 
nearly twice the percentage of deaths in the early T1D onset group (3.6%).  
The percentage of deaths due to all T1D-related underlying causes was greater 
in the early T1D onset group at 56.4% compared with the late T1D onset group 
at 42.5%. The early T1D onset also had a greater percentage of deaths 
compared with the late T1D onset group for deaths due to DKA and severe 
hypoglycaemia. For T1D-related deaths due to chronic complications, the 
percentage of deaths due to renal complications was similar between the onset 
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groups. However, the percentage of deaths due to circulatory complications in 
the early T1D onset group was around 3.5 times that of the late T1D onset 
group (Table 4.5). 
For non-T1D related deaths, the late T1D onset group had a higher percentage 
of deaths due to neoplasms, mental disorder and suicide (Table 4.6). 
 
4.3.5.1 Mortality rates. 
There was a significantly higher all-cause mortality rate for the late T1D onset 
group compared with both the all-cause mortality rate for the whole cohort and 
for the all-cause mortality incidence rate for the early T1D onset group. When 
examining cause-specific mortality, only deaths due to non-T1D related causes 
had a significantly higher mortality rate for the late T1D onset group compared 
with the whole cohort and the early T1D onset group (Table 4.7). 
 
4.3.5.2 Survival analysis. 
Cumulative mortality curves by onset group show higher mortality over T1D 
duration for the early T1D onset group compared with the late T1D onset group 
(Figure 4.11).  
 
Figure 4.11: Cumulative mortality curves by age at type 1 diabetes (T1D) onset 
group. 
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Log-rank test found that there was a statistically significant difference in 
cumulative mortality between the onset groups (Table 4.11). 
 
Table 4.11: Log-rank tests for Kaplan-Meier estimators by socio-demographic 
group 1 and socio-demographic group 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Statistically significant difference in cumulative mortality between socio-demographic group 1 and socio-
demographic group 2. 
 
Cox regression modelling found that late T1D onset had over a three-fold 
significantly higher risk of all-cause mortality compared with early T1D onset, 
when adjusted for sex, year of diagnosis and deprivation (Table 4.12). Separate 
analysis of both early and late onset groups showed that those diagnosed in 
later years had a significantly lower risk of all-cause mortality, where for each 
one year increase in year of diagnosis the HR was 0.97 (95% CI 0.94 to 0.99) 
and 0.93 (95% CI 0.88 to 0.99), respectively (Table 4.12).  
For all T1D-related mortality, Cox regression modelling found that the late onset 
group had a significantly higher risk of death compared with the early onset 
group (Table 4.13). However, no significant differences between the onset 
groups were found for acute complications, DKA or severe hypoglycaemia. 
There was a significantly higher HR for deaths due to T1D-related chronic 
complications for the late onset group compared with the early onset group by 
over six-fold.  
For non-T1D related mortality, Cox regression modelling found significantly 
higher HRs for the late onset group compared with the early onset group for all 
non-T1D related deaths and deaths due to neoplasms, accidents and violence, 
mental disorder and suicide (Table 4.14).  
Socio-demographic group 1 Socio-demographic group 2 p-value 
Early T1D onset Late T1D onset <0.00* 
Males Females <0.00* 
White South Asian 0.02* 
Least deprived fifth 2nd least deprived fifth 0.85 
Least deprived fifth 3rd most deprived fifth 0.51 
Least deprived fifth 2nd most deprived fifth 0.28 
Least deprived fifth Most deprived fifth 0.28 
2nd least deprived fifth 3rd most deprived fifth 0.60 
2nd least deprived fifth 2nd most deprived fifth 0.34 
2nd least deprived fifth Most deprived fifth 0.33 
3rd most deprived fifth 2nd most deprived fifth 0.61 
3rd most deprived fifth Most deprived fifth 0.65 
2nd most deprived fifth Most deprived fifth 0.95 
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Table 4.12: Cox regression hazard ratios (and 95% CI) by age at type 1 diabetes (T1D) onset group for all-cause mortality. 
Age at T1D diagnosis Late onset vs early onset 
Females vs 
males 
Year of 
diagnosis 
Most deprived 
fifth vs least 
deprived fifth 
2nd most 
deprived fifth 
vs least 
deprived fifth 
3rd most 
deprived fifth 
vs least 
deprived fifth 
2nd least 
deprived fifth 
vs least 
deprived fifth 
All 3.69 (2.63 to 5.16)** 
0.45 
(0.34 to 0.61)* 
0.96 
(0.94 to 0.98)* 
1.47 
(0.93 to 2.33) 
1.55 
(0.97 to 2.49) 
1.36 
(0.84 to 2.21) 
1.15 
(0.68 to 1.93) 
0 to 14 years (early 
onset) - 
0.46 
(0.33 to 0.65)* 
0.97 
(0.94 to 0.99)* 
1.32 
(0.75 to 2.33) 
1.36 
(0.76 to 2.44) 
1.15 
(0.63 to 2.09) 
1.01 
(0.53 to 1.93) 
15 to 29 years (late 
onset) - 
0.44 
(0.25 to 0.76)* 
0.93 
(0.88 to 0.99)* 
1.72 
(0.78 to 3.77) 
1.9 
(0.85 to 4.26) 
1.86 
(0.82 to 4.27) 
1.41 
(0.59 to 3.35) 
*Statistically significantly lower hazard ratio. 
**Statistically significantly higher hazard ratio. 
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Table 4.13: Cox regression hazard ratios (and 95% CI) by age at type 1 diabetes (T1D) onset group for T1D-related mortality. 
Underlying 
cause of death 
Age at T1D 
diagnosis 
Late onset vs 
early onset 
Females vs 
males 
Year of 
diagnosis 
Most deprived 
fifth vs least 
deprived fifth 
2nd most 
deprived fifth 
vs least 
deprived fifth 
3rd most 
deprived fifth 
vs least 
deprived fifth 
2nd least 
deprived fifth vs 
least deprived 
fifth 
All T1D-related 
deaths 
All 3.05  (1.86 to 5)** 
0.49  
(0.33 to 0.73)* 
0.96  
(0.93 to 0.995)* 
1.21  
(0.63 to 2.32) 
1.7  
(0.89 to 3.25) 
1.45  
(0.74 to 2.81) 
1.05  
(0.5 to 2.18) 
0 to 14 years 
(early onset) -  
0.48  
(0.31 to 0.75)* 
0.96  
(0.93 to 0.999)* 
0.81  
(0.39 to 1.69) 
1.24  
(0.61 to 2.53) 
1.1  
(0.53 to 2.28) 
0.84  
(0.37 to 1.91) 
15 to 29 years 
(late onset) - 
0.53  
(0.24 to 1.19) 
0.96  
(0.88 to 1.05) 
3.8  
(0.83 to 17.37) 
4.47  
(0.96 to 20.68) 
3.3  
(0.66 to 16.36) 
2.12  
(0.39 to 11.57) 
T1D-related 
deaths due to 
acute 
complications 
All 1.81  (0.91 to 3.62) 
0.55  
(0.31 to 0.96)* 
0.99  
(0.95 to 1.03) 
0.94  
(0.37 to 2.35) 
1.35  
(0.55 to 3.32) 
1.25  
(0.5 to 3.14) 
1.25  
(0.5 to 3.14) 
0 to 14 years 
(early onset)  - 
0.51  
(0.27 to 0.96)* 
0.99  
(0.94 to 1.03) 
0.65  
(0.23 to 1.83) 
1.08  
(0.41 to 2.88) 
1.05  
(0.39 to 2.83) 
0.63  
(0.19 to 2.08) 
15 to 29 years 
(late onset)  - 
0.68  
(0.2 to 2.17) 
1.05  
(0.92 to 1.19) 
3.07  
(0.34 to 27.5) 
2.86  
(0.3 to 27.52) 
2.09  
(0.19 to 23.08) 
3.22  
(0.33 to 31) 
T1D-related 
deaths due to 
acute 
complications 
(DKA) 
All 1.85  (0.87 to 3.92) 
0.52  
(0.27 to 1.01) 
1.01  
(0.96 to 1.06) 
1.4  
(0.44 to 4.42) 
1.58  
(0.49 to 5.06) 
1.71  
(0.54 to 5.49) 
1.48  
(0.43 to 5.05) 
T1D-related 
deaths due to 
acute 
complications 
(severe 
hypoglycaemia) 
All 1.8  (0.31 to 10.49) 
0.61  
(0.2 to 1.82) 
0.93  
(0.84 to 1.02) 
0.33  
(0.05 to 1.96) 
1.04  
(0.25 to 4.4) 
0.64  
(0.13 to 3.17) 
0.27  
(0.03 to 2.64) 
T1D-related 
deaths due to 
chronic 
complications 
All 6.26  (2.25 to 17.46)** 
0.64  
(0.34 to 1.2) 
0.9  
(0.84 to 0.97)* 
1.32  
(0.41 to 4.23) 
2.26  
(0.73 to 6.96) 
1.74  
(0.54 to 5.58) 
1.27  
(0.36 to 4.51) 
0 to 14 years 
(early onset)  - 
0.56  
(0.27 to 1.14) 
0.89  
(0.82 to 0.97) 
0.69  
(0.19 to 2.44) 
1.5  
(0.47 to 4.79) 
1.01  
(0.3 to 3.46) 
1.18  
(0.33 to 4.18) 
15 to 29 years 
(late onset)  - 
1.04  
(0.29 to 3.69) 
0.93  
(0.76 to 1.13) - - - - 
*Statistically significantly lower hazard ratio. 
**Statistically significantly higher hazard ratio. 
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Table 4.14: Cox regression hazard ratios (and 95% CI) for non-type 1 diabetes (T1D) related mortality. 
Underlying 
cause of 
death 
Age at T1D 
diagnosis 
Late onset vs 
early onset 
Females vs 
males 
Year of 
diagnosis 
Most deprived 
fifth vs least 
deprived fifth 
2nd most 
deprived fifth 
vs least 
deprived fifth 
3rd most 
deprived fifth 
vs least 
deprived fifth 
2nd least 
deprived fifth 
vs least 
deprived fifth 
All non-T1D 
related deaths 
All 4.35  (2.74 to 6.91) 
0.41  
(0.27 to 0.63) 
0.96  
(0.93 to 0.99) 
1.78  
(0.93 to 3.4) 
1.37  
(0.68 to 2.76) 
1.25  
(0.61 to 2.57) 
1.26  
(0.6 to 2.64) 
0 to 14 years 
(early onset)  - 
0.44  
(0.26 to 0.74) 
0.97  
(0.94 to 1.01) 
2.45  
(0.94 to 6.34) 
1.64  
(0.6 to 4.52) 
1.25  
(0.44 to 3.61) 
1.38  
(0.46 to 4.11) 
15 to 29 years 
(late onset)  - 
0.37  
(0.17 to 0.8) 
0.91  
(0.85 to 0.99) 
1.12  
(0.43 to 2.94) 
1.16  
(0.42 to 3.19) 
1.46  
(0.54 to 3.92) 
1.21  
(0.44 to 3.34) 
Neoplasms All 14.27  (2.63 to 77.54)** 
0.55  
(0.17 to 1.78) 
0.92  
(0.81 to 1.05) 
1.49  
(0.29 to 7.74) 
0.78  
(0.11 to 5.59) 
0.81  
(0.11 to 5.84) 
0.91  
(0.13 to 6.44) 
Accidents and 
violence All 
3.57  
(1.37 to 9.29)** 
0.5  
(0.22 to 1.15) 
0.92  
(0.87 to 0.98)* 
1.79  
(0.49 to 6.55) 
0.91  
(0.2 to 4.1) 
0.96  
(0.21 to 4.32) 
1.74  
(0.43 to 6.96) 
Mental 
disorder All 
13.6  
(2.79 to 66.41)** 
0.59  
(0.15 to 2.29) 
0.94  
(0.84 to 1.04) 
2.61  
(0.29 to 23.49) 
0.82  
(0.05 to 13.25) 
2.71  
(0.28 to 26.22) 
0.96  
(0.06 to 15.46) 
Suicide All 4.21  (1.17 to 15.09)** 
0.09  
(0.01 to 0.71)* 
0.98  
(0.89 to 1.08) 
0.39  
(0.06 to 2.36) 
1  
(0.22 to 4.5) 
0.52  
(0.09 to 3.12) 
0.91  
(0.18 to 4.54) 
*Statistically significantly lower hazard ratio. 
**Statistically significantly higher hazard ratio.
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4.3.5.3 Standardised mortality ratios (SMRs). 
Despite differences found between the early and late T1D onset groups for all-
cause mortality incidence rates and Cox regression modelling, there were no 
significant differences in SMRs between the onset groups. The SMRs were 4.1 
(95% CI 3.6 to 4.8) for the early T1D onset group and 4.7 (95% CI 3.8 to 5.9) for 
the late T1D onset group.  
For T1D-related underlying causes of death, there were 16 deaths due to IHD 
with an SMR of 8.5 (95% CI 5.2 to 13.9). In early onset, there were 14 deaths, 
beginning in the 20 to 24-0year age group, with a median age at death of 35.1 
years and SMR of 13.8 (95% CI 8.2 to 23.3). There was no significant excess in 
deaths due to IHD in the late onset group (SMR 2.3 (95% CI 0.6 to 9.3)) where 
there were 2 deaths (both male) which occurred in the 35 to 39 and the 50 and 
over age group.  
Suicide was the only non-T1D related underlying cause of death where there 
was an excess in deaths for both early (SMR 2.1 (95% CI 1.0 to 4.2)) and late 
T1D onset (SMR 3.5 (95% CI 1.6 to 7.7)).  
 
4.3.6 Mortality analysis of the Yorkshire Register of Diabetes in 
Children and Young People (YRDCYP) cohort by sex. 
The percentage of deaths in males was higher at 7.2% compared with the 
percentage of deaths in females which was 3.0%.  
The percentage of deaths due to all T1D-related underlying causes was higher 
in the females (56.3%) compared with males (50.3%). Females had a slightly 
greater percentage of deaths compared with males for deaths due to DKA and 
severe hypoglycaemia. For T1D-related deaths due to chronic complications, 
the percentage of deaths due to circulatory complications was similar for both 
sexes. However, the percentage of deaths due to renal complications in 
females was around 3 times that of males (Table 4.5). 
For non-T1D related deaths, the percentages of deaths for respiratory failure, 
neoplasms, accidents and violence and mental disorder were similar between 
the sexes. However, there were 7.9% of male deaths due to suicide, compared 
with 1.6% of female deaths due to suicide (Table 4.6). 
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4.3.6.1 Mortality rates. 
All-cause mortality rate for males was significantly higher compared with the all-
cause mortality rate for the whole cohort and for the all-cause mortality rate for 
females. The all-cause mortality rate for females was significantly lower than the 
all-cause mortality rate for the whole cohort (Table 4.7).  
Cause-specific mortality rate found that T1D-related deaths was significantly 
different between the sexes, where males had a significantly higher mortality 
rate compared with females. There were no significant differences between the 
sexes for T1D-related deaths due to acute or chronic complications (Table 4.7) 
or for non-T1D related causes (Table 4.8).  
 
4.3.6.2 Survival analysis. 
Cumulative mortality curves by sex show a higher mortality over T1D duration 
for males compared with females (Figure 4.12). The log-rank test found that 
there was a statistically significant difference in cumulative mortality between 
the sexes (Table 4.11). 
 
Figure 4.12: Cumulative mortality curves by sex. 
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Cox regression modelling found that females had a lower mortality risk from all-
cause mortality (Table 4.12), T1D-related (Table 4.13), all non-T1D related 
deaths and suicide (Table 4.14). Females also had lower mortality risk in the 
early T1D onset only for all-cause (Table 4.12), T1D-related mortality (Table 
4.13). Both early and late onset groups had significantly lower risk of death for 
females compared with males for all non-T1D related mortality (Table 4.14). 
However, there were no significant differences in mortality risk between males 
and females by T1D-related acute (including DKA and severe hypoglycaemia) 
or chronic complications (Table 4.13).  
 
4.3.6.3 Standardised mortality ratios (SMRs). 
Although most deaths occurred in males, the SMR for males (4.4 (95% CI 3.8 to 
5.2); n=165) was similar to females (4.0 (95% CI 3.2 to 5.2); n=64). 
Mental disorder deaths were significantly higher for males (SMR 4.2 (95% CI 
2.0 to 8.7) and females 8.4 (SMR 95% CI 2.7 to 26.03) compared with the 
general population. Males only had a significant excess in deaths for suicide 
(SMR 2.8 (95% CI 1.6 to 4.8)) and respiratory failure (SMR 4.1 (95% CI 1.7 to 
9.8)).  
 
4.3.7 Mortality analysis of the Yorkshire Register of Diabetes in 
Children and Young People (YRDCYP) cohort by ethnicity. 
The percentage of deaths for white ethnic origin was higher at 5.1% compared 
with the percentage of deaths for South Asian origin which was 3%. There were 
no deaths for the ‘Other’ ethnicity group. 
The percentage of deaths due to all T1D-related underlying causes was 50.3% 
in the white ethnicity group compared with 22.2% in the South Asian ethnicity 
group. There were no T1D-related deaths due to acute complications for South 
Asian ethnicity and there was only one T1D-related death due to renal 
complications for South Asian ethnicity (Table 4.5).  
 
4.3.7.1 Survival analysis. 
The cumulative mortality curves between white and South Asian ethnicity 
showed higher mortality for the white ethnic origin group (Figure 4.13). The log-
rank test found a statistically significant difference between cumulative mortality 
curves between white and South Asian ethnicity (Table 4.11). 
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Figure 4.13: Cumulative mortality curves by ethnicity. 
 
4.3.7.2 Standardised mortality ratios (SMRs). 
Both white and South Asian ethnicity had a significant excess in mortality 
compared with the general population. However, the SMR was significantly 
higher for white ethnicity compared to South Asian (8.1 (95% CI 6.9 to 9.4) vs. 
3.4 (95% CI 1.7 to 6.4)).   
White ethnicity had an excess in mental health-related mortality (12.9 (95% CI 
6.7 to 24.8)) and exhibited an excess of deaths due to accidents (2.8 (95% CI 
1.8 to 4.1)). South Asian ethnicity had an excess in deaths due to neoplasms 
(SMR 6.5 (95% CI 2.1 to 20.1). 
 
4.3.8 Mortality analysis of the Yorkshire Register of Diabetes in 
Children and Young People (YRDCYP) cohort by deprivation 
group. 
The percentage of deaths is similar between each deprivation group at around 
5%. The highest percentage was found in the most deprived fifth at 5.4% and 
the lowest percentage was found in the 2nd least deprived fifth at 4.9% (Table 
4.4). 
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4.3.8.1 Mortality rates. 
The most deprived fifth had the highest all-cause mortality rate of the five 
deprivation groups and the least deprived fifth had the lowest mortality rate. 
However, there were no significant differences in mortality rates between any of 
the deprivation groups. Mortality rates by cause-specific mortality also found no 
significant differences by deprivation groups (Table 4.7, Table 4.8). 
 
4.3.8.2 Survival analysis. 
Cumulative mortality curves show higher mortality in the most deprived fifth 
compared with the least deprived fifth from around 10 years T1D duration, 
particularly during 20 to around 34 years since T1D diagnosis (Figure 4.14). 
However, log-rank tests showed that there was no significant difference 
between these two groups. Log rank tests were performed between all other 
deprivation groups and no other significant difference in mortality over T1D 
duration was found between any other deprivation groups (Table 4.11). 
 
 
Figure 4.14: Cumulative mortality curves by deprivation groups. 
 
Cox regression modelling found no significant difference in mortality risk 
between each of the four most deprived fifths and the least deprived fifth for 
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overall all-cause, T1D-related and non-T1D related mortality. There were no 
other significant differences by deprivation by onset group and underlying cause 
(Table 4.13).  
 
4.3.8.3 Standardised mortality ratios (SMRs). 
All deprivation categories had an excess of deaths compared to the general 
population. Although there is a slight visible decreasing trend in SMRs from the 
most deprived fifth to the least deprived fifth, there were no significant 
differences found in SMRs between any of the deprivation groups (Figure 4.15).  
 
 
Figure 4.15: Standardised mortality ratios (SMRs) for all-cause mortality by 
deprivation group. 
 
4.3.9 Cox regression modelling diagnostics. 
The test for proportional hazards assumptions for the Cox regression models 
found no evidence that the proportional hazards assumption had been violated 
(Table 4.15). 
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Table 4.15: Global test results for proportional hazards assumption. 
Underlying cause of death Global test for proportional hazards assumption 
All causes 
0.5138 
0.1999 
0.7137 
T1D-related deaths 
0.6916 
0.4715 
0.9133 
Non-T1D related deaths 
0.6731 
0.4793 
0.8549 
 
4.4 Summary of results. 
Analysis by age at death showed some evidence for more deaths during the 
transitional care period. T1D-related deaths due to DKA had a significantly 
higher mortality rate in the 15 to 19-year age group compared with the over 40 
DKA mortality rate. However, T1D-related deaths due to severe hypoglycaemia, 
renal and circulatory complications mostly appeared after the transitional age 
group. 
Analysis by age at T1D onset groups found significantly higher mortality in the 
late onset group. Cox regression models found statistically significantly higher 
mortality in the late onset group for all-cause, T1D-related and non-T1D related 
mortality. There was, however, a significant excess in deaths due to IHD in 
early onset which was not found in the late onset group. 
Males were shown to have significantly higher mortality compared with females 
for all-cause and T1D-related mortality. For non-T1D related deaths, males had 
a higher percentage of deaths due to suicide compared with females. There 
was also an excess of deaths by suicide compared with the general population 
in males but not females. 
There was significantly higher mortality in the white ethnic origin group 
compared with South Asian ethnicity, although there was a large percentage of 
the cohort where ethnicity could not be classified. 
There was no evidence of any significant differences in all-cause or cause-
specific mortality by deprivation groups. 
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4.5 Overall summary analysis compared with previous studies.  
The overall SMR (ratio between the observed and the expected number of 
deaths) for the YRDCYP (4.3; 95% CI 3.8 to 4.9) was similar to the SMR found 
on the previous analysis of the dataset (4.7; 95% CI 3.8 to 5.6), indicating an 
excess of deaths in the T1D population compared with the general population 
(175). An excess in deaths was also found across different countries in a review 
for 23 studies by Morgan and colleagues, where the SMR ranged between 0 to 
8.54 (266). This review mostly included individuals with early T1D onset, so 
direct comparison of SMRs with these studies should be treated with caution. 
The only other cohort to include individuals diagnosed with both early and late 
T1D onset (under 30 years old) was in the New Zealand Canterbury Diabetes 
Registry; Brown and colleagues found an overall SMR of 2.64 (95% CI 2.36 to 
2.96), around half the excess number of deaths compared with this analysis 
(267). The YRDCYP cohort included a larger number of individuals (n=5,498) 
compared with the Canterbury cohort (n=1,008) and covered a longer follow-up 
period (9 years vs. 35 years), which may explain the difference in SMRs 
between the two datasets. 
 
4.6 Health outcomes by attained age groups before, during 
and after the transitional care period. 
There are few previous studies to have included SMRs by age, particularly 
comparing time periods before, during and after the transitional care period. For 
all-cause mortality in the YRDCYP, there was a non-significant trend of 
increasing SMRs with age at death. There was a peak during the transitional 
care period, with the highest SMR in the 25 to 29 age group (5.9 (95% CI 4.4 to 
7.8)), before decreasing after the transitional care period. This trend was similar 
to results by Brown and colleagues in the New Zealand Canterbury Diabetes 
Registry, although the peak SMR occurred in the 30 to 39-year age group at 
9.23 (95% CI 4.77 to 16.15), before decreasing with older age groups (267). 
There was no age breakdown in the Canterbury cohort before and during the 
transitional care period. Dahlquist and Kallen (2005) did include age groups 
before and after the transitional care period and found that the highest SMR 
occurred in the 10 to 14-year age group (SMR (4.38 (95% CI 1.14 to 4.37)) 
(192). However, this Swedish cohort only included individuals with early onset 
T1D.  
For T1D-related mortality, analysis by age at death in the YRDCYP showed 
some evidence for more deaths during the transitional care period compared 
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with other age groups. The 15 to 19-year age group was the only age group to 
have a significantly higher overall T1D-related and DKA mortality rates 
compared with the overall mortality rate for all ages.  
 
4.7 Health outcomes by onset before and during the 
transitional care period.  
There was no significant difference in SMRs between early (0 to 14 years) and 
late T1D onset (15 to 29 years) for all-cause mortality. Survival analysis showed 
there was a significantly higher all-cause mortality risk in the late onset group up 
to 20 years of diabetes duration. As the late onset group were older than the 
early onset group, early death observed in early onset could be due to longer 
duration of T1D, allowing for risk factors of mortality to develop at an earlier 
age. Previous research has seen similar findings with all-cause mortality where 
pre-pubertal groups (diagnosed before 12 in males and before 11 in females) 
have lower mortality risk than in pubertal groups (diagnosed between 12 and 16 
in males and 11 and 16 in females) (268,269). In those diagnosed in older ages 
(30 years and over), Florkowski (2003) found a decreasing excess mortality with 
increasing age at T1D diagnosis and duration of those diagnosed with T1D 
under 30 and survived to 50 years of age had the same life expectancy as the 
general population (193). 
For cause-specific mortality, the HR was significantly higher in the late T1D 
onset group for chronic T1D-related complications and deaths due to mental 
health disorder and suicide. An explanation for these differences between onset 
groups could be due to the difference in experience and knowledge of 
managing T1D. For example, a child diagnosed with T1D may have had more 
preparation in managing T1D through the transitional care period compared 
with someone diagnosed during the transitional care period. Gibb and 
colleagues found some evidence for this where they also found a higher risk of 
DKA mortality and recurrent DKA hospitalisations in those diagnosed in 
adolescence compared with those diagnosed as children (270). 
 
4.8 Health outcomes by socio-demographic groups. 
No significant differences were found in all-cause SMRs between sexes. The 
New Zealand Canterbury cohort (193,267) and a multi-centre Danish cohort 
(196) also found no significant differences in all-cause SMRs between males 
and females. However, other studies have shown a significantly higher SMR for 
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females compared with males in Japan and Finland (176,271), Australia (186), 
Sweden (192) and Italy (197). This may be due to differences between 
countries in mortality rates in the general population. For example, in 2016 the 
adult mortality rate for 15 to 60-year olds in the UK for females was 52 per 
1,000 population. In Japan, the mortality rate was lower at 36 per 1,000 
population (263). An excess in deaths in the T1D population may appear larger 
for females in Japan when the mortality rate in the general population is low. 
For cause-specific mortality, sex differences were found for both T1D and non-
T1D related deaths. Cox regression found that only sex was significantly 
associated with mortality risk from T1D acute complications, with a notable 
increased risk in males. However, it was difficult to ascertain whether deaths 
due to acute complications were self-inflicted with the intention of suicide. This 
could mean that suicide rates were underestimated. The number of suicides 
was highest in males with nearly 10% of all male deaths due to suicide. Higher 
suicide rates were also reported for males compared with females in Harjutsalo 
and colleagues’ study in Finland and also in the DCCT cohort (172,176). The 
DCCT cohort also found nominally more suicides in the intensive treatment 
group compared with the conventional treatment group, suggesting that the 
introduction of intensive insulin treatment may be associated with an increase in 
mental health issues, although this link needs more examination (172).  
Few UK studies have analysed mortality by ethnicity, possibly due to difficulties 
in collecting ethnicity data. However, there was evidence from the Allegheny 
cohort (USA) that excess deaths were associated with black ethnicity compared 
with white ethnicity due to diabetes complications (201,202). Ethnicity is often 
linked with deprivation, where minority ethnic groups are more likely to be most 
deprived. Collier and colleagues found no differences between African-
Americans and white low socio-economic status Americans (173). White 
ethnicity had a significantly higher SMR compared with South Asians, 
contradicting international studies where minority ethnicities are associated with 
higher mortality risk (177,197,201). However, around 32% of the cohort had 
incomplete full names, so could not be classified to an ethnicity group by 
Onomap software. Additionally, Onomap had limitations in ability to consider 
marital status name changes and identification of mixed ethnicities. This could 
mean that the South Asian total could be underestimated.  
There were no significant differences for all-cause or cause-specific SMRs by 
deprivation. Few studies have included analysis by deprivation. Where there 
has been analysis, having lower socio-economic status increased risk of death 
(186,197,198,270,272–275). However, it is difficult to compare results with other 
studies where different definitions of deprivation are used. 
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4.9 Chapter summary. 
Analysis of mortality in a cohort of individuals with T1D showed some evidence 
of an increase of death during the transitional care period, with a peak in SMRs 
for all-cause mortality in the 25 to 29-year age group and a significantly higher 
rate of deaths due to DKA in the 15 to 19-year age group. DKA was further 
examined in the LCYPDS for individuals receiving CSII in chapter 5.  
There was also evidence to suggest that there was a difference in mortality 
between age at T1D onset groups, where the late onset group had a 
significantly higher risk of death due to chronic T1D-related complications, 
mental health and suicide.  
Analysis by socio-demographics found significant differences between sexes 
and ethnicity. There was an increased risk of death due to acute T1D-related in 
males compared with females. Males also had a higher percentage of deaths 
due to suicide. White ethnicity had a significantly higher SMR for all-cause 
mortality compared with South Asian ethnicity, in contrast to international 
studies where ethnic minority groups were found to have an increase in death. 
Chapter 5 continues using a T1D cohort (LCYPDS) to examine negative health 
outcomes, focusing on individuals receiving CSII therapy. Although limited in 
follow-up time and age coverage, the LCYPDS cohort provided valuable insight 
into the patient pathway assessing hospitalisations and sex differences in 
negative health outcomes.
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Chapter 5 Continuous Subcutaneous Insulin Infusion (CSII) 
therapy for type 1 diabetes (T1D). 
This chapter describes the statistical methodology used and results from 
analysis of the LCYPDS dataset. It begins by defining the categorisations of the 
data and continues with a description of the statistics used in the analysis and 
reports the results. 
There were two main health outcomes measured using the LCYPDS dataset: 
1. HbA1c value since T1D diagnosis before and after CSII therapy initiation. 
2. Hospitalisation rates since T1D diagnosis before and after CSII therapy 
initiation. 
 
5.1 Variable definitions. 
5.1.1 Pre-, during and after continuous subcutaneous insulin 
infusion (CSII) therapy time periods.  
Details on categorising HbA1c values and hospitalisations between pre-, during 
and post-CSII are found in section 3.2.2.  
 
5.1.2 Continuous subcutaneous insulin infusion (CSII) therapy 
status. 
The CSII therapy status referred to whether an individual continued or 
discontinued CSII therapy whilst attending the LCYPDS. Any individual with a 
CSII therapy end date was classed as having discontinued CSII therapy. 
Individuals with no CSII end date were classed as having continued CSII 
therapy up to their last recorded appointment date. It could not be determined 
whether CSII therapy continued beyond that date. 
 
5.1.3 Continuous subcutaneous insulin infusion (CSII) duration 
categorisation. 
CSII duration was categorised by one year time periods. Further subgrouping 
was completed for the first year by ‘under 3 months’, ‘3 to under 6 months’ and 
‘6 months to under 1 year’. This subgrouping was useful analysis for individuals 
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new to CSII therapy. Individuals attending the LCYPDS were invited to attend 
appointments every 3 months. As HbA1c measures average blood glucose over 
two to three months, examining HbA1c values by 3 month periods after the CSII 
start date would be sufficient in detecting any changes in HbA1c values due to 
CSII therapy. Hospitalisation rates were examined using the same CSII duration 
groups for comparison. 
 
5.1.4 Cause-specific hospitalisation categorisation. 
Hospitalisations were categorised by T1D-related and non-T1D related causes. 
T1D-related causes for hospitalisation included DKA, severe hypoglycaemia 
and re-stabilisation/control of diabetes. There was no subgrouping of non-T1D 
related causes as these were not recorded in the dataset. All other causes for 
hospitalisation were either categorised as ‘other’ or ‘unknown’ if the cause was 
not recorded. 
 
5.2 Statistical methodology. 
5.2.1 Multi-level modelling to examine differences in HbA1c values 
before and after continuous subcutaneous insulin infusion 
(CSII) therapy initiation. 
Comparing differences in HbA1c values before and after the start of CSII 
therapy by using t-tests or ANOVAs would rely on the assumption of 
independence between observations. In the LCYPDS dataset, repeated HbA1c 
observations were recorded for the same individuals at different appointment 
attendances. This violated the assumption of independence and could 
potentially result in erroneous conclusions with these methodologies. Therefore, 
multi-level modelling methodology was used to account for these repeated 
measures within the same individuals by considering the variation between 
individuals (level 1) as well as within individuals (level 2), reducing bias due to 
mathematical coupling and regression to the mean compared with single level 
modelling (137). This modelling approach has previously been used on the 
LCYPDS cohort (138). In this study, additional analysis included comparisons 
by CSII duration period, sex and by CSII therapy status.  
A multi-level random intercept model assumed that the relationship between 
pre- and during CSII HbA1c values was the same for all individuals. An overall 
random intercept model was run for the cohort. Separate models were also run 
by sex and for different CSII duration periods by sex and CSII therapy status.  
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Multi-level random slope models assumed that the relationship between pre- 
and during CSII HbA1c values differed between individuals. A random slope 
model was run to determine if there were any differences between individuals 
who continued and discontinued CSII. This model was compared by model fit 
with the equivalent random intercept model by calculating Akaike’s information 
criterion and Bayesian information criterion (Appendix C). 
To test whether the multi-level models were better than an ordinary logistic 
regression model, log likelihood tests were performed. 
There was one individual who restarted CSII therapy around 4 years after 
originally discontinuing CSII therapy. This individual was included twice in the 
models with a two different level 2 identifiers. Although it could be argued that a 
previous instance of CSII therapy may influence the results of the second pre-
CSII period, it was clinically judged that the gap was long enough for any effect 
to be at a minimum. As a second CSII therapy occurrence was only found in 
one individual, it was felt that including their second CSII occurrence with a 
separate identifier would not have much bias on the overall results. 
To determine which variables should be adjusted for in the models, a DAG was 
completed (Figure 5.1) based on discussions with and advice from clinical 
specialists. This DAG included pre-CSII HbA1c as the exposure variable and 
HbA1c and hospitalisation rates after CSII initiation as two outcome variables. 
The variables sex and age at diabetes diagnosis were found as confounders 
and were adjusted for in all models. Pre-CSII hospitalisation was found to be a 
mediator, so was excluded from the models. 
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Confounders = sex, age at diagnosis 
Proxy confounders = age at CSII start, pre-CSII diabetes duration 
Mediator = pre-CSII hospitalisation 
Figure 5.1: Directed Acyclic Graph (DAG) for multi-level modelling for HbA1c 
level in the Leeds Children and Young People’s Diabetes Service (LCYPDS) 
cohort. 
 
5.2.2 Calculation of hospitalisation rates. 
Hospitalisation rates were calculated for the pre- and during CSII periods by 
sex, both overall and by CSII status. Hospitalisation rates were calculated by 
dividing the total number of hospitalisations by the total person-years of follow-
up for the whole LCYPDS cohort. Hospitalisation rates were calculated for 
overall hospitalisations, T1D-related non-T1D related causes.  
 
5.3 Results of analysis from the Leeds Children and Young 
People’s Diabetes Service (LCYPDS). 
5.3.1 Demographics. 
A total of 161 individuals were included in this study, with one individual with 
two instances of CSII therapy. Table 5.1 shows the cohort by sex and CSII 
status with median age of T1D diagnosis and CSII initiation.
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Table 5.1: Number (and percentage) of individuals, HbA1c and hospitalisation observations and median (and range) of ages and time 
periods by sex and continuous subcutaneous insulin infusion (CSII) status. 
  Sex CSII status Total 
Males Females Continued Discontinued 
Total individuals 70  
(43.2%) 
92  
(56.8%) 
132  
(81.5%) 
30  
(18.5%) 
162 
Males - - 62  
(88.6%) 
8  
(11.4%) 
70 
Females - - 70  
(76.1%) 
22  
(23.9%) 
92 
Total HbA1c observations – pre-CSII 257  
(42.8%) 
343  
(57.2%) 
479  
(79.8%) 
121  
(20.2%) 
600 
Total HbA1c observations – during 
CSII  
688  
(42.5%) 
929  
(57.5%) 
1317  
(81.4%) 
300  
(18.6%) 
1,617 
Total HbA1c observations – after CSII 62  
(44.6%) 
77  
(55.4%) 
- 139  
(100%) 
139 
Total hospitalisations - pre-CSII 19  
(33.3%) 
38  
(66.7%) 
42  
(73.7%) 
15  
(26.3%) 
57 
Total hospitalisations - during CSII 23  
(29.1%) 
56 (70.9%) 67  
(84.8%) 
12  
(15.2%) 
79 
Median (range) age at T1D diagnosis 7 
(0.9 to 13.7) 
5.6 
(1.1 to 14.4) 
6.3 
(0.9 to 13.7) 
6.5 
(1.1 to 14.4) 
6.3 
(0.9 to 14.4) 
Median (range) age at CSII start 12.1 
(1.1 to 17.6) 
11.2 
(1.9 to 16.7) 
11.7 
(1.1 to 17.6) 
12.7 
(6.5 to 16.7) 
11.9 
(1.1 to 17.6) 
Median (range) follow- up pre-CSII 0.8 
(0.01 to 1.88) 
0.8 
(0.04 to 1.97) 
0.8 
(0.01 to 1.97) 
0.8 
(0.21 to 1.58) 
0.8 
(0.01 to 1.97) 
Median (range) CSII duration 2.2 
(0.1 to 7.1) 
2.5 
(0 to 8.1) 
2.3 
(0 to 8.1) 
2.5 
(0.1 to 5.2) 
2.3 
(0 to 8.1) 
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There were more females than males (56.8% vs. 43.2%) in the LCYPDS cohort 
who started CSII therapy. The percentage of HbA1c observations pre- and 
during CSII therapy by sex were split similarly to the overall percentages for the 
total number of individuals by sex. However, the percentage of females with a 
hospitalisation was greater at around 70% versus 30% in males in both pre- and 
during CSII time periods (Table 5.1).  
There were 30 individuals (18.5%) who discontinued CSII therapy, most of 
whom were female (n=22; 73.3%). The percentage of pre-CSII hospitalisations 
by CSII status was higher in the discontinued group (26.3%) compared with the 
overall percentages for the total number of individuals by CSII status (Table 
5.1). 
The median ages at T1D onset and CSII start were similar by sex and CSII 
status. However, where the youngest age at CSII start was 1 year in the 
continued group, the youngest age at CSII start was 6 years in the discontinued 
group (Table 5.1). 
There were more HbA1c and hospitalisations observations during CSII 
compared with pre-CSII therapy. Median follow-up time from first recorded pre-
CSII HbA1c value to CSII initiation was around three times shorter that the 
median CSII therapy duration (0.8 years (range 0.01 to 1.97 years) vs. 2.3 
years (range 0 to 8.1 years)) (Table 5.1). Therefore, there was less follow-up 
time pre-CSII for HbA1c observations and hospitalisations to occur compared 
with the CSII. 
There were more T1D-related hospitalisations compared with non-T1D related 
hospitalisations, both pre- and during CSII. The overall percentage of T1D-
related hospitalisations was around 10% higher in the discontinued CSII group 
(n=11; 73.3%) compared with those who continued CSII (n=25; 59.5%) for the 
pre-CSII period (Table 5.2). There were no hospitalisations recorded for the 
discontinued CSII group after a CSII end date. 
 
5.3.2 HbA1c levels before and after the initiation of continuous 
subcutaneous insulin infusion (CSII). 
For the overall cohort, the median HbA1c value pre-CSII was 8.9% (range 5.5 
to 15.9%) compared with 8.3% (range 5.4 to 14.4%) during CSII (Table 5.3).
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 Table 5.2: Number (and percentage) of hospitalisations by sex and continuous subcutaneous insulin infusion (CSII) status. 
 Hospitalisation type 
CSII period and CSII status Sex T1D-related DKA Severe hypoglycaemia Non-T1D related Total*  
Pre-CSII: all 
All 36 (63.2%) 15 (26.3%) 8 (14%) 10 (17.5%) 57 
Males 12 (63.2%) 2 (10.5%) 4 (21.1%) 4 (21.1%) 19 
Females 24 (63.2%) 13 (34.2%) 4 (10.5%) 6 (15.8%) 38 
Pre-CSII: continued CSII 
All 25 (59.5%) 14 (33.3%) 3 (7.1%) 7 (16.7%) 42 
Males 7 (50%) 2 (14.3%) 0  4 (28.6%) 14 
Females 18 (64.3%) 12 (42.9%) 3 (10.7%) 3 (10.7%) 28 
Pre-CSII: discontinued CSII 
All 11 (73.3%) 14 (93.3%) 5 (33.3%) 3 (20%) 15 
Males 5 (100%) 0  4 (80%) 0  5 
Females 6 (60%) 1 (10%) 1 (10%) 3 (30%) 10 
During CSII: all 
All 43 (54.4%) 27 (34.2%) 6 (7.6%) 22 (27.8%) 79 
Males 14 (60.9%) 11 (47.8%) 1 (4.3%) 7 (30.4%) 23 
Females 29 (51.8%) 16 (28.6%) 5 (8.9%) 15 (26.8%) 56 
During CSII: continued CSII 
All 35 (52.2%) 20 (29.9%) 6 (9%) 21 (31.3%) 67 
Males 13 (65%) 10 (50%) 1 (5%) 6 (30%) 20 
Females 22 (46.8%) 10 (21.3%) 5 (10.6%) 15 (31.9%) 47 
During CSII: discontinued 
CSII 
All 8 (66.7%) 7 (58.3%) 0  1 (8.3%) 12 
Males 1 (33.3%) 1 (33.3%) 0  1 (33.3%) 3 
Females 7 (77.8%) 6 (66.7%) 0  0  9 
*Total includes ‘Unknown’ hospitalisation type. 
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Table 5.3: HbA1c values by sex, continuous subcutaneous insulin infusion (CSII) period and CSII status. 
 CSII period and CSII status  Sex Total HbA1c observations 
Mean HbA1c 
value (%) 
Median (range) HbA1c 
value (%) 
Standard 
deviation of 
HbA1c value (%) 
Pre-CSII: all 
All 600 9.2 8.9 (5.5 to 15.9) 1.6 
Males 257 9.2 9.1 (5.5 to 14.7) 1.5 
Females 343 9.1 8.8 (6.2 to 15.9) 1.7 
Pre-CSII: continued CSII 
All 479 9.0 8.8 (5.5 to 15.9) 1.5 
Males 225 9.2 9.1 (5.5 to 14.7) 1.6 
Females 254 8.8 8.7 (6 to 15.9) 1.5 
Pre-CSII: discontinued CSII 
All 121 9.9 9.5 (7.1 to 14) 1.7 
Males 32 9.6 9.45 (7.4 to 12.8) 1.3 
Females 89 10.0 9.5 (7.1 to 14) 1.8 
During CSII: all 
All 1,617 8.5 8.3 (5.4 to 14.4) 1.4 
Males 688 8.4 8.2 (5.4 to 14.04) 1.4 
Females 929 8.6 8.4 (5.5 to 14.4) 1.4 
During CSII: continued CSII 
All 1,317 8.3 8.2 (5.4 to 12.8) 1.2 
Males 614 8.3 8.1 (5.4 to 12.8) 1.2 
Females 703 8.3 8.28 (5.5 to 12.6) 1.2 
During CSII: discontinued 
CSII 
All 300 9.5 9.2 (5.6 to 14.4) 1.8 
Males 74 9.5 9.3 (6.5 to 14.04) 1.8 
Females 226 9.5 9.2 (5.6 to 14.4) 1.8 
After CSII: discontinued CSII 
All 139 9.5 9.1 (6.2 to 14.04) 1.9 
Males 62 9.1 8.85 (6.2 to 12.1) 1.3 
Females 77 9.8 9.3 (6.9 to 14.04) 2.2 
  
106 
106	
The results from the random intercept model for the overall cohort found a 
significantly higher reduction in mean HbA1c value during CSII of 0.62% (95% 
CI 0.53% to 0.72%) (Table 5.4).  
Table 5.4: Mean HbA1c value change during (and after) continuous 
subcutaneous insulin infusion (CSII) therapy from pre-CSII values by CSII 
period and status and sex. 
CSII period and CSII status Sex Mean HbA1c value change (and 95% 
CI) from pre-CSII vales (%) 
During CSII – all  
All -0.62 (-0.72 to -0.53)* 
Males -0.78 (-0.92 to -0.64)* 
Females -0.5 (-0.63 to -0.38)* 
During CSII – 
continued CSII 
All -0.67 (-0.77 to -0.58)* 
Males -0.86 (-1 to -0.72)* 
Females -0.51 (-0.64 to -0.38)* 
During CSII – 
discontinued CSII 
All -0.43 (-0.71 to -0.15)* 
Males -0.12 (-0.64 to 0.4) 
Females -0.54 (-0.87 to -0.21)* 
After CSII discontinuation -   
discontinued CSII 
All 0.11 (-0.23 to 0.44) 
Males -0.03 (-0.57 to 0.51) 
Females 0.25 (-0.17 to 0.67) 
*Statistically significant decrease in mean HbA1c value from pre-CSII values 
 
Random intercept models by CSII duration found that there was an overall 
significant decrease in HbA1c maintained for up to 4 years (Figure 5.2).  
 
Figure 5.2: Mean HbA1c value change during continuous subcutaneous insulin 
infusion (CSII) therapy from pre-CSII values by CSII duration. 
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After 4 years, HbA1c values returned to pre-CSII levels until 7 years CSII 
duration. The 7 years and over category had the largest change in HbA1c with a 
decrease of 0.89% (0.38 to 1.39%), although small numbers were observed in 
this category (Table 5.5). 
Table 5.5: Number of individuals and mean HbA1c value change during 
continuous subcutaneous insulin infusion (CSII) therapy from pre-CSII values 
by CSII duration. 
CSII duration Total individuals Mean HbA1c value change 
(and 95%CI) from pre-CSII 
value (%) 
Under 3 months 132 -0.74 (-0.92 to -0.56)* 
3 to <6 months 133 -0.79 (-0.97 to -0.61)* 
6 months to <1 year 142 -0.78 (-0.93 to -0.63)* 
1 year to <2 years 130 -0.63 (-0.76 to -0.5)* 
2 years to <3 years 93 -0.53 (-0.7 to -0.36)* 
3 years to <4 years 63 -0.35 (-0.56 to -0.14)* 
4 years to <5 years 36 -0.2 (-0.55 to 0.15) 
5 years to <6 years 20 -0.39 (-0.84 to 0.06) 
6 years to <7 years 15 0.25 (-0.35 to 0.84) 
7 years and over 4 -0.89 (-1.39 to -0.38)* 
*Statistically significant decrease in mean HbA1c value from pre-CSII values 
**Statistically significant increase in mean HbA1c value from pre-CSII values 
 
5.3.3 Hospitalisation rates before and after the initiation of 
continuous subcutaneous insulin infusion (CSII). 
The overall incidence rate of all hospitalisations was significantly higher during 
CSII (24.27 per 100 person-years (95%CI 19.47 to 30.26 per 100 person-
years)) compared to pre-CSII (8.39 per 100 person-years (95%CI 6.48 to 10.88 
per 100 person-years) (Table 5.6).
  
108	
Table 5.6: Hospitalisation incidence rates per 100 person-years (and 95%CI) by sex, hospitalisation type, CSII period and CSII status in 
the LCYPDS. 
CSII period 
and CSII 
status 
Sex All hospitalisations T1D-related DKA Severe hypoglycaemia Non-T1D related 
Pre-CSII: all 
All 8.39 (6.48 to 10.88) 
5.22 
(3.77 to 7.24) 
2.16 
(1.3 to 3.59) 
1.13 
(0.57 to 2.27) 
1.45 
(0.78 to 2.7) 
Males 6.8 (4.34 to 10.66) 
4.17 
(2.37 to 7.34) 
0.69 
(0.17 to 2.76) 
1.36 
(0.51 to 3.63) 
1.41 
(0.53 to 3.76) 
Females 9.51 (6.92 to 13.07) 
5.98 
(4.01 to 8.93) 
3.22 
(1.87 to 5.55) 
0.97 
(0.36 to 2.59) 
1.49 
(0.67 to 3.31) 
Pre-CSII: 
continued CSII 
All 7.73 (5.71 to 10.46) 
4.52 
(3.05 to 6.69) 
2.52 
(1.49 to 4.25) 
0.53 
(0.17 to 1.64) 
1.27 
(0.61 to 2.67) 
Males 5.56 (3.29 to 9.39) 
2.69 
(1.28 to 5.64) 
0.77 
(0.19 to 3.06) 
- 1.57 
(0.59 to 4.17) 
Females 9.59 (6.62 to 13.89) 
6.14 
(3.87 to 9.74) 
4.07 
(2.31 to 7.16) 
0.99 
(0.32 to 3.08) 
1.02 
(0.33 to 3.15) 
Pre-CSII: 
discontinued 
CSII 
All 11.08 (6.68 to 18.37) 
8.11 
(4.49 to 14.65) 
2.52 
(1.49 to 4.25) 
3.64 
(1.52 to 8.76) 
2.19 
(0.71 to 6.78) 
Males 17.94 (7.47 to 43.1) 
17.94 
(7.47 to 43.1) 
- 14.25 
(5.35 to 7.98) 
- 
Females 9.3 (5 to 17.28) 
5.57 
(2.5 to 12.39) 
0.92 
(0.13 to 6.53) 
0.92 
(0.13 to 6.51) 
2.75 
(0.89 to 8.53) 
During CSII: all 
All 24.27 (19.47 to 30.26)* 
12.06 
(8.94 to 16.26)* 
7.4 
(5.08 to 10.8)* 
1.48 
(0.67 to 3.3) 
5.85 
(3.85 to 8.88)* 
Males 16.12 (10.71 to 24.26)* 
9.23 
(5.47 to 15.58) 
7.15 
(3.96 to 12.91)* 
0.59 
(0.08 to 4.21) 
4.36 
(2.08 to 9.15) 
Females 30.63 (23.57 to 39.8)* 
14.15 
(9.83 to 20.36)* 
7.59 
(4.65 to 12.39) 
2.11 
(0.88 to 5.08) 
6.95 
(4.19 to 11.54)* 
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During CSII: 
continued CSII 
All 25.05 (19.72 to 31.83)* 
11.84 
(8.5 to 16.5)* 
6.56 
(4.23 to 10.16) 
1.8  
(0.81 to 4) 
6.86 
(4.47 to 10.52)* 
Males 15.84 (10.22 to 24.55) 
9.68 
(5.62 to 16.66) 
7.32 
(3.94 to 13.61)* 
0.67 
(0.09 to 4.73) 
4.19 
(1.88 to 9.33) 
Females 33.29 (25.01 to 44.31)* 
13.65 
(8.99 to 20.73) 
5.93 
(3.19 to 11.03) 
2.72 
(1.13 to 6.54) 
- 
During CSII: 
discontinued 
CSII 
All 20.69 (95%CI 11.75 to 36.44) 
13.08 
(95%CI 6.54 to 26.16) 
11.74 
(95%CI 5.6 to 24.62) 
- 1.43 
(95%CI 0.2 to 10.13) 
Males 18.35 (95%CI 5.92 to 56.89) 
5.77 
(95%CI 0.81 to 40.97) 
5.77 
(95%CI 0.81 to 40.97) 
- 5.76 
(95%CI 0.81 to 40.91) 
Females 21.61 (95%CI 11.25 to 41.54) 
15.97 
(95%CI 7.61 to 33.5) 
14.18 
(95%CI 6.37 to 31.57) 
- - 
*Statistically significant increase in hospitalisation incidence rate during CSII from pre-CSII rates.
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There were also significant increases in hospitalisation incidence during CSII 
compared with pre-CSII incidence for T1D-related hospitalisation, DKA and 
non-T1D-related hospitalisations. The increase in DKA incidence was over 3-
fold (Table 5.6). There was no significant difference between pre- and during 
CSII incidence for severe hypoglycaemia.  
Analysis by CSII duration found that DKA hospitalisations were significantly 
higher compared with pre-CSII levels for up to one year of therapy (Figure 5.3). 
 
 
Figure 5.3: Hospitalisation incidence rate per 100 person-years of diabetic 
ketoacidosis (DKA) by continuous subcutaneous insulin infusion (CSII) duration. 
 
For severe hypoglycaemia, there were no significant differences in 
hospitalisation incidence rate during any time period of CSII duration compared 
with pre-CSII incidence (Figure 5.4). 
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Figure 5.4: Hospitalisation incidence rate per 100 person-years of severe 
hypoglycaemia by continuous subcutaneous insulin infusion (CSII) duration. 
 
5.3.4 HbA1c change and hospitalisation rates by sex. 
Table 5.3 showed that there were similar HbA1c means and medians between 
males and females for the cohort overall during the pre-CSII cohort. There was 
a lower HbA1c mean and median for females in the continued group pre-CSII 
but a slightly higher HbA1c level was found in the discontinued group. However, 
these differences between the sexes were not found to be significant.  
Table 5.4 showed significant decreases in HbA1c overall and in the continued 
group for both sexes during CSII. For the discontinued groups, only females 
saw a significantly decrease during CSII therapy and no change in HbA1c was 
found in males. After CSII discontinuation, HbA1c levels were no different from 
pre-CSII level for both sexes, even in females where an improvement was 
found during CSII.  
Figure 5.5 showed that a significant decrease from pre-CSII values for HbA1c 
was sustained up to 6 years CSII duration for all males.  
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Figure 5.5: Mean HbA1c value change during (and after) continuous 
subcutaneous insulin infusion (CSII) therapy from pre-CSII values by CSII 
duration for males. 
 
However, this improvement was only sustained for up to 3 years CSII duration 
in females (Figure 5.6). 
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Figure 5.6: Mean HbA1c value change during (and after) continuous 
subcutaneous insulin infusion (CSII) therapy from pre-CSII values by CSII 
duration for females. 
 
For hospitalisations, there was a significant increase in overall hospitalisations 
in males and females during CSII compared to pre-CSII. Although there was a 
significant increase in all T1D-related hospitalisations during CSII in females, 
there were no significant differences from pre-CSII rates for DKA and severe 
hypoglycaemia during CSII therapy. However, there were increases in DKA 
hospitalisations during CSII compared with pre-CSII rates for males for both the 
continued group (Table 5.6).  
 
5.3.5 HbA1c change and hospitalisation rates by continuous 
subcutaneous insulin infusion (CSII) status. 
The continued CSII group had a similar median HbA1c value pre-CSII 
compared with the overall cohort. The discontinued group had a higher median 
pre-CSII value at 9.5% (range 7.1 to 14%), although this was not statistically 
significantly higher than the continued group (Table 5.3).  
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The random intercept models found significant decreases in HbA1c values 
during CSII therapy from pre-CSII values for both the continued and 
discontinued groups. The decrease was less for the discontinued group at 
0.43% (95%CI 0.15 to 0.71%) compared with the continued group (0.67% 
(95%CI 0.58 to 0.77%) (Table 5.4). There was no significant difference in 
HbA1c decrease between the continued and discontinued groups.  
By duration, those who continued CSII therapy had a significant decrease in 
HbA1c value from pre-CSII values during CSII for up to 5 years (Figure 5.7). For 
those who discontinued CSII, improvements in HbA1c was only sustained up to 
the first year of CSII duration (Figure 5.8). 
 
 
Figure 5.7: Mean HbA1c value change during (and after) continuous 
subcutaneous insulin infusion (CSII) therapy from pre-CSII values by CSII 
duration for individuals who continued CSII therapy. 
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Figure 5.8: Mean HbA1c value change during (and after) continuous 
subcutaneous insulin infusion (CSII) therapy from pre-CSII values by CSII 
duration for individuals who discontinued CSII therapy. 
 
There was a significant increase in overall hospitalisations for the continued 
group during CSII compared with pre-CSII hospitalisations. For the discontinued 
group, there was no significant difference for overall hospitalisations during CSII 
compared with pre-CSII. Only DKA for the discontinued group saw a significant 
increase during CSII therapy (Table 5.6).   
 
5.4 Summary of results. 
There was a significant reduction in HbA1c values during CSII therapy 
compared with pre-CSII values. Overall, this reduction was sustained up to 4 
years of CSII duration, before HbA1c returned to pre-CSII levels. However, 
males were shown to have an extended period of sustained improvement of up 
to 6 years, whereas females had a shorter duration of improvement of up to 3 
years.  
Females were also more likely to discontinue CSII therapy. However, the 
discontinued males showed no improvement in HbA1c values during CSII, in 
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contrast to females who did have significantly lower HbA1c values during CSII 
compared with pre-CSII values. For both males and females who discontinued 
CSII, there were no significant differences in HbA1c values between pre-CSII 
and after CSII periods. 
Despite improvements in HbA1c, hospitalisation rates increased with CSII 
therapy in the continued CSII group. No significant increase in hospitalisations, 
apart from DKA were found in the discontinued group. Analysis by CSII duration 
found that DKA increased during CSII, particularly in the first year of CSII 
therapy. There were no significant differences in severe hypoglycaemia 
between pre- and during CSII time periods. 
 
5.5 Overall summary analysis compared with previous studies. 
With a maximum of 8 years follow-up time, the LCYPDS showed improved 
HbA1c levels during CSII therapy for up to 4 years. The few previous studies 
with more than 5 years follow-up time showed that improved HbA1c levels were 
maintained for between 2 to 6 years of CSII therapy (276,277), so the results 
from the LCYPDS fall mid-way between this period.  
In previous research, the highest reported proportion of discontinuation of CSII 
therapy was 11.3% (150). The LCYPDS found a higher proportion of 18.3%. 
Those who eventually discontinued CSII therapy had similar overall HbA1c 
improvements with CSII therapy compared with those who continued. However, 
after discontinuation of CSII HbA1c increased to pre-CSII levels. This provided 
evidence for the clinical importance of remaining on CSII therapy to lower 
HbA1c levels.  
For hospitalisations, severe hypoglycaemia incidence did not change with CSII 
therapy. In other studies, only a few found no change in hospitalisation for 
hypoglycaemia after CSII (136,146). Many other studies have shown a 
decrease in hospitalisations during CSII (130,132,278–281,135,139–145). An 
explanation for these differences may be due to the inconsistency between 
studies in defining severe hypoglycaemia and distinguishing between mild and 
severe episodes. In this study, severe hypoglycaemia was defined as an 
inpatient admission or an A&E attendance. Treatment without hospitalisation, 
for example, treatment from ambulance services, were not included. This may 
give an underestimation of total cases of severe hypoglycaemia in the cohort. 
Research on DKA hospitalisations showed more variation, with some studies 
showing lower rates of DKA hospitalisation with CSII therapy 
(134,140,141,145), whilst other studies have found no change in DKA 
  
117 
117	
hospitalisation incidence (136,143,146,147). Few studies have reported higher 
DKA hospitalisation rates (131,144), consistent with findings from the LCYPDS. 
Recent national findings from the latest NPDA report have also suggested that 
CSII therapy increased the risk of a DKA admission (126). Contrary to results 
from the LCYPDS where an increase in DKA admissions was limited to the first 
year of CSII therapy, the NPDA found that an increased risk of a DKA 
admission was associated with longer duration of diabetes. It is difficult to 
compare the results of this study with national data from the logistic regression 
model used in the NPDA, as this included individuals up to 25 years and 
individuals on MDIs. However, both results showed the need to address this 
increase in DKA admissions rates at both a national and local level.  
 
5.6 Health outcomes by attained age groups. 
Hospitalisation for DKA was found to be high in the LCYPDS cohort, particularly 
in the first year of CSII treatment. DKA often occurs due to poor management of 
T1D. This increase in DKA deaths and hospitalisations during the transitional 
care period may indicate problems with self-management. Recurrent DKA 
hospital admissions have also been shown to be higher at younger ages (282) 
and could increase the risk of mortality (270).  
 
5.7 Health outcomes by socio-demographic groups. 
Overall, females had less sustained improvement in HbA1c levels with CSII 
therapy compared with males in the LCYPDS. The decrease in HbA1c levels 
was sustained for longer in males by 3 years and over twice the proportion of 
females discontinued CSII compared with males (23.9% vs. 11.4%). Of those 
who discontinued CSII, HbA1c values for males showed no significant 
differences to pre-CSII levels during CSII, whilst females had improved HbA1c 
levels. These gender differences have previously been reported in survey data 
in a recent study by Tanenbaum and colleagues. They found that even though 
females had higher CSII therapy uptake, females identified more barriers with 
using the CSII device, contributing to higher levels of distress and more 
concerns about body image due to the attachment of the CSII device (39). 
Ritholz and colleagues also reported body image concerns from female adults 
and these attitudes were associated with HbA1c values (40). This suggested 
clear gender differences with CSII therapy which need to be addressed with 
specialist intervention. 
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Outcomes by ethnicity and deprivation could not be examined in the LCYPDS 
cohort due to the unavailability of these data items. No previous studies have 
assessed HbA1c and hospitalisations with CSII therapy by ethnicity and 
deprivation, so it is not known whether these are predictors for negative health 
outcomes.  
 
5.8 Chapter summary. 
Hospitalisation for DKA was found to be high in the LCYPDS cohort, particularly 
in the first year of CSII treatment. Whether this is associated with an increased 
rate of DKA death in the YRDCYP cannot be verified. Overall, females had half 
the length of sustained improvement in HbA1c levels with CSII therapy 
compared with males in the LCYPDS and were more likely to discontinue. More 
females were also starting CSII therapy. This suggests that females are having 
more issues with HbA1c and CSII therapy. This is in contrast to the mortality 
data for the YRDCYP which found more deaths in males. Without data from the 
LCYPDS, these differences between sexes during different aspects of the 
treatment journey would could be identified.
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Chapter 6 Cancer hospitalisations. 
This chapter describes the methodology and results of analysis from data on 
the Yorkshire Specialist Register of Cancer in Children and Young People 
(YSRCCYP) cohort. The YSRCCYP was linked to Hospital Episode Statistics 
(HES) data (inpatient, outpatient and A&E datasets) and the Mental Health 
Minimum Dataset (MHMDS). Each HES dataset and the MHMDS were 
examined separately and were also combined to measure the following health 
outcomes: 
1. Mental health admission by age at first known admission and cancer 
type. 
2. Outpatient appointment by attendance status, age at appointment, 
cancer type and complication type. 
a. Outpatient appointment attendance status following a first known 
mental health admission. 
3. Inpatient admissions by age at inpatient admission, cancer type and 
complication type. 
a. Inpatient admission following a first known mental health 
admission. 
b. Inpatient admission within 90 days of an outpatient appointment 
by attendance status. 
4. A&E attendances by age at A&E attendance and cancer type. 
a. A&E attendance following a first known mental health admission. 
b. A&E within 90 days of an outpatient appointment by attendance 
status. 
Analysis of health outcomes using the HES datasets covered the follow-up 
period of 5 years since initial cancer diagnosis. The MHMDS and inpatient data 
were used to determine first known mental health admissions recorded before, 
on or after the date of initial cancer diagnosis. It was possible for individuals to 
have multiple occurrences of outpatient appointments, A&E attendances and 
inpatient admissions. Mental health admission analysis categorised individuals 
as either having received or not received a mental health admission at any time.  
This chapter begins by defining variable categorisations and continues with 
defining the statistical approach used in the analysis and reports the results 
from these data analyses. All analyses were performed using STATA 14 (257). 
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6.1 Variable definitions. 
The methodologies for defining cancer type diagnosis and the follow-up period 
were described in section 3.3.1.  
 
6.1.1 Age categories at cancer diagnosis.  
Individuals from the YSRCCYP diagnosed with cancer before the transitional 
care period (under 15 years) were described as having ‘early cancer onset’. 
Individuals diagnosed during the transitional care period (15 to 29 years) were 
described as having ‘late cancer onset’.  
 
6.1.2 Defining complication type. 
The HES inpatient and outpatient datasets included up to 12 diagnosis code 
fields, using ICD-10 coding. These fields described the type of complication an 
individual was receiving hospital treatment for. In this analysis, only the first 
diagnosis code was included in the analysis and categorised by ICD-10 chapter 
groups (see Appendix D). 
Unfortunately, diagnosis codes were incomplete for HES outpatient data as 
there was no mandatory collection for these variables. As a proxy, the treatment 
specialty field was used instead of diagnosis. Treatment specialty was defined 
as the “specialised service within which the patient was treated” (260, p.302). 
There were over 200 codes for treatment specialty, with no standardised 
groupings as with ICD-10 codes. Therefore, clinical guidance was needed to 
group treatment specialty for analysis (see Appendix E). To compare inpatient 
complications with outpatient data, inpatient data were also analysed by 
treatment specialty. If an individual had more than one outpatient appointment 
on the same day at different treatment specialities, all outpatient appointments 
were included in the outpatient analysis.  
The inpatient data were analysed at continuous inpatient spell (CIPS) level 
(defined in section 3.3.5.5). Therefore, inpatient admissions occurring on the 
same day would count as being part of the same CIPS. The admission with the 
earliest admission time was used to categorise the complication type for the 
CIPS. 
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6.1.3 Outpatient appointment data – did not attend (DNA) status. 
The ‘ATTENDED’ variable in the outpatient HES data determined the attended 
status for an appointment. For this analysis, these codes were categorised as 
either ‘Attended’, ‘Did not attend’ (DNA) or ‘Unknown’ (Table 6.1). 
 
Table 6.1: Codes for 'ATTENDED' field in outpatient HES data and 
categorisation for analysis. 
Code Code description Attended/Did not attend (DNA) status 
2 Appointment cancelled by, or on behalf of, the patient Attended 
3 Did not attend – no advance warning given DNA 
4 Appointment cancelled or postponed by the Health Care Provider Attended 
5 
Seen, having attended on time or, if late, 
before the relevant care professional was 
ready to see the patient 
Attended 
6 
Arrived late, after the relevant care 
professional was ready to see the patient, 
but was seen 
Attended 
7 Did not attend – patient arrived late and could not be seen DNA 
9 Not known Not known 
 
6.1.4 Accident and emergency (A&E) – arrival mode. 
The A&E arrival mode described how a patient arrived at A&E. A&E 
attendances were either categorised by ‘Ambulance’ (this included helicopter or 
air ambulance), ‘Other’ or ‘Unknown’. 
 
6.1.5 Earliest recorded mental health admission from Mental Health 
Minimum Data set (MHMDS) and mental health inpatient data. 
The MHMDS included a date field for the first known mental health admission. 
This included dates before the coverage period for the MHMDS dataset, i.e. 
before 01/04/2007. Individuals were also included in the mental health data if 
they had a mental health-related inpatient admission with a primary diagnosis 
ICD-10 code between F01 to F99 (mental behavioural and neurodevelopmental 
disorders). If these individuals were not identified from the MHMDS, the date of 
earliest admission on the inpatient data was used as the recorded first mental 
health admission. These individuals were also included in the inpatient analysis. 
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6.2 Statistical methodology. 
6.2.1 Incidence rates for outpatient appointment non-attendance, 
accident and emergency (A&E) attendance, inpatient and 
mental health admissions. 
Incidence rates for the follow-up period were calculated for outpatient 
appointments with a DNA status, A&E attendances and CIPS by age at onset 
group. To compare incidence rates with the HES datasets, incidence rates of 
mental health admissions were also calculated for the follow-up period only. 
These incidence rates were calculated by dividing the total number of outpatient 
appointments with a DNA status, A&E attendances, inpatient CIPS and first 
known mental health occurrence by the total person-years of follow-up from 5 
years after cancer diagnosis date. The incidence rates were expressed as per 
1,000 person-years with a 95% confidence interval calculated using the Poisson 
distribution. Incidence rates by age, sex, ethnicity, deprivation and cancer type 
were calculated for comparison against total cohort rates.  
 
6.2.2 Confounder variables for statistical modelling. 
Confounder variables included in all statistical models were determined by 
DAGs based on discussions with and advice from clinical specialists. DAGs for 
all statistical models where the exposure variable was either age at 
hospitalisation or cancer type found the variables sex, deprivation and ethnicity 
to be confounders (see Appendix F). As age at cancer onset was not found to 
be a confounder variable in any DAGs, separate models were run for early and 
late cancer onset groups. Additionally, as age at cancer onset was associated 
with cancer type, producing separate models prevented issues around 
collinearity. Reference groups for each variable included in the models are 
presented in Table 6.2.  
Table 6.2: Reference groups for variables included in statistical models. 
Variable Reference group 
Age at hospitalisation – early cancer onset 10 to 14 years 
Age at hospitalisation – late cancer onset 40 and over years 
Sex Males 
Ethnicity White 
Deprivation Least deprived fifth 
Cancer type – early cancer onset IV Neuroblastoma 
Cancer type – late cancer onset VIII Malignant bone 
Treatment specialty (outpatient data) Oncology 
Diagnosis type (inpatient data) Neoplasms 
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The reference groups were chosen for their ease of interpretation of results. 
The choice of reference groups did not alter the results of the model. The 
cancer type reference groups were different for each age at cancer onset group 
due to the differences of prevalence of certain cancer types by age. Therefore, 
different reference cancer types were determined separately for each age at 
onset group. 
 
6.2.3 Single-level and mixed effects Poisson regression. 
Mixed effects Poisson regression was used to determine which variables were 
predictors for the relative risk of A&E attendance and inpatient admissions. A 
multi-level modelling approach was used to account for repeated attendances 
and admissions within the same individual. For mental health analysis, only the 
first known mental health admission was included in analysis. As there was no 
repeated data for individuals, a single-level Poisson modelling approach was 
used. To prevent issues around collinearity due to associations between cancer 
type with age at cancer onset, treatment specialty and diagnosis type, separate 
models were performed for age at cancer onset group, cancer type, treatment 
specialty and diagnosis type. 
 
6.2.4 Mixed effects logistic regression. 
To compare the odds of an DNA outpatient appointment compared with an 
attended appointment and to determine which variables were predictors for the 
odds of a DNA appointment, mixed effects logistic regression was used. Mixed 
effects logistic regression accounted for repeated measures within the same 
individual and reduced bias compared with single-level logistic regression. As 
with the Poisson regression models, separate models were performed for age 
at cancer onset group, cancer type and treatment specialty to prevent issues 
surrounding collinearity. Odds ratios were equivalent to relative risk for rare 
events, where the outcome was 10% or less (284). 
 
6.2.5 Sensitivity analysis. 
Due to the differences in time coverage of the YSRCCYP dataset and HES 
datasets (Figure 3.7), the HES data were not complete for all individuals so 
results may have exhibited selection bias. To assess this bias, sensitivity 
analysis was conducted for outpatient, inpatient and A&E data, whereby the 
statistical analysis was completed for a subset of the YSRCCYP, excluding any 
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individuals diagnosed more than 5 years before the start date of the beginning 
of the HES coverage period.   
If an individual had a mental health admission before 01/04/2007 but had no 
other mental health admissions during the MHMDS coverage period 
(01/04/2007 to 31/03/2015), these individuals could not be identified in our 
analysis. This would also cause selection bias in results, as with the other HES 
datasets which did not cover the entire time period of the YSRCCYP cohort. 
However, sensitivity analysis was not completed for the mental health data as 
there would have been difficulty in determining the sensitivity cohort without 
creating further bias. For example, only including individuals diagnosed with 
cancer since 01/04/2007 would exclude a large proportion of individuals with a 
mental health admission after their initial cancer diagnosis.   
 
6.3 Results of analysis from the Yorkshire Specialist Register 
of Cancer in Children and Young People (YSRCCYP). 
6.3.1 Demographics. 
There were 7,238 individuals in the YSRCCYP up to February 2017, with more 
individuals diagnosed with late cancer onset (n=3,866; 53.4%) compared with 
early cancer onset (n=3,372; 46.6%). There were more males (n=4,279; 59.1%) 
than females (n=2,959; 40.9%).  
Ethnicity was completed for 77.4% (n= 5,605) of the YSRCCYP, with most 
individuals classified with white ethnic origin (n=4,987; 68.9%). The second 
largest ethnicity group was South Asian (n=530; 7.3%). The rest of the cohort 
with recorded ethnicity were classified as Black (n=28; 0.4%), East Asian (n=29; 
0.4%) or other (n=31; 0.4%) (Figure 6.1).  
Deprivation group was determined for 94.5% (n=6,840) of the YSRCCYP. Most 
of the cohort were classified in the most deprived fifth (n=1,748; 24.2%). The 
second most deprived fifth had the least individuals (n=1,207; 16.7%). 
Lymphoma was the most common cancer diagnosis (n=1,485; 20.5%), followed 
by leukaemias (n=1,382; 19.1%), germ cell tumours (n=1,243; 17.2%) and CNS 
neoplasms (n=1,225; n=16.9%). After the ‘Other and unspecified’ group, hepatic 
tumours (n=45; 0.6%), retinoblastomas (n=138; 1.9%) and neuroblastomas 
(n=187; 2.6%) were the least diagnosed cancer types (Figure 6.1). Apart from 
lymphomas, germ cell tumours and other malignant epithelial neoplasms, all 
other cancer types were mostly diagnosed in early onset. No individuals were 
diagnosed with retinoblastoma in late cancer onset.
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Figure 6.1: Percentage (and number) of individuals by cancer type and socio-demographic groups.
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As well as being characterised by late onset, individuals with germ cell tumours 
were mostly male (n=1,095; 88.1%) and also had the highest proportion with 
white ethnicity (n=980; 78.8%). The cancer type with the highest proportion of 
individuals with South Asian/Other ethnicity was hepatic tumours at 17.8% 
(n=8). Hepatic tumours also had the highest proportion of individuals resident in 
the most deprived fifth (n=19; 42.2%). The most deprived fifth had the highest 
percentage of individuals for all cancer types.  
 
6.3.2 Mental health admissions data analysis. 
6.3.2.1 Demographics. 
A total of 602 individuals in the YSRCCYP (8.3%) had a mental health 
admission recorded either on the MHMDS or on the HES inpatient data. There 
were more individuals with a mental health admission who had late cancer 
onset (n=372; 61.8%) compared with early cancer onset (n=230; 38.2%). More 
males (n=348; 57.8%) than females (n=254; 42.4%) and more individuals with 
white ethnicity (n=471; 78.2%) compared with South Asian/Other ethnicity 
(n=40; 6.6%) had a mental health admission. The most deprived fifth had the 
highest total of individuals with a mental health admission (n=192; 31.9%) and 
had over two and a half times the total of the least deprived fifth, which had the 
lowest total of individuals (n=75; 12.5%). 
Most individuals with late cancer onset who had a mental health admission 
were diagnosed with lymphomas (n=101; 77.1%) or germ cell tumours (n=107; 
92.2%). CNS neoplasms and lymphomas had slightly more males with a mental 
health admission compared with females. However, for germ cell tumours, the 
percentage of males with a mental health admission was around 90%.   
The first known recorded mental health admission mostly occurred during the 
transitional care period (n=318; 53%) and after cancer diagnosis (n=508; 
84.4%) (Figure 6.2). Two thirds of individuals had their first mental health 
admission during the follow-up period at least 5 years after their initial cancer 
diagnosis (n=399; 66.3%).  
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Figure 6.2: Percentage (and number) of individuals with a mental health 
admission by socio-demographic groups, cancer type and time since cancer 
diagnosis. 
 
6.3.2.2 Incidence rates for mental health admissions. 
Incidence for first known mental health admission was 6.6 per 1,000 person-
years (95% CI 6.1 to 7.1 per 1,000 person-years) for the overall cohort, 4.5 per 
1,000 person-years (95% CI 4.0 to 5.1 per 1,000 person-years) in early cancer 
onset (Figure 6.3) and 9.2 per 1,000 person-years (95% CI 8.3 to 10.2 per 
1,000 person-years) in late cancer onset (Figure 6.4). No significant differences 
in incidence rates were found by sex, ethnicity and cancer type and there were 
increasing trends in first mental health admission from the ‘Least deprived fifth’ 
to the ‘Most deprived fifth’. 
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Both onset groups had an increasing trend in incidence by 5-year age group. 
However, in early cancer onset there is a five-fold increase in incidence from 
the 15 to 19 year age group to the 20 to 24 year age group (Figure 6.3).  
 
 
Figure 6.3: Incidence rate per 1,000 person-years for mental health incidence - 
early cancer onset. 
 
This increase in incidence for the same age groups was less pronounced in late 
cancer onset, where there was an increase of around 60% from the 15 to 19-
year age group to the 20 to 24-year group, although there was no statistically 
significant difference between the groups in late onset (Figure 6.4).  
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Figure 6.4 : Incidence rate per 1,000 person-years for mental health incidence – 
late cancer onset. 
 
6.3.2.3 Mental health and age at first mental health admission. 
There were no significant differences in risk of mental health admission by age 
groups compared with the 10 to 14-year age group in early cancer onset (Figure 
6.5). However, there were significant differences by age groups found in late 
cancer onset. Compared with the 40 years and over age group, the age groups 
between 20 to 39 years had significantly higher risk of first mental health 
admission, with the highest risk in the 25 to 29-year age group at 2.07 (95% CI 
1.6 to 2.68) (Figure 6.6).  
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There were also differences between the onset groups by sex. There was a 
significantly lower risk of a mental health admission in females compared with 
males in late cancer onset by around 40% (Figure 6.6). In early onset, females 
had a lower risk of a mental health admission compared with males by around 
20%, although this was not significantly different (Figure 6.5). 
Both onset groups showed no significant differences in risk of mental health 
admission by ethnicity or deprivation groups.  
 
 
Figure 6.5: Relative risk from Poisson model with 95% confidence intervals by 
age at first mental health admission – early cancer onset with a mental health 
admission. 
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Figure 6.6: Relative risk from Poisson model with 95% confidence intervals by 
age at first mental health admission – late cancer onset with a mental health 
admission. 
 
6.3.2.4 Mental health by cancer type. 
Leukaemias, lymphomas and CNS neoplasms all had significantly higher risk of 
mental health admission compared with the reference cancer types in early and 
late cancer onset. Lymphomas had the largest relative risk in early onset at 7.6 
(95% CI 3.7 to 15.61). In late cancer onset, germ cell tumours had the largest 
relative risk of a first mental health admission compared with neuroblastoma 
with a relative risk of 6.36 (95% CI 3.62 to 11.17).  
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Figure 6.7: Relative risk from Poisson model with 95% confidence intervals by 
cancer type – early cancer onset with a mental health admission. 
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Figure 6.8: Relative risk from Poisson model with 95% confidence intervals by 
cancer type – late cancer onset with a mental health admission. 
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6.3.3 Outpatient appointment data analysis. 
6.3.3.1 Demographics.  
There were 4,735 individuals in the YSRCCYP matched to the outpatient HES 
dataset. Percentages of individuals with an outpatient appointment by all socio-
demographic categories were similar to the percentages of the overall 
YSRCCYP cohort, apart from ethnicity where the percentage of individuals with 
an outpatient appointment with white ethnic origin was slightly higher at 79.0% 
(Figure 6.9), compared with 68.9% in the overall YSRCCYP cohort (Figure 6.1).  
Of the 4,735 individuals matched to the outpatient data, 1,837 (38.3%) attended 
all their outpatient appointments. Therefore, the majority of individuals (61.2%) 
had at least one outpatient appointment with a DNA status (Table 6.3). For 
South Asian/Other ethnicity, the percentage of individuals with at least one DNA 
status was slightly higher at 67.3%. There were also differences between 
deprivation groups where the least deprived fifth had the lowest percentage at 
of at least one DNA appointment at 54.6%, compared with the most deprived 
group at 69.4%.  
By cancer type, after the ‘Other and unspecified’ group, retinoblastoma (70%), 
other malignant epithelial neoplasms (66.2%) and malignant bone tumours 
(65.5%) had the highest percentages of individuals with at least one DNA 
outpatient appointment. The cancer types with the lowest percentages of DNA 
outpatient appointments were germ cell tumours (55.3%), lymphomas (60.4%), 
CNS neoplasms (60.8%), soft tissue tumours (62.2%), neuroblastomas (62.2%) 
and leukaemias (62.6%).
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Figure 6.9: Percentage (and number) of individuals linked to outpatient data by cancer type and socio-demographic groups.
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Table 6.3: Number of individuals linked to outpatient data by attended status, socio-demographic groups and cancer type. 
 
 
Individuals with at least 
one outpatient appointment 
with a DNA status 
Individuals with no 
outpatient appointments 
with a DNA status 
Total 
individuals 
N % N % 
Age at 
cancer 
diagnosis 
0 to 15 years (early onset) 1,433 62.0 880 38.0 2,313 
15 to 29 years (late onset) 1,465 60.5 957 39.5 2,422 
Sex 
Males 1,671 60.1 1,109 39.9 2,780 
Females 1,227 62.8 728 37.2 1,955 
Ethnicity 
White 2,279 60.9 1,461 39.1 3,740 
South Asian/Other 265 67.3 129 32.7 394 
Deprivation 
Least deprived fifth 449 54.6 374 45.4 823 
2nd least deprived fifth 503 54.3 424 45.7 927 
3rd most deprived fifth 518 62.5 311 37.5 829 
2nd most deprived fifth 522 64.0 293 36.0 815 
Most deprived fifth 792 69.4 350 30.6 1,142 
Cancer type 
I Leukaemias 598 62.6 358 37.4 956 
II Lymphomas 621 60.4 407 39.6 1,028 
III CNS 445 60.8 287 39.2 732 
IV Neuroblastoma 69 62.2 42 37.8 111 
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 V Retinoblastoma 70 70.0 30 30.0 100 
VI Renal tumours 126 65.3 67 34.7 193 
VII Hepatic tumours 15 65.2 8 34.8 23 
VIII Malignant bone 116 65.5 61 34.5 177 
IX Soft tissue 156 62.2 95 37.8 251 
X Germ cell tumours 455 55.3 368 44.7 823 
XI Other malignant epithelial neoplasms 221 66.2 113 33.8 334 
Total 2,898 61.2 1,837 38.8 4,735 
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6.3.3.2 Total outpatient appointments by socio-demographic groups, 
cancer type and treatment specialty. 
There were 122,422 outpatient appointments, with a median of 16 (range 1 to 
369) appointments per individual. Around 10% of all outpatient appointments 
had a DNA status. There was a median of 3 (range 1 to 74) DNA appointments 
per individual (Table 6.4). 
There were more outpatient appointments for early cancer onset (57.6%) 
compared with late onset (42.4%). With more appointments in the early onset 
group, the median number of appointments per individual was higher by around 
7 appointments compared with the late onset group (Table 6.4). The percentage 
of outpatient appointments with DNA status was around 2% higher in the late 
cancer onset group compared with the early onset group. 
Although there were 17.4% more males with an outpatient appointment 
compared with females (Figure 6.9), the total of outpatient appointments was 
evenly split between the sexes (48.9% for males vs. 51.1% for females). 
Females had a higher median appointment per individual by 10 compared with 
males, although the percentage of outpatient appointments with DNA status 
was around 2% higher in males compared with females (Table 6.4).  
There were around three times more outpatient appointments with DNA status 
in the most deprived fifth (n=4,032) compared with the least deprived fifth (n= 
1,621). There was only a slight difference in median DNA appointments of 1 per 
individual between the most and least deprived fifths (Table 6.4). 
There was a total of 20,740 (16.9%) outpatient appointments before, 50,484 
(41.2%) during and 51,198 (41.8%) after the transitional care period. The 
percentage of appointments with a DNA status before the transitional care 
period was lower (8%; n=1,666) compared with during (11.1%; n=5,622) and 
after the transitional care period (10.4%; n=5,303). For 5-year age bands, the 
30 to 34-year age group had the highest number of DNA appointments, 
followed by the 25 to 29-year group. Mean DNA appointment per individual 
ranged between 2.7 to 3.3 for all age groups (Table 6.4). 
The highest number of outpatient appointments took place within the oncology 
treatment specialty (n=33,831; 27.6%). With the exception of retinoblastoma 
and hepatic tumours, the majority of outpatient appointments in all other cancer 
types were classified within the oncology treatment specialty. There were no 
mental health appointments for hepatic tumours (Table 6.5). After the 
other/unknown category, mental health, digestion and endocrinology had the 
highest percentage of DNA appointments.
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Table 6.4: Descriptive statistics of outpatient appointments by socio-demographic groups and age at outpatient appointment. 
 Total outpatient appointments Total outpatient appointments with DNA status 
N % of 
total  Mean 
Median 
(range) 
Standard 
deviation 
N % of 
total  
% within 
group Mean 
Median 
(range) 
Standard 
deviation 
Age at 
cancer 
diagnosis 
0 to 14 years  
(early onset) 70,476 57.6 30.5 19 (1 to 327) 33.8  6,635  52.7 9.4 4.7 3 (1 to 74) 5.8 
15 to 29 years  
(late onset) 51,946 42.4 21.4 12 (1 to 369) 26.2  5,956  47.3 11.5 4.1 2 (1 to 50) 4.6 
Sex 
Males 59,814 48.9 21.5 12 (1 to 369) 27.5  6,732  53.5 11.3 4.1 2 (1 to 74) 5.1 
Females 62,608 51.1 32.0 22 (1 to 286) 33.3  5,859  46.5 9.4 4.8 3 (1 to 48) 5.4 
Ethnicity 
 
White 95,015 77.6 25.4 15 (1 to 369) 30.1  9,719  77.2 10.2 4.3 2 (1 to 74) 5.2 
South Asian/Other 9,650 7.9 24.5 14 (1 to 148) 27.7  1,206  9.6 12.5 4.6 3 (1 to 34) 4.7 
Deprivation 
Least deprived fifth 21,135 17.3 25.7 15 (1 to 221) 30.0  1,621  12.9 7.7 3.6 2 (1 to 37) 4.1 
2nd least deprived fifth 23,612 19.3 25.5 15 (1 to 327) 31.3  1,885  15.0 8.0 3.8 2 (1 to 66) 5.2 
3rd most deprived fifth 20,564 16.8 24.8 15 (1 to 261) 28.9  2,053  16.3 10.0 4.0 3 (1 to 34) 4.2 
2nd most deprived fifth 22,564 18.4 27.7 18 (1 to 369) 32.3  2,495  19.8 11.1 4.8 3 (1 to 47) 5.3 
Most deprived fifth 29,955 24.5 26.2 16 (1 to 314) 29.9  4,032  32.0 13.5 5.1 3 (1 to 74) 6.2 
Age at 
outpatient 
appointment 
5 to 9  7,027  5.7 11.8 6 (1 to 126) 15.8  642  5.1 9.1 3.2 2 (1 to 34) 4.0 
10 to 14 13,713  11.2 14.5 9 (1 to 157) 17.3  1,024  8.1 7.5 3.0 2 (1 to 31) 3.2 
15 to 19 15,938  13.0 13.4 8 (1 to 181) 17.2  1,564  12.4 9.8 3.1 2 (1 to 25) 3.1 
20 to 24 15,230  12.4 10.9 6 (1 to 98) 12.9  1,855  14.7 12.2 2.9 2 (1 to 36) 3.0 
25 to 29 19,316  15.8 11.5 6 (1 to 159) 15.8  2,203  17.5 11.4 2.8 2 (1 to 34) 3.2 
30 to 34 21,411  17.5 10.6 6 (1 to 153) 13.9  2,317  18.4 10.8 2.7 2 (1 to 22) 2.6 
35 to 39 17,240  14.1 11.7 7 (1 to 181) 15.6  1,823  14.5 10.6 2.8 2 (1 to 45) 3.2 
40 and over 12,547  10.2 14.6 8 (1 to 164) 19.9  1,163  9.2 9.3 3.3 2 (1 to 29) 4.0 
Total 122,422 100.0 25.9 16 (1 to 369) 30.5 12,591  100.0 10.3 4.4 3 (1 to 74) 5.3 
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Table 6.5: Number of outpatient appointments by treatment specialty and cancer type. 
 
I Leukaemias II Lymphomas III CNS IV Neuroblastoma 
V 
Retinoblastoma 
N % N % N % N % N % 
Circulatory  1,020  3.7  550  2.3  216  0.8  67  2.1  17  0.6 
Digestion  686  2.5  510  2.2  377  1.5  43  1.4  31  1.2 
Ears/Nose/ 
Throat  873  3.1  758  3.2  1,161  4.5  246  7.8  93  3.5 
Endocrinology  1,787  6.4  659  2.8  2,871  11.1  269  8.6  15  0.6 
Eyes  997  3.6  488  2.1  2,931  11.3  106  3.4  1,086  40.3 
Joints/Muscles/Skin  2,678  9.6  2,769  11.8  2,194  8.5  417  13.3  184  6.8 
Maternity/Obstetrics/ 
Gynaecology  1,948  7.0  2,636  11.2  1,000  3.9  177  5.6  130  4.8 
Mental health  265  1.0  223  0.9  712  2.8  24  0.8  43  1.6 
Nephrology  554  2.0  446  1.9  358  1.4  83  2.6  8  0.3 
Neurology  651  2.3  357  1.5  4,392  17.0  101  3.2  48  1.8 
Oncology  10,541  37.8  8,984  38.2  4,403  17.0  552  17.5  486  18.0 
Oral health  1,066  3.8  765  3.3  752  2.9  179  5.7  159  5.9 
Respiratory  270  1.0  346  1.5  217  0.8  83  2.6  7  0.3 
Surgery  858  3.1  1,904  8.1  851  3.3  138  4.4  80  3.0 
Total  27,876  100.0  23,502  100.0  25,833  100.0  3,146  100.0  2,693  100.0 
Figures in bold represent the 3 treatment specialties with the highest total of outpatient appointments within the cancer type category.
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Table 6.5 continued: Number of outpatient appointments by treatment specialty and cancer type. 
 
VI Renal tumours VII Hepatic tumours VIII Malignant bone IX Soft tissue 
X Germ cell 
tumours 
XI Other malignant 
epithelial 
neoplasms  
N % N % N % N % N % N % 
Circulatory  222   4.2   9   1.8   237   4.7   275   3.9   364   3.0   83   0.9  
Digestion  146   2.8   117   22.8   87   1.7   171   2.4   345   2.8   338   3.8  
Ears/Nose/ 
Throat  278   5.3   45   8.8   158   3.1   300   4.2   365   3.0   691   7.8  
Endocrinology  140   2.7   -     -     170   3.3   413   5.8   773   6.4   1,070   12.1  
Eyes  228   4.3   9   1.8   176   3.5   309   4.3   534   4.4   404   4.6  
Joints/Muscles/
Skin  364   6.9   53   10.3   921   18.1   637   8.9   1,885   15.5   726   8.2  
Maternity/ 
Obstetrics/ 
Gynaecology 
 504   9.6   28   5.4   468   9.2   760   10.7   853   7.0   1,292   14.7  
Mental health  53   1.0   -     -     50   1.0   84   1.2   318   2.6   54   0.6  
Nephrology  806   15.4   4   0.8   182   3.6   358   5.0   877   7.2   241   2.7  
Neurology  88   1.7   8   1.6   78   1.5   189   2.6   534   4.4   179   2.0  
Oncology  1,215   23.1   103   20.0   1,487   29.2   1,406   19.7   2,880   23.7   1,641   18.6  
Oral health  154   2.9   20   3.9   161   3.2   566   7.9   329   2.7   458   5.2  
Respiratory  86   1.6   2   0.4   78   1.5   124   1.7   181   1.5   67   0.8  
Surgery  307   5.8   24   4.7   233   4.6   654   9.2   864   7.1   824   9.3  
Total  5,250   100.0   514   100.0   5,089   100.0   7,134   100.0   12,172   100.0   8,817   100.0  
 
Figures in bold represent the 3 treatment specialities with the highest total of outpatient appointments within the cancer type category.
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6.3.3.3 Incidence rates for outpatient appointments with a ‘did not attend’ 
(DNA) status. 
The overall incidence rate of DNA appointments in the YSRCCYP was 391.2 
per 1,000 person-years (95% CI 384.5 to 398.1 per 1,000 person-years). The 
incidence rate of DNA appointments in early cancer onset was significantly 
lower than in late cancer onset (312 per 1,000 person-years (95% CI 304.6 to 
319.6 per 1,000 person-years) vs. 545.6 per 1,000 person-years (95% CI 531.9 
to 559.6 per 1,000 person-years)) (Figure 6.10; Figure 6.11).  
In both early and late cancer onset, females had significantly higher incidence 
rates of DNA appointments compared with males. South Asian/Other ethnicity 
also had significantly higher incidence rates of about 50% compared with white 
ethnicity (unknown ethnicity was 135 per 1,000 person-years (95% CI 128 to 
141 per 1,000 person-years) in early cancer onset and 189 per 1,000 person-
years (95% CI 98 to 363 per 1,000 person-years) in late cancer onset). 
Incidence rates of DNA appointments by deprivation groups showed decreasing 
rates from the ‘Most deprived’ group to the ‘Least deprived’. The two most 
deprived groups had significantly higher DNA incidence rate compared with the 
overall rate and three least deprived groups (Figure 6.10; Figure 6.11).  
For early cancer onset, there was an increasing incidence rate by age group 
from the 10 to 14-year age group which was the only age group to have 
significantly lower incidence compared with the overall early cancer onset 
incidence. The 30 to 34 and 35 to 39-year age groups had significantly higher 
incidence rates compared with the overall early onset incidence (Figure 6.10). 
In late cancer onset, there was a decreasing trend in incidence rate up to the 40 
and over age group which had the highest DNA appointment incidence rate and 
was the only age group with a significantly higher incidence rate compared with 
the overall late onset incidence rate (Figure 6.11). 
In early cancer onset, lymphomas had significantly lower incidence of DNA 
appointments and retinoblastoma, germ cells and other malignant epithelial had 
significantly higher incidence compared with the overall early onset rate (Figure 
6.10). In late cancer onset, CNS, hepatic, malignant bone, soft tissue and germ 
cell tumours had significantly lower incidence of DNAs and leukaemias, 
lymphomas, renal tumours and other malignant epithelial neoplasms had 
significantly higher incidences of DNAs compared with the overall late onset 
cohort (Figure 6.11).  
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Figure 6.10: Incidence rate per 1,000 person-years for outpatient appointments 
with 'did not attend' (DNA) status - early onset group. 
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Figure 6.11: Incidence rate per 1,000 person-years for outpatient appointments 
with 'did not attend' (DNA) status - early onset group. 
 
6.3.3.4 Outpatient appointments by age at outpatient appointment. 
Mixed effects logistic regression modelling was used to assess odds of a DNA 
outpatient appointment by age at outpatient appointment. For the sensitivity 
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analysis, models were run only for individuals matched on the outpatient 
dataset who were diagnosed since 1st April 1998.  
In early cancer onset, all age groups at outpatient appointment, apart from the 5 
to 9 age group, had a significantly higher odds of a DNA outpatient appointment 
compared with the 10 to 14-year age group. During the transitional care period, 
the odds of a DNA appointment was significantly lower in the 15 to 19-year age 
group, compared with the 20 to 24 and 25 to 29-year age groups. After the 
transitional care period, there was a decreasing trend in odds from the 35 to 39-
year age group (Figure 6.12).  
In late cancer onset, no significant differences were found in odds of a DNA 
outpatient appointment with any age groups (Figure 6.13). Similar trends were 
found in the equivalent sensitivity cohorts, although the odds of a DNA 
appointment in the 25 to 29-year age group in early cancer onset was more 
than double that in the total cohort at 5.82 (95% CI 4.28 to 7.93) and the wide 
95% confidence intervals for the 30 to 34-year age group meant that the odds 
were no longer significantly different compared with the 10 to 14-year age 
group. 
Females were found to have a significantly lower odds of an outpatient 
appointment with a DNA status compared with males both in early (Figure 6.12) 
and late cancer onset (Figure 6.13). The odds of females not attending an 
outpatient appointment compared with males was significantly lower in late 
cancer onset (0.61 (95% CI 0.54 to 0.70)) compared with early cancer onset 
(0.84 (95% CI 0.73 to 0.95). Odds ratios for females were similar in all 
equivalent sensitivity cohorts. 
Individuals in the three most deprived fifths had significantly higher odds of a 
DNA outpatient appointment compared with individuals in the least deprived 
groups in both early (Figure 6.12) and late cancer onset (Figure 6.13). There 
were no significant differences in odds between the 2nd least deprived fifth 
compared with the least deprived fifth. The sensitivity cohorts found similar 
decreasing trends in odds with decreasing deprivation. However, in early cancer 
onset only the most deprived fifth had a significantly higher odds of a DNA 
appointment compared with the least deprived fifth and in late onset, only the 
two most deprived groups had significantly higher odds of a DNA appointment 
compared with the least deprived fifth. 
In both early (Figure 6.12) and late cancer onset (Figure 6.13), there were no 
significant differences in DNA outpatient appointments between South 
Asian/Other ethnicity and white ethnicity. 
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Figure 6.12: Odds ratios of 'did not attend' (DNA) status from mixed effects logistic regression model with 95% confidence intervals by 
age at appointment – early cancer onset (a.) and equivalent sensitivity cohort (b.).
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Figure 6.13: Odds ratios of 'did not attend' (DNA) status from mixed effects logistic regression model with 95% confidence intervals by 
age at appointment – late cancer onset (a.) and equivalent sensitivity cohort (b.).
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6.3.3.5 Outpatient appointments by cancer type. 
The mixed effects logistic regressions models by cancer type showed similar 
results by socio-demographic groups to the age at outpatient appointment 
models in early and late cancer onset.  
For early cancer onset, individuals diagnosed with CNS neoplasms (0.67; 95% 
CI 0.48 to 0.93) had a significantly lower odds of DNA appointments compared 
with individuals diagnosed with neuroblastomas. All other cancer types had no 
significant difference in odds of a DNA appointment compared with 
neuroblastoma. This was also found for the sensitivity cohort (Figure 6.14).  
In late cancer onset, compared with malignant bone tumours, lymphomas (1.82; 
95% CI 1.24 to 2.68), renal tumours (1.96; 95% CI 1.03 to 3.71), germ cell 
tumours (1.63; 95% CI 1.14 to 2.32) and other malignant epithelial neoplasms 
(1.8; 95% CI 1.23 to 2.62) had significantly higher odds of a DNA outpatient 
appointment. However, no cancer types in the sensitivity cohort showed any 
significant differences of odds for a DNA appointment compared with malignant 
bone tumours (Figure 6.15).  
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Figure 6.14: Odds ratios of 'did not attend' (DNA) status from mixed effects logistic regression model with 95% confidence intervals by 
cancer type – early cancer onset (a.) and equivalent sensitivity cohort (b.).
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Figure 6.15: Odds ratios of 'did not attend' (DNA) status from mixed effects logistic regression model with 95% confidence intervals by 
cancer type – late cancer onset (a.) and equivalent sensitivity cohort (b.).
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6.3.3.6 Outpatient appointments by treatment specialty. 
The odds of an outpatient appointment with a DNA status was highest for the 
mental health treatment specialty and was significantly higher than the oncology 
treatment speciality in both early (1.45; 95% CI 1.1 to 1.9) (Figure 6.16) and late 
cancer onset (2.23; 95% CI 1.75 to 2.85) (Figure 6.17). Only 
maternity/obstetrics/gynaecology had significantly lower odds of a DNA 
appointment compared with oncology in both early (0.65; 95% CI 0.55 to 0.76) 
and late cancer onset (0.52; 95% CI 0.46 to 0.6). 
The odds ratios in the sensitivity cohort for mental health and 
maternity/obstetrics/gynaecology were similar to all sensitivity cohorts. There 
were some differences for other treatment specialties where the odds of a DNA 
appointment were found to be significantly different compared with oncology in 
the YSRCCYP cohort but not in the sensitivity cohort, and vice versa. Despite 
these differences, there were no significant differences in odds between the 
models.
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Figure 6.16: Odds ratios of 'did not attend' (DNA) status from mixed effects logistic regression model with 95% confidence intervals by 
treatment specialty – early cancer onset (a.) and equivalent sensitivity cohort (b.).
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Figure 6.17: Odds ratios of 'did not attend' (DNA) status from mixed effects logistic regression model with 95% confidence intervals by 
treatment specialty – late cancer onset (a.) and equivalent sensitivity cohort (b.).
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6.3.3.7 Outpatient appointment attendance status by mental health 
admission. 
The YSRCCYP cohort was linked to both the mental health and outpatient HES 
data to determine whether having a previous mental health admission was 
associate with outpatient appointment status.  
Of the 4,735 individuals with an outpatient appointment, 490 (10.3%) had a 
mental health admission before any outpatient appointment. There was a higher 
percentage of individuals with a mental health admission in the late cancer 
onset group (n=288; 11.9% of the late cancer onset total) compared with early 
cancer onset (n=202; 8.7% of the early cancer onset total). 
By deprivation group, there were twice the number of individuals with a mental 
health admission in the most deprived group (n=150; 13.1% of the most 
deprived fifth total) compared with the least deprived fifth (n=63; 7.7% of the 
least deprived fifth total) (Table 6.6). 
 
Table 6.6: Number of individuals with a mental health admission any time 
before an outpatient appointment by socio-demographic groups. 
 
Total individuals with a mental 
health admission before an 
outpatient appointment 
Total 
individuals 
with an 
outpatient 
appointment N 
% of 
group 
% of 
total 
Age at 
cancer 
diagnosis 
0 to 14 years 
(early onset) 
       202          8.7           4.3          2,313  
15 to 29 years 
(late onset)         288        11.9           6.1          2,422  
Sex 
Males         273          9.8           5.8          2,780  
Females         217        11.1           4.6          1,955  
Ethnicity 
White         378        10.1           8.0          3,740  
South Asian/Other           36          9.1           0.8             394  
Deprivation 
Least deprived 
fifth           63          7.7           1.3             823  
2nd least deprived 
fifth           86          9.3           1.8             927  
3rd most deprived 
fifth           84        10.1           1.8             829  
2nd most deprived 
fifth           90         11.0           1.9             815  
Most deprived fifth         150         13.1           3.2          1,142  
Total 490        10.3         10.3  4,735 
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Individuals diagnosed with soft tissue tumours had the highest percentage of 
individuals with a mental health admission before an outpatient appointment at 
13.9% (n=35), followed by CNS neoplasms (n=98; 13.4%) and other malignant 
epithelial neoplasms (n=38; 11.4%) (Table 6.7). 
 
Table 6.7: Number of individuals with a mental health admission any time 
before an outpatient appointment by cancer type. 
 
Total individuals with a 
mental health admission 
before an outpatient 
appointment 
Total 
individuals 
with an 
outpatient 
appointment N % of 
group 
% of 
total 
I Leukaemias 80 8.4 1.7            956  
II Lymphomas 107 10.4 2.3         1,028  
III CNS 98 13.4 2.1            732  
IV Neuroblastoma 10 9.0 0.2            111  
V Retinoblastoma 7 7.0 0.1            100  
VI Renal tumours 14 7.3 0.3            193  
VIII Malignant bone 18 10.2 0.4            177  
IX Soft tissue 35 13.9 0.7            251  
X Germ cell tumours 82 10.0 1.7            823  
XI Other malignant 
epithelial neoplasms 38 11.4 0.8            334  
Total 490 10.3 10.3         4,735  
 
Of the 122,422 outpatient appointments for the YSRCCYP cohort, 13,450 (11%) 
occurred after a mental health admission. Of these 13,450 outpatient 
appointments, 1,891 (14%) had a DNA status (Figure 6.18). This was higher 
than the percentage in the overall YSRCCYP cohort with an outpatient 
appointment of 10.3%. 
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Figure 6.18: Percentage (and number) of outpatient appointments occurring 
after a mental health admission by attendance status. 
 
Multi-level logistic regression modelling for the overall cohort found that the 
odds of not attending an outpatient appointment with a previous mental health 
admission was significantly higher than for individuals with no previous mental 
health admission by 60% (Figure 6.19).  
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Figure 6.19: Odds ratios of 'did not attend' (DNA) status from mixed effects 
logistic regression model with 95% confidence intervals by previous mental 
health admission. 
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6.3.4 Inpatient admission data analysis. 
6.3.4.1 Demographics.  
There were 3,666 individuals (62.8% of eligible individuals) matched on the 
inpatient dataset. The percentage of individuals with an inpatient admission by 
age at cancer onset group, sex and deprivation of the matched cohort were 
similar to the percentages in the overall YSRCCYP cohort and had a slightly 
higher percentage of individuals with white ethnicity at 77.4% (Figure 6.20), 
compared with 68.9% in the overall YSRCCYP cohort (Figure 6.1). 
By cancer type, the highest number of individuals with an inpatient admission 
were diagnosed with lymphomas (n=747; 20.4%), leukaemias (n=713; 19.4%) 
and CNS neoplasms (n=682; 18.6%). The cancer type with the lowest number 
of individuals with an inpatient admission were hepatic tumours (n=20; 0.5%), 
retinoblastomas (n=70; 1.9%) and neuroblastomas (n=80; 2.2%) (Figure 6.20).
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Figure 6.20: Percentage (and number) of individuals linked to inpatient data by cancer type and socio-demographic groups.
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6.3.4.2 Total continuous inpatient spells (CIPS) by socio-demographic 
groups, cancer type, diagnosis type and treatment specialty. 
There were 26,203 CIPS. The mean number of CIPS for an individual was 7.2 
(range 1 to 171). The mean number of CIPS was higher by around 2 in early 
cancer onset compared with late cancer onset. Females had a higher mean 
CIPS per individuals by 1 compared with males. Mean CIPS per individuals by 
ethnicity and deprivation categories were similar to the overall mean. The most 
deprived fifth had the highest total of CIPS (n=6,653; 25.4%), although the 
mean number of admissions individual was similar to the least deprived fifth. 
The third most deprived fifth had the smallest total of CIPS (n=3,895; 14.9%) 
and the smallest mean admission per individual at 5.9 (range 1 to 72) (Table 
6.8).  
The total number of CIPS was slightly higher during the transitional care period 
(n=11,043; 42.1%) compared with after the transitional care period (n=10,759; 
41.1%). Before the transitional care period, there was a total of 4,401 CIPS 
(16.8%). By 5-year age bands, the total of CIPS increased for each category up 
to the 25 to 29-year age group, before decreasing. The age group with the 
highest mean CIPS per individual was the 10 to 15-year group at 4.9 (range 1 to 
136) (Table 6.8). 
Table 6.8: Descriptive statistics of continuous inpatient spells (CIPS) by socio-
demographic groups. 
 Total continuous inpatient spells (CIPS) 
N 
% of 
total 
CIPS 
Mean Median (range) 
Standard 
deviation 
Age at 
cancer 
diagnosis 
0 to 14 years 
(early onset) 14,973 57.1 8.1 3 (1 to 152) 14.0 
15 to 29 years 
(late onset) 11,230 42.9 6.2 3 (1 to 171) 11.9 
Sex 
Males 13,171 50.3 6.6 2 (1 to 171) 13.7 
Females 13,032 49.7 7.9 4 (1 to 152) 12.2 
Ethnicity 
  
White 19,847 75.7 7.0 3 (1 to 171) 13.3 
South 
Asian/Other 1,951 7.4 6.9 3 (1 to 158) 13.7 
Deprivation 
Least 
deprived fifth 4,623 17.6 7.6 3 (1 to 171) 14.7 
2nd least 
deprived fifth 4,987 19.0 7.1 3 (1 to 124) 13.2 
3rd most 
deprived fifth 3,895 14.9 5.9 3 (1 to 72) 9.1 
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2nd most 
deprived fifth 4,860 18.5 7.4 3 (1 to 158) 14.1 
Most deprived 
fifth 6,653 25.4 7.5 3 (1 to 119) 11.9 
Age at 
inpatient 
admission 
5 to 9  1,678  6.4 4.7 2 (1 to 86) 9.7 
10 to 14  2,723  10.4 4.9 2 (1 to 136) 11.6 
15 to 19  3,336  12.7 4.4 2 (1 to 86) 8.6 
20 to 24  3,506  13.4 4.0 2 (1 to 145) 7.8 
25 to 29  4,201  16.0 4.0 2 (1 to 156) 8.5 
30 to 34  4,147  15.8 3.5 2 (1 to 122) 6.1 
35 to 39  3,609  13.8 3.7 2 (1 to 124) 7.2 
40 and over  3,003  11.5 4.3 2 (1 to 79) 6.7 
Total 26,203 100.0 7.2 3 (1 to 171) 13.0 
Individuals diagnosed with leukaemia (n=6,008; 22.9%), lymphomas (n=5,502; 
21%) and CNS neoplasms (n=5,251; 20%) had the highest total of CIPS. The 
cancer types with the highest mean CIPS per individual were malignant bone 
tumours (8.8 CIPS per individual; range 1 to 116), renal tumours (8.5 CIPS per 
individual; range 1 to 145) and leukaemias (8.4 CIPS per individual; range 1 to 
152). The cancer types with the lowest mean inpatient admissions per individual 
were germ cell tumours (4 CIPS per individual; range 1 to 51), hepatic tumours 
(4.4 CIPS per individual; range 1 to 14) and retinoblastoma (5.2 CIPS per 
individual; range 1 to 43) (Table 6.9). 
Table 6.9: Descriptive statistics of continuous inpatient spells (CIPS) by cancer 
type. 
 
Total inpatient admissions  
N % of total admissions Mean 
Median 
(range) 
Standard 
deviation 
I Leukaemias 6,008 22.9 8.4 3 (1 to 152) 15.2 
II Lymphomas 5,502 21.0 7.4 3 (1 to 171) 15.0 
III CNS 5,251 20.0 7.7 4 (1 to 156) 11.8 
IV 
Neuroblastoma 518 2.0 6.5 3 (1 to 65) 9.9 
V Retinoblastoma 366 1.4 5.2 3 (1 to 43) 8.0 
VI Renal tumours 1,295 4.9 8.5 3 (1 to 145) 17.7 
VII Hepatic 
tumours 88 0.3 4.4 3.5 (1 to 14) 3.7 
VIII Malignant 
bone 1,371 5.2 8.8 4 (1 to 116) 13.8 
IX Soft tissue 1,759 6.7 8.0 3 (1 to 119) 13.6 
X Germ cell 
tumours 2,275 8.7 4.0 2 (1 to 51) 5.9 
XI Other 
malignant 
epithelial 
1,721 6.6 6.9 3 (1 to 124) 12.4 
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neoplasms 
Total 26,244 100.0 7.2 3 (1 to 171) 13.0 
 
Over 30% of all CIPS had a primary diagnosis of neoplasm (n=8,305; 31.7%) 
(Table 6.10). For all cancer types, neoplasms was one of the top three highest 
totals of CIPS by primary diagnosis with a percentage ranging between 14.5% 
(n=186) for renal tumours to 38.4% (n=139) for retinoblastomas (Figure 6.11). 
Injury, poisoning and certain other consequences of external causes had the 
second highest total of CIPS (n=2,452; 9.4%) and was one of the top three 
highest total of CIPS for eight cancer types (leukaemia, CNS neoplasms, 
neuroblastomas, renal tumours, hepatic tumours, soft cell tumours, germ cell 
tumours and other epithelial tumours) (Figure 6.11). Congenital malformations 
(n=3; 0.01%), diseases of the ear (n=164; 0.6%) and mental and behavioural 
problems (n=202; 0.8%) had the lowest number of CIPS by primary diagnosis.  
Table 6.10: Descriptive statistics of continuous inpatient spells (CIPS) by 
primary diagnosis. 
 
Total inpatient admissions 
N % of total admissions Mean 
Median 
(range) 
Standard 
deviation 
Certain infectious and 
parasitic diseases 434 1.7 7.0 3 (1 to 51) 10.2 
Neoplasms 8,305 31.7 15.1 7 (1 to 156) 20.4 
Diseases of the blood 
and blood-forming 
organs and certain 
disorders involving the 
immune mechanism 
512 2.0 14.2 7.5 (1 to 152) 28.6 
Endocrine, nutritional 
and metabolic diseases 966 3.7 9.2 4.5 (1 to 122) 15.3 
Mental and behavioural 
disorders 202 0.8 6.8 3 (1 to 44) 10.1 
Diseases of the 
nervous system 740 2.8 8.6 5 (1 to 96) 12.4 
Diseases of the eye 
and adnexa 366 1.4 4.7 2 (1 to 33) 6.1 
Diseases of the ear and 
mastoid process 164 0.6 3.3 2 (1 to 17) 3.4 
Diseases of the 
circulatory system 563 2.1 6.6 3 (1 to 171) 9.6 
Diseases of the 
respiratory system 792 3.0 7.8 3 (1 to 171) 18.1 
Diseases of the 
digestive system 2,066 7.9 4.2 2 (1 to 100) 6.8 
Diseases of the skin 
and subcutaneous 
tissue 
482 1.8 4.2 2 (1 to 116) 11.4 
Diseases of the 
musculoskeletal system 
and connective tissue 
1,055 4.0 5.7 2 (1 to 105) 11.5 
Diseases of the 1,233 4.7 6.2 3 (1 to 158) 12.9 
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genitourinary system 
Pregnancy, childbirth 
and the 
puerperium/Certain 
conditions originating in 
the perinatal period 
1,836 7.0 5.4 4 (1 to 54) 5.9 
Congenital 
malformations, 
deformations and 
chromosomal 
abnormalities 
3 0.01 - 3 (3 to 3) - 
Symptoms, signs and 
abnormal clinical and 
laboratory findings, not 
elsewhere classified 
188 0.7 3.3 3 (1 to 13) 2.7 
Injury, poisoning and 
certain other 
consequences of 
external causes 
2,452 9.4 6.2 (1 to 143) 11.8 
Factors influencing 
health status and 
contact with health 
services 
1,630 6.2 4.8 2 (1 to 81) 7.5 
Total 26,203 100.0 7.2 3 (1 to 171) 13.0 
 
As with outpatient appointments, oncology had the highest total of CIPS by 
treatment specialty (n=5,804; 22.2%), followed by 
maternity/obstetrics/gynaecology (n=2,224; 8.5 5) and surgery (n=2,086; 8%). 
Mental health had the lowest number of CIPS by treatment specialty (n=99; 
0.4%). There were no mental health CIPS for individuals diagnosed with 
neuroblastoma, hepatic tumours and soft tissue tumours (Figure 6.12).
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Table 6.11: Number of continuous inpatient spells (CIPS) by cancer type and primary diagnosis. 
 
I Leukaemias II Lymphomas III CNS IV Neuroblastoma V Retinoblastoma 
 
N % N % N % N % N % 
Certain infectious and parasitic diseases  124  2.1  107  2.0  64  1.2  9  1.8  5  1.4 
Neoplasms  2,246  37.8  1,888  34.6  1,669  32.3  106  20.8  139  38.4 
Diseases of the blood and blood-forming organs and 
certain disorders involving the immune mechanism  123  2.1  219  4.0  61  1.2  16  3.1  6  1.7 
Endocrine, nutritional and metabolic diseases  310  5.2  74  1.4  250  4.8  28  5.5  -    - 
Mental and behavioural disorders  13  0.2  39  0.7  66  1.3  3  0.6  3  0.8 
Diseases of the nervous system  83  1.4  37  0.7  444  8.6  28  5.5  1  0.3 
Diseases of the eye and adnexa  81  1.4  29  0.5  89  1.7  5  1.0  35  9.7 
Diseases of the ear and mastoid process  44  0.7  15  0.3  38  0.7  7  1.4  7  1.9 
Diseases of the circulatory system  152  2.6  121  2.2  56  1.1  7  1.4  1  0.3 
Diseases of the respiratory system  140  2.4  222  4.1  113  2.2  31  6.1  11  3.0 
Diseases of the digestive system  397  6.7  496  9.1  303  5.9  35  6.9  20  5.5 
Diseases of the skin and subcutaneous tissue  92  1.5  114  2.1  72  1.4  9  1.8  9  2.5 
Diseases of the musculoskeletal system and connective 
tissue  189  3.2  221  4.0  192  3.7  25  4.9  3  0.8 
Diseases of the genitourinary system  207  3.5  334  6.1  135  2.6  33  6.5  9  2.5 
Pregnancy, childbirth and the puerperium/Certain 
conditions originating in the perinatal period  379  6.4  511  9.4  213  4.1  53  10.4  19  5.2 
Congenital malformations, deformations and 
chromosomal abnormalities  -    -  1  -  1  -  -    -  -    - 
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Symptoms, signs and abnormal clinical and laboratory 
findings, not elsewhere classified  26  0.4  10  0.2  92  1.8  8  1.6  2  0.6 
Injury, poisoning and certain other consequences of 
external causes  431  7.3  483  8.8  596  11.5  41  8.0  24  6.6 
Factors influencing health status and contact with health 
services  416  7.0  254  4.7  241  4.7  21  4.1  26  7.2 
Total  5,939  100.0  5,460  100.0  5,163  100.0  510  100.0  362  100.0 
Figures in bold represent the 3 primary diagnoses with the highest total of CIPS within the cancer type category. 
Table 6.11 continued: Number of continuous inpatient spells (CIPS) by cancer type and primary diagnosis. 
 
VI Renal 
tumours 
VII Hepatic 
tumours 
VIII Malignant 
bone IX Soft tissue 
X Germ cell 
tumours 
XI Other 
malignant 
epithelial 
neoplasms 
 
N % N % N % N % N % N % 
Certain infectious and parasitic diseases  32  2.5  8  9.1  16  1.2  20  1.1  24  1.1  15  0.9 
Neoplasms  186  14.5  13  14.8  471  35.1  562  32.2  422  18.8  494  28.8 
Diseases of the blood and blood-forming 
organs and certain disorders involving the 
immune mechanism 
 20  1.6  -    -  5  0.4  23  1.3  11  0.5  22  1.3 
Endocrine, nutritional and metabolic 
diseases  128  10.0  4  4.5  11  0.8  51  2.9  75  3.3  35  2.0 
Mental and behavioural disorders  4  0.3  -    -  3  0.2  5  0.3  46  2.1  8  0.5 
Diseases of the nervous system  6  0.5  -    -  10  0.7  13  0.7  56  2.5  37  2.2 
Diseases of the eye and adnexa  18  1.4  -    -  23  1.7  17  1.0  46  2.1  22  1.3 
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Diseases of the ear and mastoid process  10  0.8  3  3.4  2  0.1  18  1.0  9  0.4  7  0.4 
Diseases of the circulatory system  27  2.1  -    0.0  23  1.7  63  3.6  69  3.1  18  1.0 
Diseases of the respiratory system  56  4.4  2  2.3  23  1.7  56  3.2  75  3.3  41  2.4 
Diseases of the digestive system  99  7.7  4  4.5  69  5.1  132  7.6  286  12.8  207  12.1 
Diseases of the skin and subcutaneous 
tissue  32  2.5  -    -  25  1.9  38  2.2  59  2.6  29  1.7 
Diseases of the musculoskeletal system 
and connective tissue  33  2.6  2  2.3  65  4.9  66  3.8  143  6.4  111  6.5 
Diseases of the genitourinary system  75  5.8  5  5.7  45  3.4  115  6.6  154  6.9  111  6.5 
Pregnancy, childbirth and the 
puerperium/Certain conditions originating in 
the perinatal period 
 141  11.0  14  15.9  93  6.9  126  7.2  128  5.7  151  8.8 
Congenital malformations, deformations 
and chromosomal abnormalities  -    -  -    -  -    -  1  0.1  -    -  -    - 
Symptoms, signs and abnormal clinical and 
laboratory findings, not elsewhere classified  24  1.9  -    -  1  0.1  11  0.6  10  0.4  2  0.1 
Injury, poisoning and certain other 
consequences of external causes  148  11.5  12  13.6  79  5.9  161  9.2  284  12.7  156  9.1 
Factors influencing health status and 
contact with health services  55  4.3  3  3.4  211  15.7  107  6.1  189  8.4  58  3.4 
Total  1,283  100.0  88  100.0  1,340  100.0  1,744  100.0  2,240  100.0  1,715  100.0 
Figures in bold represent the 3 primary diagnoses with the highest total of CIPS within the cancer type category.
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Table 6.12: Number of continuous inpatient spells (CIPS) by cancer type and treatment specialty. 
 
I Leukaemias II Lymphomas III CNS IV Neuroblastoma 
V 
Retinoblastoma  
N % N % N % N % N % 
Circulatory  92  1.5  99  1.8  16  0.3  2  0.4  5  1.4 
Digestion  201  3.4  182  3.3  86  1.7  6  1.2  5  1.4 
Ears/Nose/ 
Throat  108  1.8  105  1.9  61  1.2  12  2.4  8  2.2 
Endocrinology  90  1.5  23  0.4  215  4.2  8  1.6  1  0.3 
Eyes  69  1.2  25  0.5  69  1.3  1  0.2  82  22.7 
Joints/Muscles/Skin  168  2.8  173  3.2  145  2.8  31  6.1  30  8.3 
Maternity/Obstetrics/ 
Gynaecology  440  7.4  630  11.5  244  4.7  62  12.2  20  5.5 
Mental health  8  0.1  13  0.2  23  0.4  -    -  3  0.8 
Nephrology  122  2.1  265  4.9  77  1.5  21  4.1  4  1.1 
Neurology  63  1.1  26  0.5  765  14.8  16  3.1  1  0.3 
Oncology  1,775  29.9  1,739  31.9  881  17.1  25  4.9  38  10.5 
Oral health  100  1.7  104  1.9  115  2.2  9  1.8  13  3.6 
Respiratory  21  0.4  63  1.2  30  0.6  10  2.0  2  0.6 
Surgery  346  5.8  480  8.8  289  5.6  41  8.0  24  6.6 
Total  5,937  100.0  5,458  100.0  5,161  100.0  510  100.0  362  100.0 
Figures in bold represent the 3 treatment specialties with the highest total of CIPS within the cancer type category.
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Table 6.12 continued: Number of continuous inpatient spells (CIPS) by cancer type and treatment specialty. 
 
VI Renal tumours VII Hepatic tumours VIII Malignant bone IX Soft tissue 
X Germ cell 
tumours 
XI Other malignant 
epithelial 
neoplasms  
N % N % N % N % N % N % 
Circulatory  9  0.7  -    -  22  1.6  60  3.4  25  1.1  15  0.9 
Digestion  151  11.8  13  14.8  18  1.3  44  2.5  123  5.5  103  6.0 
Ears/Nose/ 
Throat  24  1.9  3  3.4  12  0.9  31  1.8  37  1.7  40  2.3 
Endocrinology  3  0.2  -    -  9  0.7  9  0.5  38  1.7  101  5.9 
Eyes  23  1.8  -    -  9  0.7  15  0.9  33  1.5  19  1.1 
Joints/Muscles
/Skin  30  2.3  1  1.1  279  20.8  72  4.1  136  6.1  58  3.4 
Maternity/ 
Obstetrics/ 
Gynaecology 
 180  14.0  12  13.6  113  8.4  161  9.2  151  6.8  198  11.6 
Mental health  2  0.2  -    -  1  0.1  -    -  33  1.5  3  0.2 
Nephrology  92  7.2  -    -  24  1.8  49  2.8  187  8.4  50  2.9 
Neurology  5  0.4  -    -  9  0.7  9  0.5  57  2.5  11  0.6 
Oncology  129  10.1  10  11.4  288  21.5  309  17.7  238  10.6  318  18.6 
Oral health  22  1.7  -    -  14  1.0  35  2.0  52  2.3  38  2.2 
Respiratory  4  0.3  1  1.1  10  0.7  20  1.1  14  0.6  8  0.5 
Surgery  134  10.5  8  9.1  77  5.8  197  11.3  277  12.4  191  11.1 
Total  1,282  100.0  88  100.0  1,339  100.0  1,743  100.0  2,237  100.0  1,714  100.0 
 
Figures in bold represent the 3 treatment specialties with the highest total of CIPS within the cancer type category.
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6.3.4.3 Incidence rates for continuous inpatient spells (CIPS). 
The overall incidence rate for CIPS was 390.4 per 1,000 person-years (95% CI 
385.7 to 395.1 per 1,000 person-years), 389.9 per 1,000 person-years (95% CI 
383.7 to 396.82 per 1,000 person-years) in early cancer onset (Figure 6.21) and 
391 per 1,000 person-years (95% CI 383.8 to 398.3 per 1,000 person-years) in 
late cancer onset (Figure 6.22). 
In early cancer onset, the incidence rate of CIPS for females was around 30% 
higher than males at 445 per 1,000 person-years (95% CI 435.2 to 455.1 per 
1,000 person-years) (Figure 6.21). In late cancer onset, the incidence rate for 
females was around 69% higher compared with males at 520.4 per 1,000 
person-years (95% CI 506.7 to 534.6 per 1,000 person-years) and was 
significantly higher compared with early cancer onset (Figure 6.22).  
South Asian/Other ethnicity had a lower incidence rate for CIPS compared with 
white ethnicity in early cancer onset (unknown ethnicity in early cancer onset 
had an incidence rate of 231 per 1,000 person-years (95% CI 224.2 to 238 per 
1,000 person-years)) and had a higher incidence rate in late cancer onset. 
However, these differences were not statistically significant. 
Analysis by deprivation groups showed the two most deprived fifths had a 
higher CIPS incidence rate compared with the three least deprived fifths in both 
early and late cancer onset. The lowest CIPS incidence rate was found in the 
third most deprived fifth in early cancer onset and in the second least deprived 
fifth in late cancer onset.  
During the transitional care period, the incidence rate decreased in the 20 to 24-
year age group, which had the lowest incidence rate in early cancer onset 
(332.6 per 1,000 person-year; 95% CI 319.9 to 345.8 per 1,000 person-years). 
This contrasted with late cancer onset where the 20 to 24-year age group had 
the highest incidence rate of 635.6 per 1,000 person-year (95% CI 596.8 to 
676.8 per 1,000 person-years).  
For lymphomas (261 per 1,000 person-year; 95% CI 248.1 to 274.5 per 1,000 
person-year) and neuroblastomas (275.4 per 1,000 person-year; 95% CI 251.1 
to 301.9 per 1,000 person-year), there was a significantly lower incidence rate 
compared with the total incidence in early cancer onset. However, in late cancer 
onset, these cancer types were significantly higher than the total incidence rate. 
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Figure 6.21: Incidence rate per 1,000 person-years for continuous inpatient 
spell (CIPS) - early cancer onset. 
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Figure 6.22: Incidence rate per 1,000 person-years for continuous inpatient 
spell (CIPS) - late cancer onset. 
 
6.3.4.4 Inpatient admission by age at inpatient admission. 
The older age groups during and after the transitional care period in early onset 
had significantly higher risk of a CIPS compared with the 10 to 14-year age 
group, with the risk increasing by about 20% to 30% by each 5-year age group 
up to the 35 to 39 group, with a relative risk of 2.33 (95%CI 2.11 to 2.55). The 
relative risk then increased by two-fold for the 40 and over age group at 4.93 
(95%CI 4.45 to 5.47). However, in the sensitivity cohort in early cancer onset, 
the trend was opposite, where each increase in age category had a decreased 
risk of a CIPS (Figure 6.23).
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Figure 6.23: Relative risk of continuous inpatient spell (CIPS) from mixed effects Poisson model with 95% confidence intervals by age at 
CIPS – early cancer onset (a.) and equivalent sensitivity cohort (b.).
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Figure 6.24: Relative risk of continuous inpatient spell (CIPS) from mixed effects Poisson model with 95% confidence intervals by age at 
CIPS – late cancer onset (a.) and equivalent sensitivity cohort (b.).
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In late cancer onset, all age groups had significantly lower risk of CIPS 
compared with the 40 and over age group. The trend in the sensitivity cohort 
was similar (Figure 6.24). 
Females had a significant increased risk of CIPS compared with males, 
particularly in late cancer onset, where the risk was more than double for 
females compared with males (2.34 (95%CI 2.04 to 2.68) (Figure 6.24).  
No significant differences in risk of CIPS by ethnicity were found in early or late 
cancer onset.  
In both early and late onset, there was a significantly higher risk of CIPS in the 
most deprived fifth compared with the least deprived fifth. In the sensitivity 
analysis, risk by deprivation groups were similar in late cancer onset. In early 
cancer onset, the most deprived fifth had a slightly higher relative risk than in 
the total cohort by 20%. 
 
6.3.4.5 Inpatient admissions by cancer type. 
In early cancer onset (Figure 6.25), leukaemias, CNS neoplasms, malignant 
bone tumours and soft tissue tumours had significantly higher risk of CIPS 
compared with the reference cancer type (neuroblastoma). The trends in 
relative risk by cancer type in the sensitivity cohorts were similar, with slightly 
lower risk for each cancer type.  
In late cancer onset, there was no significant variation between cancer types. 
Lymphomas (0.6; 95% CI 0.42 to 0.87), germ cell tumours (0.41; 95% CI 0.28 to 
0.59) and other malignant epithelial tumours (0.5; 95% CI 0.34 to 0.75) had 
significantly lower risk of CIPS compared with malignant bone tumours (Figure 
6.26).
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Figure 6.25: Relative risk of continuous inpatient spell (CIPS) from mixed effects Poisson model with 95% confidence intervals by cancer 
type – early cancer onset (a.) and equivalent sensitivity cohort (b.).
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Figure 6.26: Relative risk of continuous inpatient spell (CIPS) from mixed effects Poisson model with 95% confidence intervals by cancer 
type – late cancer onset (a.) and equivalent sensitivity cohort (b.).
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6.3.4.6 Inpatient admissions by primary diagnosis. 
All primary diagnoses for CIPS had a significantly lower risk of CIPS compared 
with neoplasms. Certain infectious and parasitic diseases, diseases of the 
respiratory system, diseases of the skin and subcutaneous tissue and 
congenital malformations, deformations and chromosomal abnormalities had 
the lowest relative risks of CIPs compared with neoplasms in early and late 
cancer onset. Certain conditions originating in the perinatal period also had one 
of the five lowest relative risks of CIPS in early cancer onset. Mental and 
behavioural disorders had one of the five lowest relative risk of CIPS compared 
with neoplasms in late cancer onset.  
Endocrine, nutritional and metabolic diseases and pregnancy, childbirth and the 
puerperium were within the top five primary diagnoses with the highest relative 
risk of CIPS compared with neoplasms in early and late cancer onset. Diseases 
of the nervous system were found to have one of the five highest risks of CIPS 
compared with neoplasms in both early (0.36; 95% CI 0.35 to 0.38) and late 
onset (0.39; 95% CI 0.36 to 0.42). Although mental and behavioural disorders 
had one of the lowest risks of CIPS in late cancer onset (0.22; 95%CI 0.19 to 
0.25), this was shown to have one of the highest risks of CIPS compared with 
neoplasms in early cancer onset (0.63; 95% CI 0.58 to 0.69).
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Figure 6.27: Relative risk of continuous inpatient spell (CIPS) from mixed effects Poisson model with 95% confidence intervals by 
primary diagnosis for admission – early cancer onset (a.) and equivalent sensitivity cohort (b.).
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Figure 6.28: Relative risk of continuous inpatient spell (CIPS) from mixed effects Poisson model with 95% confidence intervals by 
primary diagnosis for admission – late cancer onset (a.) and equivalent sensitivity cohort (b.).
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6.3.4.7 Inpatient admissions by treatment specialty. 
All treatment specialties had a significantly lower risk of CIPS compared with 
oncology. Respiratory, oral health and ears/nose/throat treatment specialities 
had the lowest relative risks of CIPs compared with neoplasms in early and late 
cancer onset and in each of the equivalent sensitivity cohorts.  
Neurology was one of the top three treatment specialities with the highest 
relative risk of CIPS compared with oncology in early and late cancer onset. 
Nephrology and endocrinology were also in the top three treatment specialities 
with the highest relative risk of CIPS compared with oncology in late cancer 
onset. In early cancer onset, the other two treatment specialities with the top 
three relative risk for CIPS were Maternity/Obstetrics/Gynaecology and 
circulatory.
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Figure 6.29: Relative risk of continuous inpatient spell (CIPS) from mixed effects Poisson model with 95% confidence intervals by 
treatment specialty – early cancer onset (a.) and equivalent sensitivity cohort (b.).
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Figure 6.30: Relative risk of continuous inpatient spell (CIPS) from mixed effects Poisson model with 95% confidence intervals treatment 
specialty – late cancer onset (a.) and equivalent sensitivity cohort (b.).
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6.3.4.8 Inpatient admission by mental health admission. 
Of the 3,666 individuals with a CIPS, 404 (11%) had a mental health admission 
any time before a CIPS. There was a higher percentage of individuals with a 
mental health admission with late cancer onset (n=237; 13.1% of the late 
cancer onset total) compared with early cancer onset (n=167; 9% of the early 
cancer onset total). The number of individuals with a mental health admission in 
the most deprived group (n=121; 13.6% of the most deprived fifth total) was 
over two-fold of the least deprived fifth (n=50; 8.2% of the least deprived fifth 
total) (Table 6.13).  
Table 6.13: Number of individuals with a mental health admission any time 
before a continuous inpatient spell (CIPS) by socio-demographic groups. 
  
Total individuals with a 
mental health admission 
before a CIPS 
Total 
individuals 
with a CIPS 
  
N % of 
group 
% of total 
Age at cancer 
diagnosis 
0 to 14 years 
(early onset)         167       9.0          4.6           1,848  
15 to 29 years 
(late onset)        237     13.1           6.5           1,812  
Sex Males        204     10.2           5.6           2,001  
Females          29       1.7           0.8           1,659  
Ethnicity White        315    11.1           8.6           2,835  South Asian/Other          28       9.9           0.8              282  
Deprivation 
Least deprived fifth          50       8.2          1.4              610  
2nd least deprived 
fifth          70     10.0           1.9              699  
3rd most deprived 
fifth          71     10.7           1.9              661  
2nd most deprived 
fifth          78     11.9           2.1              653  
Most deprived fifth        121     13.6          3.3              891  
Total 404 11.0         11.0           3,660  
 
After other malignant epithelial neoplasms, individuals diagnosed with CNS 
neoplasms had the highest percentage of individuals with a mental health 
admission before a CIPS at 12.8% (n=87), followed by germ cell tumours (n=72; 
12.7%). The lowest percentages were found in retinoblastoma (n=3; 4.3%), 
neuroblastoma (n=7; 8.8%) and leukaemias (n=63; 8.8%) (Table 6.14). 
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Table 6.14: Number of individuals with a mental health admission any time 
before a continuous inpatient spell (CIPS)by cancer type. 
 
Total individuals with a mental 
health admission before a CIPS 
Total 
individuals 
with a CIPS 
 
N % of group % of total 
I Leukaemias 63              8.8            1.7  712 
II Lymphomas 78            10.5            2.1  746 
III CNS 87            12.8            2.4  680 
IV Neuroblastoma 7              8.8            0.2  80 
V Retinoblastoma 3              4.3            0.1  70 
VI Renal tumours 13              8.6            0.4  152 
VIII Malignant bone 18            11.5            0.5  156 
IX Soft tissue 26            11.9            0.7  219 
X Germ cell tumours 72            12.7            2.0  569 
XI Other malignant 
epithelial neoplasms 36            14.5           1.0  249 
Total 404            11.0         11.0  3,660 
 
Multi-level logistic regression modelling for the overall cohort found that a 
previous mental health admission did not significant increase the odds of a 
CIPS (Figure 6.31).  
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Figure 6.31: Odds ratio from mixed effects logistic regression model of 
continuous inpatient spell (CIPS) with 95% confidence intervals by previous 
mental health admission. 
 
6.3.4.9 Inpatient admission by outpatient appointment attendance status. 
In total, 2,566 individuals (54.2%) had a CIPS within 90 days of an outpatient 
appointment. The percentage of individuals with early cancer onset (n=1,307; 
56.5%) was higher than in late cancer onset (n=1,259; 52%). The percentage of 
females with a CIPS was nearly 20% higher (n=1,263; 64.6%) compared with 
males (n=1,303; 46.9%). Percentages increased by deprivation group up to the 
second most deprived fifth with 57.4% (n=468) of individuals with a CIPS 90 
days after an outpatient appointment (Table 6.15).  
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Table 6.15: Number of individuals with a continuous inpatient spell (CIPS) within 
90 days of an outpatient appointment by socio-demographic groups. 
  
Total individuals with CIPS 
within 90 days of an 
outpatient appointment 
Total 
individuals 
with an 
outpatient 
appointment 
  
N % of group 
% of 
total 
Age at 
cancer onset 
0 to 14 years 
(early onset)   1,307   56.5   27.6   2,313  
15 to 29 years 
(late onset)  1,259   52.0   26.6   2,422  
Sex Males  1,303   46.9   27.5   2,780  Females  1,263   64.6   26.7   1,955  
Ethnicity 
White  1,986   53.1   41.9   3,740  
South 
Asian/Other  199   50.5   4.2   394  
Deprivation 
Least deprived 
fifth  405   49.2   8.6   823  
2nd least 
deprived fifth  507   54.7   10.7   927  
3rd most 
deprived fifth  450   54.3   9.5   829  
2nd most 
deprived fifth  468   57.4   9.9   815  
Most deprived 
fifth  637   55.8   13.5   1,142  
Total 2,566 54.2  54.2  4,735 
 
Individuals diagnosed with CNS neoplasms (n=492; 67.2%), malignant bone 
tumours (n=117; 66.1%) and hepatic tumours (n=14; 60.9%) had the highest 
percentage of individuals with a CIPS within 90 days of an outpatient 
appointment. The lowest percentages were found in germ cell tumours (n=366; 
44.5%), retinoblastoma (n=45; 45%) and neuroblastoma (n=54; 48.6%) (Table 
6.16). 
 
 
 
 
 
 
 
 
 
  
187 
187	
Table 6.16: Number of individuals with a continuous inpatient spell (CIPS) within 
90 days of an outpatient appointment by cancer type. 
 
Total individuals with CIPS 
within 90 days of an outpatient 
appointment 
Total 
individuals 
with an 
outpatient 
appointment 
 
N % of group 
% of 
total 
I Leukaemias 504 52.7  10.6  956 
II Lymphomas 516 50.2  10.9  1028 
III CNS 492 67.2  10.4  732 
IV Neuroblastoma 54 48.6  1.1  111 
V Retinoblastoma 45 45.0  1.0  100 
VI Renal tumours 110 57.0  2.3  193 
VII Hepatic tumours 14 60.9  0.3  23 
VIII Malignant bone 117 66.1  2.5  177 
IX Soft tissue 152 60.6  3.2  251 
X Germ cell tumours 366 44.5  7.7  823 
XI Other malignant 
epithelial neoplasms 190 56.9  4.0  334 
Total 2,566 54.2  54.2  4,735 
 
There were 28,192 (23%) of outpatient appointments where a CIPS occurred 
within 90 days. Of these 28,192 outpatient appointments, 6.6% (n=1,860) had a 
DNA status. This is lower compared to the overall outpatient cohort at 10.3% 
(Table 6.4). The percentage of DNA appointments in outpatient appointments 
with no CIPS after 90 days was higher at 11.4% (n=10,731) (Table 6.17).  
By cancer type, germ cell tumours had the highest percentage of DNA 
appointments where a CIPS occurred within 90 days of the appointment at 
9.2% (n=189). This was followed by retinoblastoma at 8.8% (n=27) and renal 
tumours at 7.5% (n=104) (Table 6.18). 
Mixed effects logistic regression modelling found that individuals who did not 
attend an outpatient appointment had a significantly lower odds of a CIPS after 
90 days compared with those who attended outpatient appointments by around 
50%. A similar result was found in the sensitivity cohort (Figure 6.32).
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Table 6.17: Number of outpatient appointments and continuous inpatient spells (CIPS) by socio-demographic groups. 
  
Total outpatient appointments 
Total 
  
No CIPS CIPS within 90 days after an outpatient appointment   
Did not attend Attended Did not attend Attended   
N % N % N % N % 
Age at cancer 
diagnosis 
0 to 14 years (early 
onset)  5,600 7.9 48,764 69.2 1,035 1.5 14,975 21.2 70,476 
15 to 29 years (late 
onset) 5,131 9.9 34,583 66.6 825 1.6 11,357 21.9 51,946 
Sex Males 5,929 9.9 42,284 70.7 803 1.3 10,739 18.0 59,814 Females 4,802 7.7 41,063 65.6 1,057 1.7 15,593 24.9 62,608 
Ethnicity White 8,302 8.7 64,710 68.1 1,417 1.5 20,491 21.6 95,015 South Asian/Other 1,003 10.4 6,389 66.2 203 2.1 2,049 21.2 9,650 
Deprivation 
Least deprived fifth 1,406 6.7 15,178 71.8 215 1.0 4,313 20.4 21,135 
2nd least deprived 
fifth 1,596 6.8 16,399 69.5 289 1.2 5,308 22.5 23,612 
3rd most deprived 
fifth 1,766 8.6 14,277 69.4 287 1.4 4,192 20.4 20,564 
2nd most deprived 
fifth 2,076 9.2 15,097 66.9 419 1.9 4,937 21.9 22,564 
Most deprived fifth 3,448 11.5 19,419 64.8 584 1.9 6,479 21.6 29,955 
Total 10,731 8.8 83,347 68.1 1,860 1.5 26,332 21.5 122,422 
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Table 6.18: Number of outpatient appointments and continuous inpatient spells (CIPS) by cancer type. 
 
Total outpatient appointments 
Total 
 
No CIPS CIPS within 90 days after an outpatient appointment  
Did not attend Attended Did not attend Attended  
N % N % N % N % 
I Leukaemias 2,466 8.8 18,908 67.8 375 1.3 6,099 21.9 27,876 
II Lymphomas 2,299 9.8 15,236 64.8 433 1.8 5,510 23.4 23,502 
III CNS 1,509 5.8 17,755 68.7 382 1.5 6,154 23.8 25,833 
IV Neuroblastoma 315 10.0 2,423 77.0 27 0.9 379 12.0 3,146 
V Retinoblastoma 331 12.3 2,046 76.0 27 1.0 281 10.4 2,693 
VI Renal tumours 468 8.9 3,382 64.4 104 2.0 1,280 24.4 5,250 
VII Hepatic tumours 31 6.1 392 77.2 4 0.8 81 15.9 508 
VIII Malignant bone 379 7.5 3,570 70.2 77 1.5 1,055 20.7 5,087 
IX Soft tissue 539 7.6 4,875 68.4 92 1.3 1,613 22.6 7,127 
X Germ cell tumours 1,472 12.1 8,641 71.0 189 1.6 1,858 15.3 12,175 
XI Other malignant 
epithelial neoplasms 902 10.2 5,858 66.3 146 1.7 1,911 21.6 8,829 
Total 10,731 8.8 83,347 68.1 1,860 1.5 26,332 21.5 122,422 
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Figure 6.32: Odds ratio from mixed effects logistic regression model of a continuous inpatient spell (CIPS) within 90 days of an outpatient 
appointment with 95% confidence intervals (a.) and equivalent sensitivity cohort (b.).
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6.3.5 Accident and emergency (A&E) data analysis 
6.3.5.1 Demographics.  
There were 3,034 individuals (57.3% of eligible individuals) who were matched 
on the HES A&E dataset. The percentages of the matched YSRCCYP dataset 
by age at cancer onset group, sex and deprivation were similar to the overall 
YSRCCYP cohort. By ethnicity, the percentage of individuals with white ethnic 
origin is slightly higher at 78.6% (Figure 6.33) compared with 68.9% in the 
overall YSRCCYP cohort (Figure 6.1).  
The cancer type with the highest number of individuals with an A&E attendance 
was lymphoma (n=642; 21.2%), followed by leukaemia (n=602; 19.8%) and 
germ cell tumours (n=547, 18%). Hepatic tumours were the least likely cancer 
diagnosis in individuals with an A&E attendance (n=15) after the other and 
unspecified group (n=6).
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Figure 6.33: Percentage (and number) of individuals linked to accident and emergency (A&E) data by cancer type and socio-
demographic groups.
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6.3.5.2 Total accident and emergency (A&E) attendances by socio-
demographic groups, cancer type A&E arrival mode. 
The total number of A&E attendances was 9,985. Over three-quarters of A&E 
attendances arrived via ambulance (n=7,778; 77.9%). The mean number of 
A&E attendances for an individual was 3.3 (range 1 to 79). There were over 
twice as many A&E attendances in the most deprived fifth (n=2,925; 29.3%) 
compared with the least deprived fifth (n=1,426; 14.3%) (Table 6.19).  
The total number of A&E attendances was greatest after the transitional care 
period (n=4,699; 47.1%). There was a total of 4,048 (40.5%) attendances 
during and 1,038 (10.4%) attendances before the transitional care period. By 5-
year age bands, the total number of A&E attendances increased for each 
category, with the highest total for the 35 to 39-year age group. The age group 
with the highest mean of A&E attendances was the 40 and over group at 2.9 
(range 1 to 38) (Table 6.19). 
Table 6.19: Descriptive statistics of accident and emergency (A&E) attendances 
by socio-demographic groups, age at A&E attendance and A&E arrival mode. 
 Total A&E attendances 
N % of total  Mean 
Median 
(range) 
Standard 
deviation 
Age at 
cancer 
diagnosis 
0 to 14 years 
(early onset)  5,462  54.7 3.6 2 (1 to 66) 4.8 
15 to 29 
years (late 
onset) 
 4,523  45.3 3.0 2 (1 to 53) 3.6 
Sex Males  5,772  57.8 3.2 2 (1 to 79) 4.3 Females  4,213  42.2 3.4 2 (1 to 66) 4.8 
Ethnicity 
 
White  7,651  76.6 3.2 2 (1 to 79) 4.1 
South 
Asian/Other  875  8.8 3.5 2 (1 to 49) 4.6 
Deprivation 
Least 
deprived fifth  1,426  14.3 2.9 2 (1 to 39) 3.4 
2nd least 
deprived fifth  1,604  16.1 2.8 2 (1 to 28) 2.8 
3rd most 
deprived fifth  1,601  16.0 3.1 2 (1 to 63) 4.6 
2nd most 
deprived fifth  2,146  21.5 3.9 2 (1 to 51) 5.4 
Most 
deprived fifth  2,925  29.3 3.7 2 (1 to 79) 5.3 
Age at A&E 
admission 
5 to 9  300  3.0 1.9 1 (1 to 12) 1.7 
10 to 14  738  7.4 2.2 1 (1 to 16) 2.1 
15 to 19  1,217  12.2 2.5 2 (1 to 50) 3.5 
20 to 24  1,512  15.1 2.6 2 (1 to 37) 3.4 
25 to 29  1,519  15.2 2.3 2 (1 to 46) 2.7 
30 to 34  1,581  15.8 2.2 1 (1 to 52) 2.8 
35 to 39  1,588  15.9 2.4 1 (1 to 35) 2.9 
40 and over  1,530  15.3 2.9 2 (1 to 38) 4.0 
A&E arrival 
mode 
Ambulance 7,778 77.9 4.1 2 (1 to 79) 6.6 
Other 2,119 21.2 3.7 3 (1 to 9) 2.5 
Total  9,985  100.0 3.3 2 (1 to 79) 4.5 
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Individuals diagnosed with leukaemias, lymphomas and CNS neoplasms had 
the highest total of A&E attendances. The cancer types with the highest mean 
A&E attendances per individual were renal tumours, CNS neoplasms and soft 
tissue tumours. The cancer types with the lowest mean A&E attendances per 
individual were malignant bone tumours, germ cell tumours and lymphomas 
(Table 6.20). 
 
Table 6.20: Descriptive statistics of accident and emergency (A&E) attendances 
by cancer type. 
 
Total A&E attendances  
N % of total Mean 
Median 
(range) 
Standard 
deviation 
I Leukaemias 1,979 19.8 3.3 2 (1 to 35) 3.4 
II Lymphomas 1,958 19.6 3.0 2 (1 to 39) 3.8 
III CNS 1,817 18.2 3.7 2 (1 to 63) 5.9 
IV Neuroblastoma 239 2.4 3.5 2 (1 to 21) 3.4 
V Retinoblastoma 228 2.3 3.3 2 (1 to 30) 4.3 
VI Renal tumours 526 5.3 4.2 3 (1 to 66) 7.3 
VII Hepatic tumours 46 0.5 3.1 2 (1 to 7) 2.1 
VIII Malignant bone 319 3.2 2.9 2 (1 to 19) 2.6 
IX Soft tissue 569 5.7 3.7 2 (1 to 25) 4.0 
X Germ cell tumours 1,576 15.8 2.9 2 (1 to 79) 4.4 
XI Other malignant 
epithelial neoplasms 703 7.0 3.4 2 (1 to 53) 4.9 
Total 9,985 100.0 3.3 2 (1 to 79) 4.5 
 
6.3.5.3 Incidence rates for accident and emergency (A&E) attendances. 
The overall incidence rate was 175.7 per 1,000 person-years (95% CI 172.3 to 
179.2 per 1,000 person-years), 162.6 per 1,000 person-years (95% CI 158.3 to 
167 per 1,000 person-years) for early cancer onset (Figure 6.34) and 194.6 per 
1,000 person-years (95% CI 189 to 200.4 per 1,000 person-years) for late 
cancer onset (Figure 6.35). 
There were no statistically significant differences in A&E attendance incidence 
rates between the overall incidence rates with males or females in early (Figure 
6.34) and late cancer onset (Figure 6.35).  
In early cancer onset, the incidence rate for South Asian/Other ethnicity (331 
per 1,000 person-years; 95% CI 303 to 361.6 per 1,000 person-years) was 
significantly higher than for white ethnicity (242 per 1,000 person-years; 95% CI 
234.1 to 250.1 per 1,000 person-years) by around 40% (incidence rate for 
unknown ethnicity for early cancer onset was 82.8 per 1,000 person-years (95% 
CI 78.7 to 87.2 per 1,000 person-years)) (Figure 6.34). In late cancer onset, the 
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difference in A&E incidence rate for South Asian/Other ethnicity (224.4 per 
1,000 person-years; 95% CI 203 to 248 per 1,000 person-years) was around 
30% higher compared with white ethnicity (192.8 per 1,000 person-years; 95% 
CI 187.1 to 198.8 per 1,000 person-years) (Figure 6.35). 
Analysis by deprivation groups showed the two most deprived groups had 
significantly higher A&E attendance incidence rate compared with the three 
least deprived groups in early and late cancer onset.  
The age groups before the transitional care period had the lowest incidence 
rates for A&E attendance in early cancer onset and were significantly lower than 
the age groups during and after the transitional care period. Incidence rates 
were highest in the 40 and over group in early (240.2 per 1,000 person-years; 
95% CI 215.7 to 267.5 per 1,000 person-years) and late cancer onset (252.2 
per 1,000 person-years; 95% CI 238.3 to 266.9 per 1,000 person-years).  
In the early cancer onset cohort, lymphomas (127.5 per 1,000 person-years; 
95% CI 118.1 to 137.8 per 1,000 person-years), malignant bone tumours (134.2 
per 1,000 person-years; 95% CI 115.8 to 155.4 per 1,000 person-years) and 
soft tissue tumours (139.2 per 1,000 person-years; 95% CI 124.9 to 155.2 per 
1,000 person-years) had significantly lower A&E attendance incidence 
compared with the overall early cancer onset A&E incidence rate. CNS 
neoplasms (198 per 1,000 person-years; 95% CI 187.6 to 208.9 per 1,000 
person-years), renal tumours (197.6 per 1,000 person-years; 95% CI 180.8 to 
215.9 per 1,000 person-years), hepatic tumours (267.3 per 1,000 person-years; 
95% CI 197.5 to 361.7 per 1,000 person-years) and germ cell tumours (188.7 
per 1,000 person-years; 95% CI 168 to 212 per 1,000 person-years) had 
significantly higher A&E attendance incidence compared with the total early 
cancer onset A&E incidence rate (Figure 6.34). 
 
  
196 
196	
 
Figure 6.34: Incidence rate per 1,000 person-years for accident and emergency 
(A&E) attendances - early cancer onset. 
 
In the late onset cohort, renal tumours (124.5 per 1,000 person-years; 95% CI 
90.2 to 171.8 per 1,000 person-years) and germ cell tumours (174 per 1,000 
person-years; 95% CI 164.7 to 183.7 per 1,000 person-years) had significantly 
lower A&E attendance incidence rates compared with the total late onset rate. 
CNS neoplasms (235 per 1,000 person-years; 95% CI 215.2 to 256.7 per 1,000 
person-years), neuroblastomas (477.1 per 1,000 person-years; 95% CI 311.1 to 
731.7 per 1,000 person-years) and other malignant epithelial neoplasms (236.7 
per 1,000 person-years; 95% CI 219 to 255.9 per 1,000 person-years) had 
significantly higher incidence of A&E attendances compared with the overall late 
onset rate (Figure 6.35). 
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Figure 6.35: Incidence rate per 1,000 person-years for accident and emergency 
(A&E) attendances - late cancer onset cancer. 
 
6.3.5.4 Accident and emergency (A&E) attendance by age at attendance. 
Mixed effects Poisson modelling was used to assess relative risk of an A&E 
attendance by age at attendance. For the sensitivity analysis, models were run 
only for individuals matched on the A&E dataset who were diagnosed since 1st 
April 2002.  
In early cancer onset, before the transitional care period, the risk of an A&E 
attendance in the 5 to 9-year age group was significantly lower compared with 
the risk of attending A&E in the 10 to 14-year age group. The age groups during 
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attendance compared with the 10 to 14-year age group, with an increasing 
trend by 5-year age category. However, this is in contrast to the sensitivity 
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attendance compared with the 10 to 14-year age group or A&E attendance was 
significantly lower. There were no individuals from the 30 to 34-year age group 
included in the sensitivity cohort (Figure 6.36).  
In late cancer onset, all age groups had significantly lower risk of attending A&E 
compared with the 40 and over group. However, the sensitivity analysis showed 
the opposite results where all age groups had significantly higher risk of 
attending A&E compared with the 40 and over group (Figure 6.37). 
In both early and late cancer onset, compared with males and white ethnicity, 
no significant differences in risk of A&E attendance was found for females and 
South Asian/Other ethnicity, respectively.  
There was a significantly higher risk of attending A&E in the most deprived and 
second most deprived fifths compared with the least deprived fifth in early and 
late cancer onset. This was also found in the sensitivity cohort in early cancer 
onset. However, in late cancer onset, the risk of attending A&E was only 
significantly higher in the most deprived fifth compared with the least deprived 
fifth.
  
199	
 
Figure 6.36: Relative risk of accident and emergency (A&E) attendance from mixed effects Poisson model with 95% confidence intervals 
by age at A&E attendance – early cancer onset (a.) and equivalent sensitivity cohort (b.).
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Figure 6.37: Relative risk of accident and emergency (A&E) attendance from mixed effects Poisson model with 95% confidence intervals 
– late cancer onset (a.) and equivalent sensitivity cohort (b.).
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6.3.5.5 Accident and emergency (A&E) attendance by cancer type. 
No significant differences were found in risk of A&E attendance by any cancer 
type compared with the reference cancer type and in early (Figure 6.38) and 
late cancer onset (Figure 6.39). This was also found in the equivalent sensitivity 
cohorts.
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Figure 6.38: Relative risk of accident and emergency (A&E) attendance from mixed effects Poisson model with 95% confidence intervals 
by cancer type – early cancer onset (a.) and equivalent sensitivity cohort (b.).
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Figure 6.39: Relative risk of accident and emergency (A&E) attendance from mixed effects Poisson model with 95% confidence intervals 
by cancer type – late cancer onset (a.) and equivalent sensitivity cohort (b.).
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6.3.5.6 Accident and emergency (A&E) attendance by mental health 
admission. 
Of the 3,034 individuals in the YSRCCYP cohort with an A&E admission, 373 
(12.3%) had a mental health admission before any A&E admission. As with the 
outpatient and inpatient datasets, there was a higher percentage of individuals 
with a mental health admission in the late cancer onset group (n=219; 14.5% of 
the late cancer onset total) compared with early cancer onset (n=154; 10.1% of 
the early cancer onset total). There was also a higher number of individuals with 
a mental health admission in the most deprived group (n=119; 15% of the most 
deprived fifth total) compared with the least deprived fifth (n=46; 9.4% of the 
least deprived fifth total) (Table 6.21). 
Table 6.21: Number of individuals with a mental health admission any time 
before an accident and emergency (A&E) attendance by socio-demographic 
groups. 
  
Total individuals with 
a mental health 
admission before an 
A&E attendance 
Total 
individuals 
with an A&E 
attendance 
  
N % of group 
% of 
total 
Age at 
cancer 
diagnosis 
0 to 14 years 
(early onset)   154      10.1        5.1       1,521  
15 to 29 years 
(late onset)    219      14.5        7.2       1,513  
Sex Males    202      11.2        6.7       1,802  Females    171      13.9        5.6       1,232  
Ethnicity 
White    292      12.2        9.6       2,386  
South 
Asian/Other      22        9.6        0.7          228  
Deprivation 
Least deprived 
fifth      46        9.4        1.5          489  
2nd least 
deprived fifth      59      10.2        1.9          580  
3rd most 
deprived fifth      62      12.0        2.0          515  
2nd most 
deprived fifth      76      13.7        2.5          555  
Most deprived 
fifth    119      15.0        3.9          795  
Total 373     12.3      12.3  3,034 
 
Individuals diagnosed with soft tissue tumours (n=27; 17.4%), CNS neoplasms 
(n=77; 15.8%) and other malignant epithelial neoplasms (n=30; 14.6%) had the 
highest percentage of individuals with a mental health admission before an A&E 
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admission. As with the inpatient data, the lowest percentages were found in 
retinoblastoma (n=4; 5.7%) and neuroblastoma (n=5; 7.2%) (Table 6.22). 
Table 6.22: Number of individuals with a mental health admission any time 
before an accident and emergency (A&E) attendance by cancer type. 
 
Total individuals with a mental 
health admission before an 
A&E attendance 
Total 
individuals 
with an 
A&E 
attendance 
 
N % of group % of total 
I Leukaemias 58 9.6         1.9  602 
II Lymphomas 79 12.3         2.6  642 
III CNS 77 15.8         2.5  488 
IV Neuroblastoma 5 7.2         0.2  69 
V Retinoblastoma 4 5.7         0.1  70 
VI Renal tumours 12 9.6         0.4  125 
VIII Malignant bone 13 11.8         0.4  110 
IX Soft tissue 27 17.4         0.9  155 
X Germ cell tumours 67 12.2         2.2  547 
XI Other malignant epithelial 
neoplasms 30 14.6         1.0  205 
Total 373 12.3        12.3  3,034 
 
Multi-level logistic regression modelling for the overall cohort found that the 
odds of an A&E admission with a previous mental health admission was 
significantly higher than for individuals with no previous mental health admission 
by four-fold (4.64; 95% CI 1 to 21.55) (Figure 6.40).  
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Figure 6.40: Odds ratio of accident and emergency (A&E) attendance from 
mixed effects logistic regression model with 95% confidence intervals by 
previous mental health admission. 
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6.3.5.7 Accident and emergency (A&E) attendance and outpatient 
appointment status. 
In total, 1,733 individuals (39.2%) had an A&E attendance within 90 days of an 
outpatient appointment. The percentage of individuals with early cancer onset 
(n=933; 42.8%) was higher than in late cancer onset (n=800; 35.7%). Females 
(n=808; 43.3%) and South Asian/Other ethnicity (n=159; 42.6%) had a higher 
percentage of individuals with an A&E attendance 90 days within an outpatient 
appointment compared with males (n=925; 36.1%) and white ethnicity (n=1,370; 
39%). Percentages increased by deprivation group, with the highest percentage 
in the most deprived fifth at 43.9% (n=468) (Table 6.23). 
Table 6.23: Number of individuals with an accident and emergency (A&E) 
attendance within 90 days of an outpatient appointment by socio-demographic 
groups. 
  
Total individuals with an 
A&E attendance within 90 
days of an outpatient 
appointment 
Total 
individuals 
with an 
outpatient 
appointment 
  
N % of group 
% of 
total 
Age at 
cancer 
diagnosis 
0 to 14 years 
(early onset)  933   42.8  21.1  2,182  
15 to 29 years 
(late onset)  800   35.7  18.1  2,242  
Sex Males  925   36.1  20.9  2,563  Females  808   43.4  18.3  1,861  
Ethnicity 
White  1,370   39.0  31.0  3,509  
South 
Asian/Other  159   42.6  3.6  373  
Deprivation 
Least deprived 
fifth  275   35.6  6.2  773  
2nd least 
deprived fifth  300   34.8  6.8  861  
3rd most 
deprived fifth  293   37.8  6.6  776  
2nd most 
deprived fifth  332   43.3  7.5  766  
Most deprived 
fifth  468   43.9  10.6  1,067  
Total  1,733   39.2  39.2  4,424  
 
Individuals diagnosed with hepatic tumours (n=11; 47.8%), CNS neoplasms 
(n=320; 46.7%) and neuroblastoma (n=47; 45.2%) had the highest percentage 
of individuals with an A&E admission within 90 days of an outpatient 
appointment. The lowest percentages were found in germ cell tumours (n=220; 
29.3%), lymphomas (n=341; 35.6%) and soft tissue tumours (n=88; 37.3%) 
(Table 6.24). 
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Table 6.24: Total individuals with an accidence and emergency (A&E) 
attendance within 90 days of an outpatient appointment by cancer type. 
 
Total individuals with an A&E 
attendance within 90 days of an 
outpatient appointment 
Total 
individuals 
with an 
outpatient 
appointment 
 
N % of 
group 
% of total 
I Leukaemias  387  42.6 8.7  908  
II Lymphomas  341  35.6 7.7  957  
III CNS  320  46.7 7.2  685  
IV Neuroblastoma  47  45.2 1.1  104  
V Retinoblastoma  40  41.7 0.9  96  
VI Renal tumours  71  39.4 1.6  180  
VII Hepatic tumours  11  47.8 0.2  23  
VIII Malignant bone  74  45.1 1.7  164  
IX Soft tissue  88  37.3 2.0  236  
X Germ cell tumours  220  29.3 5.0  752  
XI Other malignant 
epithelial neoplasms  130  41.5 2.9  313  
Total  1,733  39.2 39.2  4,424  
 
There were 9,480 (10.6%) outpatient appointments where an A&E attendance 
occurred within 90 days. Of these 9,480 outpatient appointments, 11% 
(n=1,046) had a DNA status (Table 6.25). This is a similar percentage to the 
outpatient appointments with no A&E admissions within 90 days at 10.5% 
(n=8,434). 
The mixed effects logistic regression models found no significant difference in 
odds of A&E attendance within 90 days of an outpatient appointment between 
attended or DNA appointments (Figure 6.41).
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Table 6.25: Number of outpatient appointments and accident and emergency (A&E) attendances by socio-demographic groups and 
cancer type. 
  
Total outpatient appointments 
Total 
  
No A&E attendances A&E attendance within 90 days after an outpatient appointment   
Did not attend Attended Did not attend Attended   
N % N % N % N % 
Age at 
cancer 
onset 
0 to 14 years (early onset) 4,364 8.6 40,833 80.9 582 1.2 4,636 9.2 50,470 
15 to 29 years (late onset) 4,070 10.4 31,271 80.1 464 1.2 3,216 8.2 39,059 
Sex Males 4,588 10.6 34,523 79.5 546 1.3 3,743 8.6 43,441 Females 3,846 8.3 37,581 81.5 500 1.1 4,109 8.9 46,088 
Ethnicity White 6,580 9.4 56,753 80.9 819 1.2 5,972 8.5 70,186 South Asian/Other 788 11.7 5,161 76.5 93 1.4 704 10.4 6,749 
Deprivation 
Least deprived fifth 1,094 7.1 12,956 84.2 109 0.7 1,225 8.0 15,394 
2nd least deprived fifth 1,250 7.4 14,130 83.9 131 0.8 1,321 7.8 16,843 
3rd most deprived fifth 1,436 9.6 12,105 81.0 154 1.0 1,220 8.2 14,942 
2nd most deprived fifth 1,644 9.8 13,131 78.4 228 1.4 1,719 10.3 16,749 
Most deprived fifth 2,653 12.1 16,830 76.6 387 1.8 2,076 9.5 21,960 
Cancer 
type 
I Leukaemias 2,022 9.9 16,630 81.1 189 0.9 1641 8.0 20,497 
II Lymphomas 1,783 10.5 13,724 80.4 232 1.4 1305 7.6 17,060 
III CNS 1,238 6.6 15,224 80.8 176 0.9 2193 11.6 18,851 
IV Neuroblastoma 241 9.9 2,036 83.7 25 1.0 129 5.3 2,433 
V Retinoblastoma 242 12.3 1,602 81.2 12 0.6 110 5.6 1,973 
VI Renal tumours 360 9.8 2,873 78.4 40 1.1 383 10.5 3,665 
VII Hepatic tumours 17 4.3 330 83.5 5 1.3 43 10.9 395 
VIII Malignant bone 296 7.9 3,083 82.8 48 1.3 295 7.9 3,724 
IX Soft tissue 409 8.4 4,002 82.1 55 1.1 404 8.3 4,873 
X Germ cell tumours 1,069 12.0 6,979 78.5 181 2.0 646 7.3 8,887 
XI Other malignant epithelial 
neoplasms 741 10.9 5,370 78.9 80 1.2 606 8.9 6,804 
Total 8,434 9.4 72,104 80.5 1,046 1.2 7,852 8.8 89,529 
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Figure 6.41: Odds ratio of accident and emergency (A&E) attendance within 90 days of an outpatient appointment from mixed effects 
logistic regression model with 95% confidence intervals (a.) and equivalent sensitivity cohort (b.).
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6.4 Summary of results. 
Mental health admission had the lowest incidence rates of all outcomes from 
the HES and MHMDS analysis. Most of these admissions were diagnosed after 
the transitional care period and/or at least 5 years after initial cancer diagnosis. 
Risk of a mental health admission was higher for males and individuals 
diagnosed with leukaemias, lymphomas, CNS neoplasms and germ cell 
tumours. These cancer types also had the highest total of outpatient 
appointments and inpatient admissions with a mental health treatment specialty. 
Individuals with a mental health admission had a significantly higher odds of a 
DNA outpatient appointment in late cancer onset and also had an increased risk 
of an A&E attendance compared with individuals with no record of a mental 
health admission. However, there was no significant difference in inpatient 
admission between individuals with and without a previous mental health 
admission. No significant differences were found between ethnicity categories, 
nor between deprivation fifths.  
Although the DNA rate of outpatient appointments was relatively low at 10.3%, 
over 60% of individuals had at least one missed appointment. The incidence of 
a DNA appointment was significantly higher in late cancer onset compared with 
early cancer onset. In early cancer onset, during the transitional care period, the 
odds of a DNA appointment compared with the 10 to 14-year age group was 
significantly higher in the 20 to 24-year age group than in the 15 to 19-year age 
group. However, the odds were not significantly different from the age groups 
after the transitional care period. This was also found in late cancer onset, 
where the odds of a DNA appointment compared with the 40 and over group 
were not significantly different between the age groups during the transitional 
care period and age groups after the transitional care period.  
On average, around 4 appointments were missed out of 25 appointments per 
individual. Females had a higher incidence of DNA appointments compared 
with males, but their odds of a DNA appointment were significantly lower 
compared with males. There was no significant difference in DNA appointments 
between ethnicity categories or cancer types. However, there was some 
evidence for significantly higher odds for the most deprived fifth compared with 
the least deprived fifth.  
Outpatient appointments with a mental health treatment specialty, particularly in 
late cancer onset, had a higher odds of a DNA appointment compared with 
oncology appointments and also had the highest odds ratio of all other 
treatment specialities. Appointments with a treatment specialty of 
Maternity/Obstetrics/Gynaecology had the lowest odds of a DNA appointment 
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compared with oncology. DNA appointments did not increase the risk of an A&E 
attendance. However, it was found that a DNA appointment actually significantly 
decreased the odds of a CIPS by around 50%. 
Inpatient admissions had the highest incidence rates for all outcomes. There 
were no significant differences in CIPS incidence rates between early and late 
cancer onset. Incidence was higher in older ages and risk of CIPS was higher 
for older age groups, although this was disputed by the sensitivity cohort which 
showed an opposite trend. As with DNA outpatient incidence, females also had 
a higher incidence for CIPS compared with males. However, where females 
were found to have significantly lower odds of a DNA outpatient appointment 
compared with males, females had a significantly higher risk of a CIPS 
compared with males. Although the South Asian/Other category also had higher 
CIPS incidence, there was significant difference in risk of a CIPS in the South 
Asian/Other group compared with white ethnicity. There was some evidence of 
significantly higher risk of CIPS in the most deprived fifth compared with the 
least deprived fifth.  
No primary diagnoses had a significantly higher risk of CIPS compared with 
oncology. In late cancer onset, mental health behaviour had the highest risk of 
CIPS than all other diagnoses compared with oncology. However, in early onset 
mental health behaviour had one of the lowest risks of CIPS.   
The incidence rates for A&E were less than the incidence rates for CIPS. The 
incidence and risk of an A&E attendance was higher in older age groups. As 
with the outpatient and inpatient data, there were no significant differences in 
risk of A&E attendance between ethnicity groups and risk of an A&E attendance 
was higher in the most deprived fifth compared with the least deprived fifth. 
There were no significant differences in risk of A&E attendance by cancer type. 
 
6.5 Overall summary analysis compared with previous studies.  
The rate of CIPS in the YSRCCYP was over twice that of the rate found in a 
study in Amsterdam for 5-year survivors diagnosed with cancer before 18 years, 
reaching 172 hospitalisations per 1,000 person-years (205). However, this was 
only a single-centre study of 1,564 individuals, covering an 11-year period 
between 1995 to 2006. The YSRCCYP covered a 20-year period between 1997 
to 2017 with 7,238 individuals, including late onset diagnoses. In the multi-
centre Cancer in Childhood Survivor Study (CCSS), the rate was also found to 
be half the rate of the YSRCCYP at 142.1 per 1,000 person-years with 13-years 
follow-up between 1992 and 2005 (204). This may be explained by the use of 
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survey data in the CCSS to determine hospitalisation rate, which may not have 
produced accurate estimates due to reliance on recall memory compared with 
using routine data as used in this study.  
 
6.6 Health outcomes by attained age groups before, during 
and after the transitional care period. 
The relative risk of CIPS and A&E attendance in the YSRCCYP at the 
beginning of the transitional care period in the 15 to 19-year age group was 
significantly higher compared with the 10 to 14-year age group. This suggested 
an increase in negative health outcomes begins during the transitional care 
period. This increasing trend in relative risk continued after the transitional care 
period, with the highest relative risk in the oldest age group. The sensitivity 
analysis showed a decreasing trend in relative risk with increasing age groups, 
although this could be due to fewer individuals in the cohort at older age groups.  
This increase in hospitalisations with older ages was also found by Wijlaars and 
colleagues, who analysed all hospital inpatient admissions and A&E 
attendances in England over 3 years between individuals with and without an 
LTC (including non-cancer conditions). They found a significant increase in 
admission rates after transition (defined as ages 19 to 24 years) at a higher rate 
for those with an LTC compared with the general population. They also found 
an increase in hospitalisations after transition for mental health admissions for 
both LTC and non-LTC groups (285). In this study, most first known mental 
health admissions occurred during the transitional care period (n=318; 53%) 
and after cancer diagnosis (n=508; 84.4%). However, there were no significant 
differences in relative risk of first known mental health admission for any age 
group compared with the 10 to 14-year age group overall, suggesting that there 
was no significant increase in risk during the transitional care period.  
The relative risk of an outpatient appointment with a DNA status was 
significantly higher during and after the transitional care period compared with 
before. The trend in relative risk of an outpatient appointment with a DNA status 
increased significantly from 15 to 19-years to the 20 to 24-year age group. 
However, the relative risk in all older ages remained similar to the 20 to 24-year 
age group, so outpatient appointment attendance was no worse during the 
transitional care period compared with after the transitional care period. This 
suggests that older adults were similarly less compliant at outpatient 
appointment attendance than younger adults.  
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6.7 Health outcomes by onset before and during the 
transitional care period.  
The incidence rate for an A&E attendance following a cancer diagnosis was 
significantly higher in late onset compared with early onset. This may be due to 
the late cancer onset group including more individuals followed up at older 
ages, where a higher proportion of A&E attendances occur. In 2017-18, 10% of 
all A&E attendances in England occurred in 5 to 14-year olds, whilst nearly 30% 
occurred in 15 to 34-year olds (286). There were no significant differences in 
relative risk for an A&E attendance between any cancer types in either onset 
group, suggesting that initial cancer diagnosis was not associated with A&E 
attendance during follow-up. 
The incidence rates for outpatient appointment with a DNA status was also 
significantly higher for late onset compared with early onset. When assessing 
attendance at outpatient appointments for mental health in comparison with 
oncology appointments, the late onset group had a higher odds ratio of a DNA 
status compared with early onset. Significantly fewer outpatient appointments 
with a DNA status were found for those diagnosed with CNS neoplasms 
compared with the reference cancer group in early cancer onset, but not for late 
cancer onset. 
The incidence rate for first mental health admissions was also significantly 
higher in late cancer onset compared with early cancer onset. Kazak and 
colleagues found that those diagnosed during adolescence had poorer 
psychosocial outcomes compared with peers and that treatment severity was 
an important risk factor due to associations with cancer type and impact on 
quality of life (247). In both onset groups, individuals diagnosed with 
leukaemias, lymphomas and CNS neoplasms (and germ cell tumours in late 
cancer onset) all had significantly higher risk of a mental health admission when 
compared with the reference cancer types. These cancer types were the most 
frequently diagnosed in both onset groups. As in the overall cohort, there were 
no significant differences in relative risk between age groups for first mental 
health admission in early cancer onset. However, for the late cancer onset 
group, significantly higher relative risk of first mental health admission was 
found for those aged 20 to 34 compared with the 40 and over group, with a 
peak relative risk in those aged 25 to 29-years. As with the YRDCYP, this 
suggests that those diagnosed during the transitional care period may need 
increased mental health support. The YSRCCYP found that individuals in the 
latter stages of the transitional care period (25 to 29 years) in particular required 
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increased support. This age group was often overlooked in assessing 
transitional issues.  
Despite higher incidence rates in late cancer onset for DNA outpatient 
appointments, A&E attendance and first mental health admission, no significant 
difference in incidence rate for CIPS between the onset groups was found. An 
explanation for this may be due to a higher mean number of CIPS per individual 
in the early onset group. A higher mean number of total outpatient appointments 
per individual was also found in the early onset group. As more outpatient 
appointments were attended at younger ages, there could be more opportunity 
for a referral for an inpatient admission. The possible link between DNA 
outpatient appointments and inpatient referral has not been explored in 
previous research, so future examination of this association is needed. 
Almost a third of CIPS had a primary diagnosis code for neoplasms and around 
a fifth had a treatment specialty of oncology. As this analysis only included data 
from at least 5 years after diagnosis of initial cancer, it was assumed that 
treatment for the first cancer was completed so it is likely that some of these 
admissions are related to a subsequent cancer diagnosis. Previous research 
has shown a 47% increased risk of developing subsequent cancer (63). For all 
cancer types, apart from hepatic tumours, neoplasm was the most frequent 
primary diagnosis. Oncology was the most frequent treatment specialty for 
CIPS for leukaemias, lymphomas, CNS neoplasms, malignant bone tumours, 
soft tissue tumours and other malignant epithelia neoplasms. There was a level 
of uncertainty as to whether these CIPS refer to a subsequent cancer and if so, 
what types of cancer have occurred. Validation against the YSRCCYP for these 
instances was not possible as data were only available for individuals with a 
second cancer diagnosis under the age of 30, so would not capture all cases. In 
the British Childhood Cancer Survivor Study (BCCSS), it was found that the 
most frequent secondary cancers were CNS neoplasms, non-melanoma skin 
cancer, digestive, genitourinary, breast and bone cancers (70).  
 
6.8 Health outcomes by socio-demographic groups and cancer 
type. 
Females had a significantly higher two-fold relative risk of CIPS compared with 
males. Females were more likely to attend outpatient appointments, so had 
more opportunity to be referred for an inpatient admission. Relative risk of A&E 
attendance for both early and late cancer onset showed no significant difference 
between sexes. 
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The higher proportion of deaths from suicide for males in the YRDCYP T1D 
analysis suggested issues surrounding mental health in males. This was also 
shown in the YSRCCYP cohort where mental health admission was significantly 
higher in males compared with females. Males also had worse attendance at 
outpatient appointments compared with females, with the highest risk of a DNA 
status in the mental health treatment specialty. This was similar to a report on 
outpatient appointments in Scotland (including non-cancer patients), where 
there were higher DNA outpatient appointments for males and also for general 
psychiatry. However, it was deprivation rather than sex that was a significant 
predictor for non-attendance to the psychiatry appointments (287). In this study, 
there was no significant difference between deprivation groups for mental health 
admissions. There was a significantly higher odds ratio of a DNA outpatient 
appointment in the most deprived fifth compared with the least deprived fifth 
and A&E attendances were also significantly higher in the two most deprived 
groups. 
For ethnicity, there were no significant differences between the South 
Asian/Other group compared with white ethnicity for CIPS, outpatient 
appointment DNA status and A&E attendance. However, there was a 
significantly lower risk of a mental health admission for the South Asian/Other 
group compared with white ethnicity. As there were smaller numbers for mental 
health admissions and possible classification issues with Onomap, this 
significant result for mental health admissions may need to be considered with 
caution. 
 
6.9 Health outcomes by hospital outpatient appointment 
attendance. 
The total percentage of non-attended outpatient appointments (10.3%) in the 
YSRCCYP was similar to appointment outpatient attendance in the general 
population of Scotland at 10% (287). Compared with England and Wales, 13% 
of all individuals with a DNA outpatient appointment had an unplanned A&E 
attendance within 90 days. This compared to 8.4% of individuals who attended 
their outpatient appointment (288). In the YSRCCYP, 39.2% of all outpatient 
appointments were followed by an A&E attendance within 90 days. Of these 
outpatient appointments, 11% of those with a DNA status had an A&E 
attendance within 90 days, compared with 9.8% of those with an attended 
status. Therefore, the YSRCCYP had similar percentages of A&E attendance 
90 days after an outpatient appointment compared with the general population. 
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There was no significant difference in relative risk for an A&E attendance within 
90 days between attended and DNA outpatient appointments. 
The significantly lower relative risk of a CIPS 90 days after an outpatient 
appointment with a DNA status may lead to the assumption that non-attendance 
to outpatient appointments has no detrimental effects to health outcomes. There 
was also no significant difference in relative risk of an A&E attendance 90 days 
after an outpatient appointment between DNA and attended status. This 
supported the view that non-attendance does not necessarily mean non-
adherence and that appointments may be missed as they are less likely to be 
needed (115). However, non-attendance at an outpatient appointment may 
mean that there was less opportunity for a referral for an inpatient admission. 
The consequence of this may be that a higher risk of A&E attendance in the 
longer term. Previous research into the association between outpatient, 
inpatient and A&E datasets is lacking and requires further study.  
 
6.10 Health outcomes by mental health history. 
According to the latest psychiatric morbidity survey of England, it was estimated 
that around 13.1% of adults were receiving mental health treatment (289). This 
was higher than that found in the YSRCCYP, where 8.3% received a mental 
health admission either before, during or after initial cancer treatment, 
suggesting that mental health treatment is higher in the general population. 
However, the MHMDS only captured secondary care services and did not 
include GP services, so it was likely that analysis on mental health for the 
YSRCCYP was underestimated. Previous studies have shown that physical 
illness increases mental health issues. Bagur and colleagues found that 
psychiatric disorders were significantly higher in childhood cancer survivors 
compared with the general population and as much as 56.2% of survivors 
having at least one psychiatric disorder (243).  
In the YSRCCYP, a history of a mental health admission was shown to increase 
the risk of having an outpatient appointment with a DNA status and an 
increased risk of attending A&E. This suggested that mental health issues are a 
barrier to outpatient appointment attendance and a risk factor for A&E 
attendance. As most first known mental health admissions occurred after 5 
years since initial cancer diagnosis, this suggested that support for mental 
health was important not only during cancer treatment but especially during 
follow-up. In a UK focus group, Brown and colleagues (2016) found that 
childhood cancer survivors talked about how their cancer treatment not only had 
long-term consequences on physical health but also consequences on social 
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relationships and emotional perceptions of the self (290). Other surveys and 
qualitative studies have reported similar issues continuing into adulthood. It has 
also been noted that poor physical health is associated with higher rates of 
unemployment, which in turn leads to a lower quality of life and increases 
mental health issues (291) (292). In this study, although there was an increased 
incidence rate of mental health admission in the most deprived groups, there 
were no significant differences in relative risk of mental health admissions 
between any of the deprivation fifths compared with the least deprived fifth, 
suggesting that deprivation was not a predictor for a mental health admission. 
However, it could not be established with these data whether everyone who 
needed mental health services had access to care. For example, the most 
deprived groups may have been in more need of mental health services, but 
whether these groups had the same opportunities to access these services 
compared with individuals in the least deprived groups was not known.  
 
6.11 Chapter summary. 
Analysis of HES data for the YSRCCYP showed that the risk of negative health 
outcomes (CIPS, A&E attendance and DNA outpatient appointments) 
significantly increased during the transitional care period compared with before. 
However, this risk continues into older adulthood, so this increase was not 
specific to the transitional care period. Mental health admissions found no 
significant differences between before and during the transitional care period. 
However, incidence of mental health admissions, as well A&E attendances and 
DNA outpatient appointments were significantly higher in late cancer onset 
compared with early onset. 
As with T1D health outcomes, there were significant differences in CYA cancer 
health outcomes between sex groups. The risk of a mental health admission 
and a DNA outpatient appointment was significantly higher in males compared 
with females, whilst risk of CIPS was significantly higher in females compared 
with males. No significant differences were found between sex groups for A&E 
attendances.  
Mental health attendance was significantly higher in white ethnicity compared 
with South Asian ethnicity. Unlike with T1D mortality, the most deprived groups 
had significantly higher A&E attendances and DNA outpatient appointments.
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Chapter 7 Discussion 
Despite clinical recognition that the transitional care period conceptualises more 
than the transfer between paediatric to adult services, current quantitative 
research on this topic tends to only focus on analysis for attended appointments 
before and after transfer, partly due to the lack of available long-term data 
collected for the purpose of studying the effects of transition. The justification for 
specialist transition services is based on qualitative research, with no empirical 
measure of the need for these services based on assessment of long-term 
health outcomes. This study used routine population-based registry datasets 
collected over a 35-year period to overcome this paucity of quantitative 
research. These datasets were linked with mortality and hospital admissions 
data to examine the health outcomes related to the transitional care period in 
both T1D and CYA cancer. Analysis of the YRDCYP cohort linked with ONS 
death certification data (Chapter 4) found that most deaths in individuals with 
T1D occurred during the transitional care period, with deaths due to DKA at 15 
to 19 years of age exceeding the mortality rate for the overall cohort. Mortality 
was also higher in the late T1D onset group compared with early T1D onset. 
CSII therapy in the LCYPDS was shown to be effective in reducing HbA1c 
levels during the transitional care period for up to 4 years after the start of 
treatment, although females sustained HbA1c improvements for a shorter time 
period and discontinued CSII therapy more than males (Chapter 5). In the 
YSRCCYP cohort linked with HES and MHMDS data (Chapter 6), the likelihood 
of a mental health admission, a DNA outpatient appointment, A&E attendance 
and CIPS were significantly higher during the transitional care period compared 
with before in CYA cancer. As with T1D mortality, the risk of negative health 
outcomes in the YSRCCYP was higher in late onset compared with early onset.  
The results for each cohort were discussed overall (sections 4.5, 5.5 and 6.5) 
and then in relation to attained age (sections 4.6, 5.6 and 6.6), age at onset 
(sections 4.7 and 6.7) and socio-demographic characteristics (sections 4.8, 5.7 
and 6.8). For the YSRCCYP cohort, results by outpatient attendance (section 
6.9) and mental health admission (section 6.10) were discussed.  
This chapter includes a discussion of the results in the context of the study 
hypothesis (section 7.1), the major implications of this study (section 7.2), the 
strengths and weaknesses (section 7.3), future work (section 7.4) and 
conclusion (section 7.5). 
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7.1 Addressing the study hypothesis. 
This study hypothesised that there would be an increase in negative health 
outcomes during the transitional care period, compared with before and after for 
both T1D and CYA cancer. The results of analysis from both the YRDCYP and 
YRSSCYP cohorts demonstrated that rates of negative health outcomes could 
be compared before, during and after the transitional care period, with some 
evidence of an increase in negative health outcomes during the transitional care 
period, although this was not found to be consistent in all age groups. In the 
YRDCYP, DKA mortality was highest in the 15 to 19-year age group but no 
significant difference was found compared with the overall mortality rate for 
ages 20 to 29 years. Problems with DKA for under 19-year olds was also shown 
in the LCYPDS where there was a significantly higher hospitalisation rate for 
DKA in the first year of CSII, although there was insufficient data to compare 
health outcomes before, during and after the transitional care period for the 
LCYPDS cohort.  
This increase in DKA mortality risk in the younger ages of the transitional care 
period was not observed for other causes of death in the YRDCYP. For overall 
mortality in the YRDCYP, there was an increasing trend in SMRs from the 15 to 
19-year age group, peaking at 25 to 29-year age group, before decreasing at 
older ages. However, there were no significant differences found between 
during the transitional care period and afterwards. These trends were also 
shown in the YRSSCYP cohort, where there were significant increases in 
negative health outcomes beginning during the transitional care period 
compared with before, but there were no significant differences found compared 
with older age groups. These routine data indicated that the transitional care 
period marked the start of an increase in negative health outcomes across both 
T1D and CYA cancers. However, this does not provide definitive evidence for 
the need of specialist transition services across all diseases. It could not be 
determined in the data whether a reduction in negative health outcomes during 
the transitional care period could reduce the risk of negative health outcomes in 
older ages. The association between the risk of negative outcomes during the 
transitional care period and afterwards warrants further investigation.  
This study analysed socio-demographic groups to determine whether there is a 
need for further targeted interventions for specific groups of individuals. The 
analysis of the YRDCYP found a significantly lower risk of death for females 
compared with males for all causes apart from T1D acute complications, where 
there were no significant differences in risk found between males and females. 
This would suggest targeted interventions would be beneficial for males. 
However, in the LCYPDS, females were found to have higher CSII 
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discontinuation rates and less improvement in HbA1c with CSII compared with 
males. The higher percentage of females initiating CSII treatment also indicated 
a possible increase of issues surrounding HbA1c control with MDIs compared 
with males. This demonstrated that assessing a single source of routine data for 
one type of negative health outcome cannot capture the complexity of the need 
for targeted interventions for specific socio-demographic groups. This was also 
shown with the YSRCCYP cohort where males were at higher risk of a mental 
health admission and a DNA outpatient appointment compared with females, 
whereas females had a significantly higher risk of a CIPS.  
Analysis by age at LTC onset also found some notable differences between 
groups for negative health outcomes in both T1D and CYA cancer. The late 
onset groups were shown to have an increased risk of T1D mortality and higher 
incidence of DNA outpatient appointments, A&E attendance and mental health 
admission. This could be due to the inclusion of older age groups for individuals 
diagnosed with late LTC onset who were more likely to develop negative health 
outcomes. Another reason could be due to the amount of experience and 
preparation in managing an LTC in adulthood. Investigating individual 
experiences is difficult to quantify, so using routine data in isolation can be 
limited. Although qualitative data are subjective and usually only include a small 
sample of the population, they are still valuable in providing insight and context 
in explaining certain trends found using quantitative methods.  
For the YSRCCYP cohort, analysis of outpatient appointments found a 
significantly lower risk of a CIPS 90 days after a DNA outpatient appointment. 
This could indicate that non-attendance to outpatient appointments has no 
detrimental effect on health outcomes, supporting the view that non-attendance 
does not necessarily mean non-adherence in CYA cancer survivors. However, 
non-attendance at an outpatient appointment may mean that there was less 
opportunity for a referral for an inpatient admission and may lead to a higher 
risk of an A&E in the longer term or premature death. Using CIPS as a proxy 
measure for complications would therefore be questionable as this dataset 
would not be able to capture complications where there was no inpatient 
admission. To investigate this further, as with age at onset, qualitative research 
may provide some insight as to why there is a decreased risk of CIPS with DNA 
appointments, alongside further analysis of outpatient, inpatient and A&E 
datasets. 
Due to the heterogeneity of cancer, analysis was conducted by cancer type in 
the YRSCCYP. Analysis by treatment specialty and diagnosis codes was also 
completed to determine any differences between complication types for 
outpatient and inpatient data. This produced a high volume of results with no 
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significant associations. Inclusion of all of these results may not have been 
relevant for this thesis. However, they may provide some insight for future 
researchers interested in performing similar analysis for comparison.  
The analyses presented in this thesis demonstrated that routine datasets can 
be used to examine whether negative health outcomes increase during the 
transitional care period and whether certain groups of individuals were more at 
risk of negative health outcomes. However, this thesis also highlights limitations 
to using analysis of datasets in providing evidence for specialist transition 
services. Using multiple datasets revealed the underlying complexity in 
associations in risk of negative health outcomes for certain groups which would 
not have been found by assessing only one dataset for an LTC. There were 
some common significant associations found in both T1D and CYA cancer 
indicating that there are similarities surrounding transitional issues across 
diseases, but disease-specific trends also imply the need to assess LTCs 
separately.  
 
7.2 Clinical implications of this study. 
A main concern was the increased risk of mental health issues in males in the 
YRDCYP and YSRCCYP cohorts, particularly during the transitional care 
period. For T1D, the increased mortality rate in the 15 to 19-year age group 
suggests that management of T1D was poor during the transitional care period. 
This was reflected in the latest National Diabetes Audit (NDA) for 2016-17 
which showed only 33.7% of all individuals with T1D in England and Wales 
received 8 of the 9 recommended annual care processes and only 19% reach 
treatment targets for HbA1c, blood pressure and cholesterol. These 
percentages for care process completion and treatment target achievement 
were worse at younger ages (190). During adolescence, maintaining tight 
metabolic control can be difficult, not only because of increased insulin 
resistance during puberty but also due to psychosocial issues created by 
changing life stages coinciding with the period of transition between child to 
adult orientated services (293,294). In Gibb and colleague’s (2016) study on 
DKA hospitalisations in Edinburgh, 13.1% of those with recurrent DKA (5 or 
more presentations of DKA) had an inpatient admission for psychiatric care 
compared with 4.3% with a single DKA admission (270). This suggests that 
there may be a relationship between mental health and acute complications in 
T1D. However, the direction of the association (i.e. whether it is mental health 
which affects acute complications or whether acute complications affects mental 
health) has not been explored in previous research. 
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In both the YRDCYP and YSRCCYP, there were differences in mental health 
issues between the onset groups. For the YRDCYP, there was a higher risk of 
death from mental health disorders and suicide in late T1D onset compared with 
early T1D onset. In the YSRCCYP, the incidence rate of a mental health 
admission was significantly higher in late cancer onset compared with early 
cancer onset. This suggested that individuals diagnosed with a chronic illness 
within the transitional care period needed greater attention for mental health 
support. Despite a greater specialised focus in cancer treatment being in place 
for young adults compared with T1D as described in section 1.2, of all 
individuals of late cancer onset with a mental health admission, nearly a quarter 
had their first known mental health admission within the first 5 years since their 
initial cancer diagnosis. There was a significantly higher relative risk of first 
mental health admission found for those aged 20 to 34 years compared with the 
40 and over group, with a peak relative risk in the 25 to 29-year age group. This 
showed the importance of targeting mental health support for those in the older 
age groups in the transitional care period. The current NICE clinical guidelines 
have clear definitions of when transitional care should begin (20), but there is no 
recommendation for when transitional care ends. This study showed that the 
older age groups of the transitional care period should not be overlooked, and 
this should be reflected in clinical recommendations and guidelines. 
In this study, the analysis of CIPS was intended to be used as a proxy measure 
for long-term health outcomes. As there was a significantly lower relative risk of 
a CIPS 90 days after an outpatient appointment with a DNA status, this may 
lead to the assumption that non-attendance to outpatient appointments had no 
detrimental effects on health outcomes. This supports the view that non-
attendance does not necessarily mean non-adherence and that appointments 
may be missed as they are less likely to be needed (115). However, non-
attendance at an outpatient appointment meant that there was less opportunity 
for a referral for an inpatient admission. Therefore, there may have been an 
underestimation of negative health outcomes when using inpatient data in 
isolation as a proxy measure. Although there were no significant association 
between outpatient attendance status and A&E attendance, the multi-level 
modelling in this study only considered A&E attendances within 90 days. The 
consequence of not being referred for an inpatient admission due to non-
attendance at an outpatient appointment may be increased A&E attendances in 
the longer term or premature death. If this is the case, this would imply that 
preventing non-attendance at outpatient appointments is vital to avoid long-term 
negative health outcomes. Therefore, more concerted effort is needed to 
develop strategies to improve attendance rates. 
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7.3 Strength and weaknesses of this study. 
This study used registry data, covering the population of Yorkshire over a period 
of 35 years. It thus provides a complete population-level analysis comprising 
long-term follow-up information. As these were routine datasets, these were 
cost-effective and readily available for analysis. However, some data were 
missing, incomplete or incorrect. This limited some components of the analysis 
and caused some difficultly when linking the cohort data to mortality and HES 
datasets. The linkage of the YSRCCYP cohort to the individuals HES datasets 
and the second linkage between the HES datasets was time consuming due to 
the complexity of cleaning rules required. However, the final datasets could be 
used to analyse a range of research questions in addition to this study. The 
knowledge gained during the data linkage process can also be standardised for 
other HES datasets.  
Analysis by ethnicity and deprivation has been infrequently included in previous 
studies. This is due to poor completion of these data, which is not always 
mandatory in administrative datasets. In both the YRDCYP and YSRCCYP 
cohorts, Onomap software was a useful and easily applicable tool to identify 
ethnicity using full name of individuals. However, despite its good coverage of a 
large number of ethnic groups and the ability to use different dimensions of 
identity to derive a classification group (254), there were still a large number of 
individuals in both cohorts with missing ethnicity after the algorithm was applied 
(n=1,782 (32%) in the YRDCYP and n=1,633 (22.6%) in the YSRCCYP) . There 
were also problems with the algorithm in considering marital status for females 
and the identification of mixed ethnicities. Around 32% of both the YRDCYP and 
YSRCCYP had incomplete full names. The consequence of this may have led 
to an underestimation of the South Asian/Other total.  
Classification errors may also have occurred for deprivation. Larger populations 
live within the most deprived YRHA wards, leading to a higher proportion of the 
cohort classified in the most deprived fifth. The Index of Multiple Deprivation is 
calculated by Output Areas which are approximately equal in population size, so 
provides a more equal spread across the five deprivation categories. However, 
Townsend index was preferred due to its focus on material deprivation. No 
difference in trends were found in this study when using IMD in comparison to 
Townsend score.  
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7.3.1 Yorkshire Register of Diabetes in Children and Young People 
(YRDCYP) cohort linked to Office for National Statistics (ONS) 
mortality data. 
The underlying cause of death fields on the ONS mortality data were coded 
from death certification data using ICD-10 codes. Specialist clinician 
assessment of these codes was vital in producing an accurate analysis of 
cause-specific mortality as there were many inaccuracies in the coding. For 
example, deaths originally classified as renal disease with no reference to 
diabetes were reclassified ICD-10 code E10.2 (T1D with renal complications). 
According to the specialist clinician, deaths originally coded for ischaemic heart 
disease (IHD) should have been coded for T1D with IHD. However, there was 
no ICD-10 code for this cause of death, so these deaths were coded under 
E10.6 (type 1 diabetes with specified complications). Only 54% of all death 
certificates mentioned diabetes and 21% specifically mentioned T1D. The 
absence of T1D recorded on death certificates for individuals with a confirmed 
diagnosis has been highlighted previously in an Australian registry; around 38% 
of CVD deaths were underestimated after evaluation from a clinical specialist. 
However, only codes with underlying cause of death with ‘uncomplicated 
diabetes’ or ‘diabetes with circulatory complications’ were re-examined (295). A 
key strength in the analysis of this study included a systematic re-evaluation of 
all ICD-10 codes. 
The lack of clinical data to examine associations between previous health 
history with mortality limits the analysis of the YRDCYP cohort. Data on HbA1c 
levels, mental health history, lifestyle and co-morbidity for other diseases would 
have been useful in informing whether these factors were also contributors to 
excess mortality, as well as socio-demographic groupings. The NPDA 
combined with hospital admissions data to assess socio-demographic groups 
and treatment regimen in rates of acute complications over a 3-year period 
(126). Combining this with long-term mortality data would be valuable in 
identifying additional clinical predictors which increase the risk of death. 
 
7.3.2 Leeds Children and Young People’s Diabetes Service 
(LCYPDS) cohort for continuous subcutaneous insulin 
infusion (CSII) therapy. 
The analysis of HbA1c level pre-, during and after CSII therapy used multi-level 
modelling to account for the assumption of independent observations which has 
been rarely performed previously and is a major strength of this study. This was 
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not considered in other studies where HbA1c levels are examined, meaning that 
it was difficult to compare these results with previous studies. Also, as this was 
a centre-specific dataset, care must be taken when generalising these results 
nationally. The 2016-17 NPDA found that the Yorkshire and the Humber region 
had the highest percentage of CSII therapy in England and Wales (296). This 
means that the LCYPDS may represent one of the more proactive services in 
the country in prescribing CSII therapy and may have more trained staff and 
resources compared with other services across the country. 
Another weakness of this dataset was the unavailability of data for individuals 
remaining on MDIs. Due to the different stages of insulin resistance in 
adolescence, the sustainment of HbA1c improvement with CSII therapy for 4 
years could correspond to this trend (277). As the LCYPDS dataset was limited 
to individuals up to aged 19 years, it could not be determined whether HbA1c 
levels begin to decrease again in young adulthood. These fluctuations in HbA1c 
levels for those on CSII was similar to that of individuals on MDI therefore it was 
not clear which of these therapies gave optimum performance. 
 
7.3.3 Yorkshire Specialist Register of Cancer in Children and Young 
People (YSRCCYP) cohort linked to HES and MHMDS datasets. 
Although using HES data to examine health outcomes has been performed in 
previous studies, no other published studies have linked different HES datasets 
together to assess a more complete picture of the treatment journey through the 
secondary care system for a childhood or young adult cancer survivor. 
However, data for HES were not available from the start of the YSRCCYP 
diagnostic period, so there may have been missing data for individuals 
diagnosed before 2002 for at least one of the HES datasets. The sensitivity 
analysis to assess this level of bias showed opposite trends for age in models 
for CIPS for early cancer onset and A&E admissions for both early and late 
cancer onset. An explanation for this may be due to the lower numbers of 
individuals at older ages in the sensitivity cohorts. All other sensitivity models 
showed similar trends to analysis for the overall cohort. Therefore, any bias in 
this cohort appeared to have had minimal effect on the overall results and 
conclusions of this study. 
This study showed the importance of mental health in attending outpatient 
appointments and preventing A&E attendances. However, the MHMDS dataset 
was limited as it only included individuals receiving treatment from secondary 
care services and so there may have been an underestimation of mental health 
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issues in the YSRCCYP. There were also issues around the quality and 
accuracy of the MHMDS data. For some individuals with multiple admissions, 
there were different years recorded for when the first known psychiatric care 
episode took place, suggesting that this field could often be inaccurately 
recorded. Some records could be verified on the inpatient dataset, although this 
only included 10% of the dataset.  
 
7.4  Future work. 
Mental health support has been highlighted as an important topic in this study. 
Linking the MHMDS to the YRDCYP and LCYPDS cohorts along with clinical 
data such as HbA1c values would provide valuable analysis for the effect of 
mental health on self-management of T1D. It would also provide additional 
information on whether mental health is a factor for discontinuing CSII therapy, 
despite the limitations of the MHMDS dataset. The addition of primary care data 
would provide greater accuracy in determining the total number of individuals 
receiving mental health treatment. However, there would still be an 
underestimation of individuals in need of mental health services without a 
methodology to identify individuals in need of treatment but who are not known 
to any services. Data on the type of mental health condition and the type of 
treatment would further provide important details about whether the 
type/severity of mental health disorder or treatment used has any effect on 
physical health outcomes for both T1D and cancer.  
The evidence for more mental health issues in late onset compared with early 
onset in both the T1D and cancer cohorts showed that there is a need to 
examine the effects of being diagnosed with a chronic illness during the 
transitional care period. The burden of diagnosis coinciding with multiple life 
transitions may create more emotional and practical difficulties compared with 
an individual who has grown up with a chronic illness since childhood. There is 
a paucity of research on this topic and this is reflected in the lack of separate 
clinical guidelines or recommendations on this group of individuals. Due to the 
societal changes of ‘emerging adulthood’ where life transitions are extended 
over a longer period of time, such as AYAs moving out of the familial home and 
staying in full-time education at older ages, it may be that the transitional care 
period will need to include older age groups. This means that future research 
should pay close attention to these changes, leading to new issues for older 
age groups.  
The purpose of this study was to assess the empirical evidence for the need for 
specialist transition services. However, it did not evaluate whether current 
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specialist services are meeting current needs of adolescents and young adults. 
Whilst previous studies have focused on appointment attendance in these 
specialist services, few studies have assessed these services on health 
outcomes. In a future planned research study, data from the LCYPDS will 
assess whether there are differences between individuals who attended the 
service and then transferred to adult services with individuals who attended the 
transition clinics for adolescents and young adults introduced in 2008. Although 
we would not have the data to assess long-term outcomes, this study would be 
able to assess whether there has been an improvement since the introduction 
of the transition clinics for short-term outcomes.  
The finding relating to the possible association between missed outpatient 
appointments and fewer inpatient admissions requires extended examination. 
Analysis of whether a certain percentage of missed appointments or whether 
the most recent appointments are missed has any influence on inpatient 
admissions warrants closer inspection, in addition to how this possible 
association affects long-term A&E attendances and mortality. If significant 
associations were to be found, then there will be a need to determine why 
outpatient appointments are not attended. The day of the week or time of day of 
scheduled appointments could be factors for missed appointments. Ellis and 
Jenkins (2012) in Scotland found DNA highest on Mondays and lowest on 
Fridays, particularly for younger age groups (297). Qualitative methods would 
also be useful in finding out why appointments are missed.  
 
7.5  Conclusion. 
This study has shown that analysis of routine datasets provides empirical 
evidence for the need of extra support for individuals diagnosed with an LTC 
during the transitional care period to prevent negative long-term health 
outcomes. It suggests that current mental health services provisions may not be 
adequately addressed, particularly for those diagnosed during the transitional 
care period. Older age groups in the transitional care period also need greater 
attention. Previous research into the transitional care period tends to focus on 
ages under 25 years. This study shows that individuals over this age should not 
be overlooked. Socio-demographic factors should also be considered for 
targeted interventions. 
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Appendix A: International classification of childhood and 
young adult cancer. 
A.1  Classification scheme for cancers in children (22). 
Group 1 -  Leukaemias, myeloproliferative diseases, and myelodysplastic diseases  
1.1. Lymphoid leukaemias 
1.2. Acute myeloid leukaemias  
1.3. Chronic myeloproliferative diseases 
1.4. Myelodysplastic syndrome and other myeloproliferative diseases 
1.5. Unspecified and other specified leukaemias 
 
Group 2 - Lymphomas and reticuloendothelial neoplasms  
2.1. Hodgkin lymphomas 
2.2. Non-Hodgkin lymphomas (except Burkitt lymphoma)  
2.3. Burkitt lymphoma 
2.4. Miscellaneous lymphoreticular neoplasms e. Unspecified lymphomas 
 
Group 3 - CNS and miscellaneous intracranial and intraspinal neoplasms  
1.1. Ependymomas and choroid plexus tumour  
1.2. Astrocytomas 
3.3. Intracranial and intraspinal embryonal tumours  
3.4. Other gliomas 
3.5. Other specified intracranial and intraspinal neoplasms  
3.6. Unspecified intracranial and intraspinal neoplasms 
 
Group 4 - Neuroblastoma and other peripheral nervous cell tumours  
4.1. Neuroblastoma and ganglioneuroblastoma  
4.2. Other peripheral nervous cell tumours 
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Group 5 – Retinoblastoma 
 
Group 6 -  Renal tumours  
6.1. Nephroblastoma and other nonepithelial renal tumours 
6.2. Renal carcinomas  
6.3. Unspecified malignant renal tumours 
 
Group 7 - Hepatic tumours  
7.1. Hepatoblastoma 
7.2. Hepatic carcinomas  
7.3. Unspecified malignant hepatic tumours 
 
Group 8 - Malignant bone tumours  
8.1. Osteosarcomas 
8.2. Chondrosarcomas  
8.3. Ewing tumour and related sarcomas of bone  
8.4. Other specified malignant bone tumours  
8.5. Unspecified malignant bone tumours 
 
Group 9 - Soft tissue and other extraosseous sarcomas  
9.1. Rhabdomyosarcomas 
9.2. Fibrosarcomas, peripheral nerve sheath tumours, and other fibrous 
neoplasms 
9.3. Kaposi sarcoma  
9.4. Other specified soft tissue sarcomas 
9.5. Unspecified soft tissue sarcomas 
 
Group 10 - Germ cell tumours, trophoblastic tumours, and neoplasms of gonads  
10.1. Intracranial and intraspinal germ cell tumours 
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10.2. Malignant extracranial and extragonadal germ cell tumours 
10.3. Malignant gonadal germ cell tumours  
10.4. Gonadal carcinomas 
10.5. Other and unspecified malignant gonadal tumours 
 
Group 11 - Other malignant epithelial neoplasms and malignant melanomas  
11.1. Adrenocortical carcinomas  
11.2. Thyroid carcinomas 
11.3. Nasopharyngeal carcinomas 
11.4. Malignant melanomas  
11.5. Skin carcinomas 
11.6. Other and unspecified carcinomas 
 
Group 12 -  Other and unspecified malignant neoplasms  
12.1. Other specified malignant tumours 
12.2. Other unspecified malignant tumours 
 
A.2  Classification scheme for cancers in adolescents and 
young adults (23). 
Group 1 – Leukaemias  
1.1. Acute lymphoid leukaemia (ALL)  
1.2. Acute myeloid leukaemia (AML)  
1.3. Chronic myeloid leukaemia (CML)  
1.4. Other and unspecified leukaemia (Other Leuk)  
1.4.1. Other and unspecified lymphoid leukaemias  
1.4.2. Other and unspecified myeloid leukaemias  
1.4.3. Other specified leukaemias, NEC  
1.4.4. Unspecified leukaemia 
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Group 2 – Lymphomas  
2.1. Non-Hodgkin’s lymphoma (NHL)  
2.1.1. Non-Hodgkin’s lymphoma, specified subtype  
2.1.2. Non-Hodgkin’s lymphoma, subtype not specified 
2.2. Hodgkin’s disease (HD)  
2.2.1. Hodgkin’s disease, specified subtype  
2.2.2. Hodgkin’s disease, subtype not specified 
 
Group 3 – Central nervous system and other intracranial and intraspinal neoplasms 
(CNS tumours)  
3.1. Astrocytoma  
3.1.1. Specified low grade astrocytoma  
3.1.2. Glioblastoma and anaplastic astrocytoma  
3.1.3. Astrocytoma not otherwise specified 
3.2. Other gliomas  
3.3. Ependymoma  
3.4. Medulloblastoma and other primitive neuroectodermal tumours 
(Medulloblastoma) 
3.5. Other and unspecified malignant intracranial and intraspinal neoplasms 
(Other CNS) 
3.5.1. Other specified malignant intracranial and intraspinal neoplasms  
3.5.2. Unspecified malignant intracranial and intraspinal neoplasms 
3.6. Non-malignant intracranial and intraspinal neoplasms  
3.6.1. Specified non-malignant intracranial or intraspinal neoplasms  
3.6.2. Unspecified intracranial or intraspinal neoplasms 
Group 4 – Osseous and chondromatous neoplasms, Ewings tumour and other 
neoplasms of bone (bone tumours)  
4.1. Osteosarcoma  
4.2. Chondrosarcoma  
4.3. Ewing’s tumour  
  
258 
258	
4.4. Other specified and unspecified bone tumours (Other bone tumours)  
4.4.1. Other specified bone tumours  
4.4.2. Unspecified bone tumours 
 
Group 5 – Soft tissue sarcomas (STS)  
5.1. Fibromatous neoplasms (Fibrosarcoma)  
5.2. Rhabdomyosarcoma  
5.3. Other soft tissue sarcomas  
5.3.1. Other specified soft tissue sarcomas  
5.3.2. Unspecified soft tissue sarcomas 
 
Group 6 – Germ cell and trophoblastic neoplasms (germ cell tumours)  
6.1. Gonadal germ cell and trophoblastic neoplasms  
6.2. Germ cell and trophoblastic neoplasms of non-gonadal sites  
6.2.1. Intracranial germ cell and trophoblastic tumours  
6.2.2. Other non-gonadal germ cell and trophoblastic tumours 
 
Group 7 – Melanoma and skin carcinoma  
7.1. Melanoma  
7.2. Skin carcinoma 
 
Group 8 – Carcinomas (except of skin)  
8.1. Carcinoma of thyroid  
8.2. Other carcinoma of head and neck  
8.2.1. Nasopharyngeal carcinoma  
8.2.2. Carcinoma of other sites in lip oral cavity and pharynx  
8.2.3. Carcinoma of nasal cavity, middle ear, sinuses, larynx and other 
ill-defined sites in head and neck 
8.3. Carcinoma of trachea, bronchus, lung and pleura  
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8.4. Carcinoma of breast  
8.5. Carcinoma of genito-urinary (GU) tract  
8.5.1. Carcinoma of kidney  
8.5.2. Carcinoma of bladder 
8.5.3. Carcinoma of ovary and testis  
8.5.4. Carcinoma of cervix and uterus  
8.5.5. Carcinoma of other and ill-defined sites in GU 
8.6. Carcinoma of gastro-intestinal (GI) tract  
8.6.1. Carcinoma of colon and rectum  
8.6.2. Carcinoma of stomach  
8.6.3. Carcinoma of liver and ill-defined sites in GI tract 
8.7. Carcinomas of other and ill-defined sites not elsewhere classified (NEC)  
8.7.1. Adrenocortical carcinoma  
8.7.2. Other carcinomas NEC 
 
Group 9 – Miscellaneous specified neoplasms NEC  
9.1. Embryonal tumours NEC  
9.1.1. Wilms tumour  
9.1.2. Neuroblastoma  
9.1.3. Other embryonal tumours NEC 
9.2. Other rare miscellaneous specified neoplasms  
9.2.1. Paraganglioma and glomus tumours  
9.2.2. Other specified gonadal tumours NEC  
9.2.3. Myeloma, mast cell tumours and miscellaneous 
reticuloendothelial neoplasms NEC 
9.2.4 Other specified neoplasms NEC  
 
Group 10 – Unspecified malignant neoplasms NEC 
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Appendix B: Literature search strategies. 
Table B.1: Search strategy for the topic of 'transition'. 
Stage Search term Results – 
EMBASE 
Results – 
Medline 
1 transition to adult care/ 1,420 1,028 
2 limit 1 to human 1,411 1,026 
3 limit 2 to English language 1,321 951 
4 limit 3 to full text 344 177 
5 limit 4 to article 148 152 
 Manual selection 105 
Exclusions during manual selection included: 
- adolescent health with no mention of transition 
- transitioning between departments, not specifically between paediatric to 
adult services 
- pilot studies and protocols 
- editorials 
- case studies 
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Figure B.1: Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) flowchart for literature search on transition. 
 
Table B.2: Search strategy for the topic of ‘T1D outcomes’. 
Stage Search term – EMBASE Results - 
EMBASE 
Search term – 
Medline 
Results - 
Medline 
1 insulin dependent diabetes 
mellitus/ 
69833 Diabetes 
Mellitus, Type 
1/ 
41993 
2 diabetic angiopathy/ or 
diabetic cardiomyopathy/ or 
diabetic coma/ or diabetic 
foot/ or diabetic 
hypertension/ or diabetic 
ketoacidosis/ or diabetic 
macular edema/ or diabetic 
nephropathy/ or diabetic 
neuropathy/ or diabetic 
99272 Diabetes 
Complications/ 
 
21506 
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obesity/ or diabetic 
retinopathy/ or diabetic 
stomach paresis/ or 
nonketotic diabetic coma/ or 
pregnancy diabetes mellitus/ 
3 1 and 2 13459 1 and 2 1133 
4 limit 3 to human 12485 limit 3 to 
human 
1100 
5 limit 4 to English language 11014 limit 4 to 
English 
language 
899 
6 limit 5 to full text 3684 limit 5 to full 
text 
307 
7 limit 6 to article 2033 limit 6 to article 277 
8 limit 7 to last 5 years 579 limit 7 to last 5 
years 
99 
 Manual selection 70 
 
Exclusions during manual selection included: 
- case reports 
- treatment trials 
- screening research 
- no separation from type 2 diabetes 
- where T1D is a supplementary disease 
- comorbidity with other diseases 
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Figure B.2: Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) flowchart for literature search on type 1 diabetes (T1D). 
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Table B.3: Search strategy for the topic of ‘childhood cancer outcomes’. 
Stage Search term – EMBASE Results - 
EMBASE 
Search term – 
Medline 
Results - 
Medline 
1 childhood cancer/ 22951 Neoplasms/ 186425 
2 late effect*.mp. 6264 Child/ or Infant/ 922800 
3 early effect*.mp. 2906 1 and 2 12341 
4 outcome*.mp. 2158957 late effect*.mp. 3423 
5 complication*.mp. 993203 early effect*.mp. 1932 
6 follow?up.mp. 28455 outcome*.mp. 1490835 
7 long?term.mp. 14702 complication*.mp. 652315 
8 surviv*.mp. 1183991 follow?up.mp. 12660 
9 2 or 3 or 4 or 5 or 6 or 7 or 8 3615707 long?term.mp. 2949 
10 1 and 9 11911 surviv*.mp. 799888 
11 limit 10 to human 10814 3 or 4 or 5 or 6 or 7 
or 8 or 9 or 10 
2437305 
12 limit 11 to English language 10225 3 and 11 4823 
13 limit 12 to full text 2869 limit 12 to human 4823 
14 limit 13 to article 1530 limit 13 to English 
language 
4418 
15 limit 14 to last 5 years 454 limit 14 to full text 1323 
16   limit 15 to article 1265 
17   limit 16 to last 5 
years 
344 
 Manual selection 48 
Exclusions during manual selection included: 
- case reports 
- treatment trials 
- research on screening 
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Figure B.3: Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) flowchart for literature search on cancer. 
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Appendix C: Model fit comparisons for multi-level models using 
data from the Leeds Children and Young People’s Diabetes 
Service (LCYPDS) cohort. 
Both the Akaike’s Information Criterion and Bayesian Information Criterion were 
lower for the random intercept model, indicating that this was a better fitting 
model compared with the random slope mode (Table C.1). 
 
Table C.1: Akaike’s Information Criterion and Bayesian Information Criterion for 
random intercept and random slope models comparing individuals who 
continued within individuals who discontinued continuous subcutaneous insulin 
infusion (CSII) therapy. 
Multi-level model 
Akaike’s Information 
Criterion 
Bayesian Information 
Criterion 
Random intercept model 6476.524 6516.391 
Random slope model 6476.854 6522.416 
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Appendix D: International classification of Diseases (ICD). 
Table D.1: International Statistical Classification of Diseases and Related 
Health Problems 10th Revision. 
Chapter Blocks Title 
I A00-B99 Certain infectious and parasitic diseases 
II C00-D48 Neoplasms 
III D50-D89 Diseases of the blood and blood-forming organs and certain 
disorders involving the immune mechanism 
IV E00-E90 Endocrine, nutritional and metabolic diseases 
V F00-F99 Mental and behavioural disorders 
VI G00-G99 Diseases of the nervous system 
VII H00-H59 Diseases of the eye and adnexa 
VIII H60-H95 Diseases of the ear and mastoid process 
IX I00-I99 Diseases of the circulatory system 
X J00-J99 Diseases of the respiratory system 
XI K00-K93 Diseases of the digestive system 
XII L00-L99 Diseases of the skin and subcutaneous tissue 
XIII M00-M99 Diseases of the musculoskeletal system and connective tissue 
XIV N00-N99 Diseases of the genitourinary system 
XV O00-O99 Pregnancy, childbirth and the puerperium 
XVI P00-P96 Certain conditions originating in the perinatal period 
XVII Q00-Q99 Congenital malformations, deformations and chromosomal 
abnormalities 
XVIII R00-R99 Symptoms, signs and abnormal clinical and laboratory findings, not 
elsewhere classified 
XIX S00-T98 Injury, poisoning and certain other consequences of external 
causes 
XX V01-Y98 External causes of morbidity and mortality 
XXI Z00-Z99 Factors influencing health status and contact with health services 
XXII U00-U99 Codes for special purposes 
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Appendix E: Treatment specialty groupings in Hospital Episode 
Statistics (HES)  
Table E.1: Treatment specialty groupings. 
HES code HES category New category 
324 Anticoagulant Service  circulatory 
320 Cardiology  circulatory 
321 Paediatric Cardiology  circulatory 
107 Vascular Surgery  circulatory 
170 
Cardiothoracic Surgery (Where There Are 
No Separate Services For Cardiac And 
Thoracic Surgery)  
circulatory 
221 Paediatric Cardiac Surgery (From 2006-07)  circulatory 
331 Congenital Heart Disease Service (From April 2013)  circulatory 
174 
Cardiothoracic Transplantation (Recognised 
Specialist Services Only - Includes 
'Outreach' Facilities)  
circulatory 
654 Dietetics (From 2006-07)  digestion 
301 Gastroenterology  digestion 
251 Paediatric Gastroenterology (From 2006-07)  digestion 
306 Hepatology  digestion 
104 
Colorectal Surgery (Surgical Treatment Of 
Disorders Of The Lower Intestine - Colon, 
Anus And Rectum)  
digestion 
106 Upper Gastrointestinal Surgery  digestion 
105 
Hepatobiliary & Pancreatic Surgery 
(Includes Liver Surgery But Excludes Liver 
Transplantation See Transplantation 
Surgery)  
digestion 
840 Audiology (From 2008-09)  ears, nose, throat 
310 Audiological Medicine  ears, nose, throat 
254 Paediatric Audiological Medicine (From 2006-07)  ears, nose, throat 
120 Ear, Nose And Throat (Ent)  ears, nose, throat 
215 Paediatric Ear Nose And Throat (From 2006-07)  ears, nose, throat 
302 Endocrinology  endocrinology 
252 Paediatric Endocrinology (From 2006-07)  endocrinology 
307 Diabetic Medicine  endocrinology 
263 Paediatric Diabetic Medicine  endocrinology 
261 Paediatric Metabolic Disease (From 2006-07)  endocrinology 
130 Ophthalmology  eyes 
216 Paediatric Ophthalmology (From 2006-07)  eyes 
460 Medical Ophthalmology (From 1993-94)  eyes 
662 Optometry  eyes 
255 Paediatric Clinical Immunology And Allergy (From 2006-07)  immunology/allergy 
313 
Clinical Immunology And Allergy (Where 
There Are No Separate Services For Clinical 
Immunology And Allergy)  
immunology/allergy 
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316 Clinical Immunology  immunology/allergy 
317 Allergy Service  immunology/allergy 
830 Immunopathology  immunology/allergy 
110 Trauma And Orthopaedics  joints/muscles/skin 
330 Dermatology  joints/muscles/skin 
650 Physiotherapy (From 2006-07)  joints/muscles/skin 
410 Rheumatology  joints/muscles/skin 
214 Paediatric Trauma And Orthopaedics (From 2006-07)  joints/muscles/skin 
257 Paediatric Dermatology (From 2006-07)  joints/muscles/skin 
323 Spinal Injuries (From 2006-07)  joints/muscles/skin 
262 Paediatric Rheumatology (From 2006-07)  joints/muscles/skin 
161 Burns Care (Recognised Specialist Services Only - Includes 'Outreach' Facilities)  joints/muscles/skin 
657 Prosthetics  joints/muscles/skin 
325 Sport And Exercise Medicine  joints/muscles/skin 
655 Orthoptics (From 2006-07)  joints/muscles/skin 
658 Orthotics  joints/muscles/skin 
108 Spinal Surgery Service (From April 2013)  joints/muscles/skin 
501 Obstetrics For Patients Using A Hospital Bed Or Delivery Facilities  maternity/obstetrics/gynaecology 
502 Gynaecology  maternity/obstetrics/gynaecology 
560 Midwifery Service  maternity/obstetrics/gynaecology 
560 Midwifery (From October 1995)  maternity/obstetrics/gynaecology 
503 Gynaecological Oncology  maternity/obstetrics/gynaecology 
422 Neonatology  maternity/obstetrics/gynaecology 
424 
Well Babies (Care Given By The 
Mother/Substitute, With Nursing Advice If 
Needed)  
maternity/obstetrics/gynaecology 
710 Adult Mental Illness  mental health 
656 Clinical Psychology (From 2006-07)  mental health 
711 Child And Adolescent Psychiatry  mental health 
713 Psychotherapy  mental health 
720 Eating Disorders (From 2006-07)  mental health 
101 Urology  nephrology 
361 Nephrology  nephrology 
259 Paediatric Nephrology (From 2006-07)  nephrology 
360 Genitourinary Medicine  nephrology 
360 Genito-Urinary Medicine  nephrology 
211 Paediatric Urology (From 2006-07)  nephrology 
328 Stroke Medicine  neurology 
329 Transient Ischaemic Attack  neurology 
400 Neurology  neurology 
150 Neurosurgery  neurology 
421 Paediatric Neurology  neurology 
218 Paediatric Neurosurgery (From 2006-07)  neurology 
291 Paediatric Neuro-Disability (From 2006-07)  neurology 
652 Speech And Language Therapy (From 2006-07)  neurology 
700 Learning Disability (Previously Known As Mental Handicap)  neurology 
223 Paediatric Epilepsy (From April 2013)  neurology 
401 Clinical Neurophysiology (From 2008-09)  neurology 
401 Clinical Neuro-Physiology  neurology 
309 Haemophilia (Previously Part Of Clinical oncology 
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Haematology)  
260 Paediatric Medical Oncology (From 2006-07)  oncology 
303 Clinical Haematology  oncology 
303 Haematology (Clinical)  oncology 
370 Medical Oncology  oncology 
800 Clinical Oncology (Previously Known As Radiotherapy)  oncology 
823 Haematology  oncology 
253 Paediatric Clinical Haematology (From 2006-07)  oncology 
308 Bone And Marrow Transplantation (Previously Part Of Clinical Haematology)  oncology 
140 Oral Surgery  oral health 
143 Orthodontics  oral health 
142 Paediatric Dentistry (From 1999-2000)  oral health 
141 Restorative Dentistry (Endodontics, Periodontics And Prosthodontics)  oral health 
144 Maxillo-Facial Surgery  oral health 
450 Dental Medicine (From 1990-91)  oral health 
217 Paediatric Maxillo-Facial Surgery (From 2006-07)  oral health 
191 
Pain Management (Complex Pain Disorders 
Requiring Diagnosis And Treatment By A 
Specialist Multi-Professional Team)  
other 
241 Paediatric Pain Management (From 2006-07)  other 
653 Podiatry (From 2006-07)  other 
314 Rehabilitation Service  other 
344 Complex Specialised Rehabilitation Service (From April 2013)  other 
345 Specialist Rehabilitation Service (From April 2013)  other 
180 Accident & Emergency (A&E)  other 
430 Geriatric Medicine  other 
822 Chemical Pathology  other 
304 Clinical Physiology (From 2008-09)  other 
420 Paediatrics  other 
300 General Medicine  other 
950 Nursing Episode (From 2002-03)  other 
290 Community Paediatrics (From 2006-07)  other 
820 General Pathology  other 
900 Community Medicine  other 
305 Clinical Pharmacology  other 
311 Clinical Genetics  other 
812 Diagnostic Imaging (From 2008-09)  other 
811 Interventional Radiology  other 
371 Nuclear Medicine (From 2008-09)  other 
810 Radiology  other 
350 Infectious Diseases  other 
192 Critical Care Medicine (Also Known As Intensive Care Medicine)  other 
651 Occupational Therapy (From 2006-07)  other 
315 Palliative Medicine  other 
264 Paediatric Cystic Fibrosis  respiratory 
343 Adult Cystic Fibrosis Service  respiratory 
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340 Respiratory Medicine (Previously Known As Thoracic Medicine)  respiratory 
340 Thoracic Medicine  respiratory 
258 Paediatric Respiratory Medicine (From 2006-07)  respiratory 
341 Respiratory Physiology (Previously Known As Sleep Studies)  respiratory 
173 Thoracic Surgery  respiratory 
190 Anaesthetics  surgery 
100 General Surgery  surgery 
160 Plastic Surgery  surgery 
103 
Breast Surgery (Includes Suspected 
Neoplasms, Cysts Etc, Does Not Include 
Cosmetic Surgery)  
surgery 
171 Paediatric Surgery  surgery 
102 
Transplantation Surgery (Includes Renal 
And Liver Transplants, Excludes 
Cardiothoracic Transplantation)  
surgery 
212 Paediatric Transplantation Surgery (From 2006-07)  surgery 
219 Paediatric Plastic Surgery (From 2006-07)  surgery 
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Appendix F: Directed acyclic graphs (DAGs) for statistical 
models used in analysis of the Yorkshire Specialist Register of 
Cancer in Children and Young People 
 
Confounders: ethnicity, sex, deprivation. 
Proxy confounders: Age at cancer onset, cancer type. 
Figure F.1: Mental health admission - age at first mental health admission. 
 
 
 
Confounders: ethnicity, sex, deprivation. 
Mediators: Age at cancer onset, age at first mental health admission. 
Figure F.2: Mental health admission - cancer type. 
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273	 Confounders: ethnicity, sex, deprivation. Proxy confounders: Age at cancer onset, cancer type. Mediators: Outpatient appointment treatment specialty, month of the year, day of the week. 
Figure F.3: Outpatient attendance - age at outpatient appointment. 
 
 
 
Confounders: ethnicity, sex, deprivation. 
Mediators: Outpatient appointment treatment specialty, age at outpatient appointment, age at 
cancer onset, month of the year, day of the week. 
Figure F.4: Outpatient appointment attendance - cancer type. 
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274	 Confounders: ethnicity, sex, deprivation. Proxy confounders: Age at cancer onset, cancer type, age at outpatient appointment. 
Mediators: month of the year, day of the week. 
Figure F.5: Outpatient appointment attendance - treatment specialty. 
 
 
 
Confounders: ethnicity, sex, deprivation. 
Proxy confounders: Age at cancer onset, cancer type age at mental health admission. 
Competing exposures: Outpatient appointment treatment specialty, age at outpatient 
appointment, month of the year, day of the week. 
Figure F.6: Outpatient appointment attendance - mental health admission. 
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Confounders: ethnicity, sex, deprivation. 
Proxy confounders: Age at cancer onset, cancer type age at mental health admission. 
Mediators: Inpatient primary diagnosis, inpatient treatment specialty, month of the year, day of 
the week. 
Figure F.7: Inpatient admission - age at inpatient attendance. 
 
 
 
Confounders: ethnicity, sex, deprivation. 
Mediators: Age at cancer onset, age at inpatient admission, inpatient primary diagnosis, 
inpatient treatment specialty, month of the year, day of the week. 
Figure F.8: Inpatient admission - cancer type. 
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Confounders: ethnicity, sex, deprivation. 
Proxy confounders: cancer type, age at cancer onset, age at inpatient admission. 
Mediators: inpatient treatment specialty, month of the year, day of the week. 
Figure F.9: Inpatient admission - inpatient primary diagnosis. 
 
 
Confounders: ethnicity, sex, deprivation. 
Proxy confounders: cancer type, age at cancer onset, age at inpatient admission, inpatient 
primary diagnosis. 
Competing exposures: month of the year, day of the week. 
Figure F.10: Inpatient admission - inpatient treatment specialty. 
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277	 Confounders: ethnicity, sex, deprivation. Proxy confounders: cancer type, age at cancer onset, age at mental health admission. 
Mediators: inpatient primary diagnosis, inpatient treatment specialty, month of the year, day of 
the week. 
Competing exposure: age at inpatient admission. 
Figure F.11: Inpatient admission - mental health admission. 
 
 
 
Confounders: ethnicity, sex, deprivation. 
Proxy confounders: cancer type, age at cancer onset, age at outpatient appointment, outpatient 
appointment treatment specialty, month of the year (outpatient appointment), day of the week 
(outpatient appointment). 
Competing exposures: inpatient primary diagnosis, age at inpatient admission, inpatient 
treatment specialty, month of the year (inpatient admission), day of the week (inpatient 
admission). 
Figure F.12: Inpatient admission - outpatient appointment attendance. 
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278	 Confounders: ethnicity, sex, deprivation. 
Proxy confounders: cancer type, age at cancer onset.  
Mediators: A&E arrival mode, A&E attendance month, A&E attendance day of the week, A&E 
attendance time of day.  
Figure F.13: A&E attendance - age at A&E attendance. 
 
 
 
Confounders: ethnicity, sex, deprivation. 
Mediators: Age at cancer onset, age at A&E attendance, A&E arrival mode, A&E attendance 
month, A&E attendance day of the week, A&E attendance time of day.  
Figure F.14: A&E attendance - cancer type. 
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279	 Confounders: ethnicity, sex, deprivation. 
Proxy confounders: Age at cancer onset, cancer type, age at mental health admission. 
Competing exposures: Age at A&E attendance, A&E arrival mode, A&E attendance month, A&E 
attendance day of the week, A&E attendance time of day.  
Figure F.15: A&E attendance - mental health admission. 
 
 
 
Confounders: ethnicity, sex, deprivation. 
Proxy confounders: Age at cancer onset, cancer type, age at outpatient appointment, outpatient 
appointment treatment specialty, month of the year (outpatient), day of the week (outpatient). 
Competing exposures: Age at A&E attendance, A&E arrival mode, A&E attendance month, A&E 
attendance day of the week, A&E attendance time of day.  
Figure F.16: A&E attendance - outpatient appointment attendance. 
